

# Sources and prices of selected medicines and diagnostics for people living with HIV/AIDS

JUNE 2003

A JOINT UNICEF – UNAIDS – WHO – MSF PROJECT



## This report is also available

### On the following web pages:

UNICEF: [www.unicef.org](http://www.unicef.org)

UNICEF Supply Division: [www.supply.unicef.dk](http://www.supply.unicef.dk)

UNAIDS: [www.unaids.org](http://www.unaids.org)

WHO/ Department of Essential Drugs and Medicines Policy: [www.who.int/medicines](http://www.who.int/medicines)

WHO/ Department of HIV/AIDS: [www.who.int/HIV\\_AIDS](http://www.who.int/HIV_AIDS)

Médecins Sans Frontières (MSF): [www.accessmed-msf.org](http://www.accessmed-msf.org)

### Or by contacting:

Pharmaceuticals & Micronutrients Group

UNICEF Supply Division

Fax: +45 35 269421

Essential Drugs and Medicines Policy (EDM)

World Health Organization

Fax: +41 22 7914167

Department of Policy Strategy and Research

UNAIDS

Fax: +41 22 7914741

Campaign for Access to Essential Drugs

Médecins Sans Frontières

Fax: +41 22 8498404

Information on HIV/AIDS diagnostic support, HIV test kit evaluations and bulk procurement are available on the WHO/ Department of Blood Safety and Clinical Technology website: [www.who.int/bct](http://www.who.int/bct)

Information on HIV/AIDS and substance abuse dependence is available from [www.who.int/substance\\_abuse](http://www.who.int/substance_abuse)

© World Health Organization, UNICEF Supply Division, Joint United Nations Programme on HIV/AIDS (UNAIDS), Médecins Sans Frontières, 2003. All rights reserved.

Published by WHO, also on behalf of UNICEF, the UNAIDS Secretariat, and Médecins Sans Frontières.

WHO, UNICEF, the UNAIDS Secretariat, and Médecins Sans Frontières have made every effort to ensure the accuracy of price, supplier, and other information presented in this report. Reader's attention is drawn to the introduction, which describes the specific sources and limitations of information provided in this report.

Reader's attention is also drawn to the importance of quality assurance for pharmaceutical products. Licensing authorities in the respective countries of manufacture are expected to be responsible for the review and approval of the detailed composition and formulation when authorizing a pharmaceutical product to be marketed, including the specifications of its ingredients, as submitted by the manufacturer of the dosage form, and to oversee compliance with Good Manufacturing Practice requirements as recommended by WHO.

The data and information contained herein are being provided as is and WHO, UNICEF, the UNAIDS Secretariat, and Médecins Sans Frontières make no representations or warranties, either expressed or implied, as to their accuracy, completeness or fitness for a particular purpose. Neither WHO, UNICEF, the UNAIDS Secretariat, nor Médecins Sans Frontières accepts any responsibility or liability with regard to the reliance on, or use of, such data and information.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO, UNICEF, the UNAIDS Secretariat or Médecins Sans Frontières in preference to others of a similar nature that are not mentioned. Errors or omissions excepted, the names of proprietary products are distinguished by initial capital letters.

The designations employed and the presentation of the material in this report, including tables and maps, do not imply the expression of any opinion whatsoever on the part of WHO, UNICEF, the UNAIDS Secretariat and Médecins Sans Frontières concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

Design and layout by minimum graphics

Printed in France

# Contents

Glossary	v
1. Introduction	1
2. Pricing	3
3. Access to quality HIV/AIDS medicines and diagnostics	5
4. Sources and prices of medicines	7
5. Variation in price between surveys	14
Annex 1 A. Registration status of products included in the sources and prices survey	15
B. Index of manufacturers	33
C. Geographical distribution of participating manufacturers	40
Annex 2 WHO Bulk Procurement Scheme 2003	41
Annex 3 A. Summary of main characteristics of methods for CD4/CD8 lymphocyte determination	44
B. Summary of main characteristics of Viral Load Technologies	45
Annex 4 Further reading, references and contacts	48
Annex 5 Feedback and enquiry form	51
Annex 6 Untangling the web of price reductions: a pricing guide for the purchase of ARVs for developing countries	53
<b>Tables</b>	
Table 1. Anti-infective medicines	7
Antibacterials	7
Antifilarials	8
Antifungal medicines	8
Anthelmintics	9
Antiprotozoal medicines	9
Antiviral medicines	9
Antiretroviral medicines	9
Table 2. Antineoplastic medicines	11
Cytotoxic medicines	11
Table 3. Psychotherapeutic medicines	12
Medicines used in depressive disorders	12
Medicines used in generalized anxiety and sleep disorders	12




Table 4. Analgesics	12
Opioid analgesics	12
Medicines used in the treatment of opioid dependence	12
Table 5. Gastrointestinal medicines	13
Antacids and other antiulcer medicines	13
Antiemetic medicines	13
Laxatives	13
Table 6. Variation in the price of ciprofloxacin and fluconazole between surveys	14

# Glossary

**AIDS**<sup>1</sup> Acquired Immune Deficiency Syndrome – the late stage of HIV disease. AIDS involves the loss of function of the immune system as CD4 cells are infected and destroyed, allowing the body to succumb to opportunistic infections (e.g., *Pneumocystis carinii pneumonia*, toxoplasmosis) that are generally not pathogenic in people with intact immune systems.

**COF** Consejo General de Colegios Oficiales de Farmacéuticos – Spanish organization of Pharmaceutical Colleges, which represents all colleges in the national and international forum, develops norms, rules, and professional policy, and acts as the interlocutor with Spanish Ministries.

**Diagnostics** Laboratory tests used in the diagnosis of HIV infection.

**ELISA** Enzyme-linked immunosorbent assay – first HIV antibody test which requires a machine to measure color change in test wells.

**Endemic**<sup>1</sup> The continuous presence of a disease in a geographic location, community or population.

**Epidemic**<sup>1</sup> An outbreak of a disease within a population. See also pandemic.

**EXW**<sup>2</sup> Ex-works – (... named place) the seller's only responsibility is to make the goods available at the seller's premises, i.e., the works or factory. The seller is not responsible for loading the goods on the vehicle provided by the buyer unless otherwise agreed. The buyer bears the full costs and risk involved in bringing the goods from there to the desired destination. Ex works represents the minimum obligation of the seller.

**FCA (nearest port)**<sup>2</sup> Free Carrier – (... named place) This term has been designed to meet the requirements of multimodal transport, such as container or roll-on, roll-off traffic by trailers and ferries. It is based on the same name principle as F.O.B. (free on board), except the seller fulfils its obligations when the goods are delivered to the custody of the carrier at the named place. If no precise place can be named at the time of the contract of sale, the parties should refer to the place where the carrier should take the goods into its charge. The risk of loss or damage to the goods is transferred from seller.

**FOB**<sup>2</sup> Free-on-board – (... named port of shipment) Under "F.O.B" the goods are placed on board the ship by the seller at a port of shipment named in the sales agreement. The risk of loss of or damage to the goods is transferred to the buyer when the goods pass the ship's rail (i.e., off the dock and placed on the ship). The seller pays the cost of loading the goods.

**Generic medicine**<sup>3</sup> The term "generic product" has somewhat different meaning in different jurisdictions. In many technical documents, use of this term is avoided, and the term 'multisource pharmaceutical product' is used instead. In this document, where the term generic medicine is used, it means a pharmaceutical product usually intended to be interchangeable with the innovator product, which is usually manufactured without a license from the innovator company and marketed after expiry of patent or other exclusivity rights where these have previously existed. Generic products may be marketed either under the non-proprietary approved name or under a new brand (proprietary) name. They may sometimes be marketed in dosage forms and/or strengths different from those of the innovator products.

**Generic pharmaceutical manufacturers** Manufacturers who produce generic medicines

**GMP** Good Manufacturing Practice

**HAART** Highly Active Antiretroviral Therapy

**HDI** Human Development Index

**HIV** Human Immunodeficiency Virus – a slow-acting retrovirus of the lentivirus family, believed to be the sole or primary cause of AIDS. HIV is transmitted sexually, through blood or vertically (from mother to child). There are 2 known types: HIV-1 and HIV-2.

**HIV Test kit** There are 3 main types of test for detecting the presence of HIV antibodies: simple/rapid tests, ELISA tests, and confirmatory tests.

<sup>1</sup> AIDS Education Global Information System

<sup>2</sup> International Chamber of Commerce

<sup>3</sup> World Health Organization. *Quality Assurance of Pharmaceuticals. A compendium of guidelines and related materials.* Vol 1, 1997.

**International Price Indicator Guide 2002** A joint publication by the World Health Organization and Management Sciences for Health (MSH). Provides a spectrum of prices from non-profit drug suppliers, procurement agencies, and ministries of health, based on their current catalogs or price lists.

**Manufacturing license** Granted by national licensing authorities and gives authorization to manufacture a specific product in a specified manufacturing plant.

**MSF** Médecins Sans Frontières – setting up medical humanitarian aid missions around the world since 1971.

**MSH** Management Sciences for Health – private, non-profit educational and scientific organization working to close the gap between knowledge and action in public health.

**MTCT** Mother-to-child transmission (of HIV)

**Opportunistic infections**<sup>1</sup> (OI) An illness caused by a micro-organism that usually does not cause disease in persons with healthy immune systems, but which may cause serious illness when the immune system is suppressed. Common OI in HIV positive people include *Pneumocystis carinii* pneumonia (PCP), *Mycobacterium avium* complex (MAC) and cytomegalovirus (CMV) infection.

**Palliative care**<sup>4</sup> Pain and symptom management, and psycho-social support for persons living with a terminal illness, as well as for their families and caregivers.

**Pandemic**<sup>1</sup> A widespread disease outbreak affecting the population of an extensive area of the world. See also epidemic.

**Patents**<sup>5</sup> A title granted by the public authorities conferring a temporary monopoly for the exploitation of an invention upon the person who reveals it, furnishes a sufficiently clear and full description of it, and claims this monopoly.

**PLWA** People Living With HIV/AIDS

**Protease inhibitor (PI)** Type of antiretroviral medicine

**Proprietary medicines** Medicines that are under patent restrictions belonging to a company, institution, or government.

**Research based pharmaceutical manufacturers** Manufacturers that produce mainly innovative medicines

**Reverse transcriptase inhibitor** Type of ARV medicine. Can be divided into two classes: Nucleoside Reverse Transcriptase Inhibitor (NRTI) and Non Nucleoside Reverse Transcriptase Inhibitor (NNRTI)

**Simple/rapid test** Can generally be carried out in 15 minutes and results are read with the naked eye. They are easy to use and require limited training and little or

no equipment, making them particularly suitable for use in Voluntary Counselling and Testing (VCT) centres.

**The World Bank Group** Established in July 1, 1944 it is one of the world's largest sources of development assistance. In Fiscal Year 2002, the institution provided more than US\$19.5 billion in loans to its client countries.

**TRIPS**<sup>6</sup> Agreement on Trade Related Aspects of Intellectual Property Rights

**UNAIDS** The Joint United Nations Programme on HIV/AIDS (UNAIDS) – by the mid-1990s, it became clear that the epidemic's devastating impact on all aspects of human development, were creating an emergency that would require a greatly expanded United Nations effort. UNAIDS created in 1995 was tasked to coordinate this effort.

**UNFPA** United Nations Population Fund, began operations in 1969. It is the largest international source of population assistance. About a quarter of all population assistance from donor nations to developing countries is channelled through UNFPA.

**UNICEF** United Nations Children's Fund – Created by the United Nations General Assembly in 1946 to help children after World War II in Europe. Headquartered in New York, UNICEF carries out its work through eight regional offices and 126 country offices covering more than 160 countries, territories and areas.

**WHO** World Health Organization – Founded in 1948, the World Health Organization leads the world alliance for Health for All. WHO promotes technical cooperation for health among nations, carries out programmes to control and eradicate disease and strives to improve the quality of human life.

**WIPO** World Intellectual Property Organization – Founded in 1970, WIPO administers 23 international treaties dealing with different aspects of intellectual property protection.

**WTO** World Trade Organization – succeeded the General Agreement on Tariffs and Trade (GATT), first signed in 1947 by 23 countries and aimed at protecting and regulating international trade.

<sup>4</sup> Council on palliative care, Canada

<sup>5</sup> *Globalization and access to drugs—perspectives on the WTO TRIPS Agreement*. Health Economics and Drugs EDM Series 7. WHO, Geneva, 1999

<sup>6</sup> WTO



# 1. Introduction

## 1.1 Background

Improving access to medicines for people living with HIV/AIDS presents a challenge for all countries, and an even greater challenge for the developing nations. By the end of 2002, UNAIDS estimated that the total number of people living with HIV/AIDS stood at 42 million, including 5 million new infections. In the same year, an estimated 3.1 million people died of the disease. Over 95% of the people infected live in developing countries.

The national ownership, initiative, and responsibility taken by National AIDS programme managers, health directors and Health Ministers in these countries is commendable, but the issue of inadequate funding still remains.

To reduce the disparity between needs and funding, successful proposals from low income countries are receiving much needed grants from the Global Fund to Fight AIDS, TB, and Malaria as well as other International Development Assistance, for strategies to prevent new infections, including prevention of mother to child transmission, and treatment and care of infected people. With this new funding, the number of people being treated with antiretrovirals is expected to increase six-fold. This scale-up will require the careful identification, selection, and procurement of medicines.

The high price of many of the HIV-related medicines offered by common suppliers—especially antiretroviral medicines—is one of the main barriers to their availability in developing countries.<sup>7</sup> These medicine prices may be governed by the following factors:

- Patents<sup>8</sup>
- Limited volume
- Limited price competition
- High import duties, tariffs, and local taxes
- High mark-ups for wholesaling, distribution, and dispensing
- Individual country pricing strategies—for example, price fixing by the government, policies of price freedom for new products or even agreements with industry on profit control.

Even where affordable alternatives exist, many decision-makers do not have the information they need to identify those manufacturers that can supply these medicines. They require easier access to comparative prices.

## 1.2 Aim

This report sets out to provide market information that can be used to help procurement agencies make informed decisions on the source of medicines and serve as the basis for negotiating affordable prices. The aim is to help increase access to medicines for people living with HIV/AIDS in developing countries.

The data provided by the manufacturers serves to highlight the multiplicity of suppliers and the variation in price of some essential HIV/AIDS-related medicines on the international market. Without this information, there is a risk that low-income countries may be paying more than needed to obtain essential medicines. Price variations are highlighted through the tables and graphs included.

Provision of price information addresses only one barrier to access to medicines in countries with limited resources and, it is appreciated that many other factors will affect the availability of medicines. Some of the other issues that must be considered in relation to the purchase of medicines for HIV/AIDS and related conditions are health infrastructure, human resources, and supply and distribution systems.<sup>9</sup>

<sup>7</sup> UN agencies and partners are working together to help expand access to the full range of HIV-related medicines, within the context of local health care systems and national HIV/AIDS plans and priorities. A four-part strategy has been adopted to guide and coordinate action on access to HIV-related medicines: (1) rational selection and use of HIV-related medicines (2) affordable prices (3) sustainable financing and (4) reliable health supply systems.

<sup>8</sup> For further information on Patents and the TRIPS agreement, refer to Annex 4, Further Reading: Intellectual Property Rights and pharmaceuticals.

<sup>9</sup> Management Sciences for Health and the World Health Organization second edition of *Managing Drug Supply* provides a complete overview as well as step-by-step approaches on how to manage pharmaceutical systems effectively.

### 1.3 Generating the Report

This report is the fourth in a series of annual reports of sources and prices surveys commenced in 1999. These surveys will be continued and the report will be regularly updated and made available when appropriate.

A survey, carried out from Dec 2002 through to Feb 2003, of 388 manufacturers in 50 different countries was the basis of this report. The number of manufacturers reached has greatly increased since the first survey in 1999 as more resources are made available via industry websites and cooperation with other international organizations; allowing this publication to include **61 manufacturers**. Manufacturers that participated in previous surveys, those held in various databases, and those belonging to National Pharmaceutical Associations were contacted and asked to fill in a comprehensive questionnaire. The response to the questionnaire was accompanied by a National GMP certificate and associated documents relating to the company and the products.

The UNAIDS Secretariat, UNICEF, MSF, and WHO have worked jointly to conduct the survey, and put together the responses into an easy to use, comprehensive publication, whilst respecting the manufacturers' requests for confidentiality with respect to their individual pricing information.

It must be pointed out however that the companies included in this report have been screened only through the completeness of the documents they have provided. Inclusion in the report does not necessarily constitute prequalification or approval of any sort by UNICEF, WHO, UNAIDS or MSF. Only those products identified in Annex 1A in bold and with an asterisk (\*) have (at the time of publication of this document) been approved through the ongoing ***Pilot Procurement Quality and Sourcing Project*** (see section 3.)

### 1.4 Selection of medicines

The report includes antiretroviral medicines, medicines used to treat a range of opportunistic infections, medicines for use in palliative care, medicines for the treatment of HIV/AIDS-related cancers and medicines for the management of opioid dependence. It also provides information on a range of test kits available for diagnosis of HIV.

The medicines included in the report were selected based on recommendations from available WHO treatment guidelines. The list is not intended to be exhaustive but to broadly cover the most commonly used medicines or medicine categories, in order to ensure that combined with their own resources, purchasing agencies can have at their disposal all medicines required for the comprehensive treatment of HIV/AIDS.

Alternative medicines often are provided as they may be helpful due to:

- Greater cost offset by greater safety, e.g. fluconazole instead of ketoconazole.
- Fewer unwanted adverse effects, e.g. alternatives to amitriptyline

For this survey, paediatric forms have been included wherever possible.

#### Antiretroviral therapy

Since October 2000, the report has included information on the availability and price range of antiretroviral medicines for use in Highly Active Antiretroviral Therapy (HAART). More specific information on treatment schedules should be obtained from the WHO department of HIV/AIDS at the following webpage [http://www.who.int/HIV\\_AIDS](http://www.who.int/HIV_AIDS).

#### Antituberculosis medicines

This report does not include data on sources and prices of medicines for the treatment of tuberculosis as this information is available on the website of the International Price Indicator Guide 2002<sup>10</sup> or of the Global Drug Facility at <http://www.stoptb.org/GDF/drugsupply/drugs.available.html>.

<sup>10</sup> The International Price Indicator Guide 2002 is a joint publication of MSH and WHO. For more information refer to Annex 4, Websites: Drug Prices.



## 2. Pricing

### 2.1 Context

The prices listed generally apply in the context of bulk procurement i.e. the working unit is one batch. Although batch sizes vary greatly among formulations and manufacturers, the following sizes are typical: capsules and tablets in batches of 100,000 to 500,000 (these are not minimum purchases, batches of over 1 million are not uncommon); vials and bottles in batches of 5,000 to 20,000.

Prices are ex-works (EXW) or free-on-board (FOB). They do not include the added cost of items such as freight, insurance, import duties or taxes. For this reason the prices quoted in this report cannot be compared with consumer prices. Many countries continue to impose considerable import duties and taxes on the price of essential medicines.<sup>11</sup> In addition, wholesale and retail mark-ups vary from one country to the other. As a result, the ex-works price is often less than half of the end-price to the consumer.

Price information and exchange rates are subject to variation, and relate to the date at which the offer was made.

### 2.2 Offers of donation and price reductions

Public pressure, advocacy, competition from generic manufacturers and initiatives from pharmaceutical companies have led to reduced prices of some drugs for developing countries. There is no systematic approach to the differential pricing. Each company determines its own eligibility criteria for countries, sectors and institutions that may benefit from its reduced price. Some companies offer donations of medicines for specific indications such as to prevent mother-to-child transmission of HIV, or to treat certain opportunistic infections affecting PLWAs.

The prices that are quoted in Section 4 of this publication do not necessarily reflect all agreements that may have been negotiated with individual countries. Information on price offers for antiretroviral medicines publicly announced by pharmaceutical manufacturers, including information on countries eligible for the offers and other conditions, can be found in the MSF report "Untangling the web of price reductions: a pricing guide for the purchase of ARVs

for developing countries" included in this publication as Annex VI.

### 2.3 Additional methods of cost reduction

In addition to generic competition and advocacy for the reduced pricing of HIV medicines in line with the purchasing power of countries, important parallel avenues to be pursued by governments include, for example, the active use of compulsory licensing, government use of patents and parallel importation. As agreed by the Member States of the World Trade Organization in 2001, least developed countries (LDCs) are not obliged to enforce pharmaceutical patents until at least 2016.<sup>12</sup> LDCs should make use or avail themselves of this provision to purchase lowest cost medicines on the world market. The Global Fund "encourages recipients to comply with national laws and applicable international obligations in the field of intellectual property including the flexibilities provided in the TRIPS agreement and referred to in the Doha Declaration in a manner that achieves the lowest possible price for products of assured quality."<sup>13</sup> Other measures may include reducing or eliminating import duties and taxes, and increasing demand through pooled procurement.

### 2.4 Information accompanying each medicine

The prices indicated in this report are based on the price data of 1st quarter 2003, unless indicated otherwise.

The following information is provided for each medicine:

- **The number of manufacturers that gave an indicative price**

<sup>11</sup> See *Policy and programming options for reducing the procurement costs of essential medicines in developing countries*, Levinson, L, Boston University School of Public Health, 2003

<sup>12</sup> Doha Declaration on the TRIPS agreement and Public Health, paragraphs 6 & 7

<sup>13</sup> *The Global Fund to Fight AIDS, Tuberculosis and Malaria, Report of the Third Board Meeting*, GF/B4/2, page 25, para 10 (a).

- **The indicative price**

### Unit

The price quoted relates to the unit described, for example, if the unit is “tab” the price quoted is for a single tablet.

### Maximum price

The maximum price listed represents the highest price among products, with no differentiation among original or generic products.

### Minimum price

The minimum price listed represents the lowest price among products, with no differentiation among original or generic products.

### Median price

The median price is the middle price, or where there is an even number of prices listed, it is the mean of the two middle numbers. This means that half the prices quoted are above this median price, and the other half are below it.

### 25th percentile

The value point representing the first quartile of quoted prices in ascending order. It is used to give some indication of the dispersion of prices for a given product.

### No. < than 25th percentile

This is used to indicate how many manufacturers can produce the medicine below the 25th percentile price range.

- **The Brazilian list price**

The Brazilian list price included in this report represents the minimum price payable by Brazilian health institutions for the product and is taken from the Brazilian databank of health purchases. Where the entry reads “none”, this indicates no purchase has been made for that product, therefore no minimum price payable is available.

- **The Spanish list price**

This price is ex-works and has been calculated by applying the new margins (as stated in the Royal Decree 286/2001) to the consumer price as published by Consejo General de Colegios Oficiales de Farmacéuticos in Spain ([www.cof.es](http://www.cof.es)). It should be noted that Spanish list prices are generally considered the lowest in Europe. In most cases, the indicative prices listed in the report are a fraction of the comparative prices in the Spanish list.

## 3. Access to quality HIV/AIDS medicines and diagnostics

### 3.1 Pilot Procurement Quality and Sourcing Project

The Pilot Procurement, Quality and Sourcing Project was started by WHO in collaboration with other United Nations Organizations (UNAIDS Secretariat, UNICEF, and UNFPA, supported by the World Bank) in March 2001, as part of a UN-wide strategy to improve access to HIV-related treatment.

This pilot project evaluates pharmaceutical products according to WHO recommended standards of quality and compliance with Good Manufacturing Practices. It is the beginning of an ongoing process that will expand as participation of suppliers increases. A list of suppliers whose HIV-related medicines have been found acceptable, in principle, for procurement by UN agencies is now available on the web sites of collaborating UN agencies.

As of March 2003, 160 product dossiers for various products and dosage forms from 21 manufacturers were received and 74 of these products, from 11 manufacturers, have been fully reviewed and listed as pre-qualified products. The remaining products are currently under review. The products evaluated include antiretroviral medicines, and medicines for the treatment of opportunistic infections and cancers. A list of products evaluated under this pilot project is regularly updated through the websites of collaborating UN agencies. Interested readers are advised to consult these sites for the latest versions, or to access the list via the WHO website: (<http://www.who.int/medicines/organization/qsm/activities/pilotproc/suppliers.doc>)

The survey on Sources and Prices of Selected Medicines and Diagnostics for People Living with HIV/AIDS is a pricing service, not a prequalification service. Every effort has been made to ensure the accuracy of the price information presented here and screening of the products included in this survey has been carried out as indicated on page 2. This screening, however, in no way constitutes an in depth review of product quality. Products that have been pre-qualified by the **Pilot Procurement, Quality and Sourcing Project** are marked in Annex Ia of this document in bold and with an asterisk (\*). Other products listed in this document should, in relation to purchase, be subject to pre-qualification review as indicated in the WHO

### General Procedure for Prequalification of Suppliers of Pharmaceutical Products.

(Please refer to <http://www.who.int/medicines> for more information.)

### 3.2 Product registration

Annex 1A provides information on countries in which the majority of products listed are currently registered. This information is given as supplied by manufacturing companies, and is subject to change.

### 3.3 Diagnostics

In 1989, WHO established a HIV test kit bulk-procurement scheme, which now is operated in collaboration with other United Nations organizations (UNAIDS Secretariat, UNICEF, UNFPA, and World Bank). The aim is to provide national AIDS programmes, blood transfusion services, large hospitals, non-governmental organizations, reference laboratories, UN agencies, donor-supported AIDS projects, and regulatory authorities in developing countries with high quality tests at the lowest possible cost.

Since 1988, WHO has provided objective assessments of commercially available test kits. This ongoing evaluation programme is coordinated by the Department of Blood Safety and Clinical Technology. All HIV tests available through the scheme have been evaluated by the WHO evaluation programme and meet specific, rigorous criteria (see Annex 2 for further details). Bulk purchase prices for all assays in the scheme are directly negotiated with the manufacturers, a process that enables the scheme to offer a per test cost approximately half that of tests purchased on the open market, which has resulted in substantial cost savings.

The test kits on the list are reviewed annually and cover the three broad categories, including simple/rapid test, ELISA tests and supplemental tests. Annex 3A provides an overview of the assays included in the HIV test kit bulk procurement scheme 2003.

Over recent years there has been an increase in the availability and demand for simple/rapid tests. These are easy-

to-use tests that require little or no equipment and limited training to perform and can provide accurate same-day results. This makes them particularly suitable for use in voluntary counselling and testing (VCT) centres and in antenatal clinics for prevention of mother to child transmission of HIV. When initial tests are reactive for HIV, confirmation of the test results is needed to rule out any false positive results. Information on recommended WHO testing strategies is available in *Weekly Epidemiological Record*, 1997, 72, 81–88.

Increased access to antiretroviral (ARV) medicines has also highlighted the need for appropriate and cost effective diagnostic support. Diagnostic support is essential

to monitor the progression of the disease, the effectiveness of the treatment and the development of resistance. The existing systems for assessment and procurement of HIV test kits is being expanded to include technologies used to monitor ARV therapy (CD4 counts and Viral Load) and drug resistance. An overview of available types of CD4 T-cell enumeration technologies are given in Annex 3A, whilst information on HIV Viral Load technologies and HIV resistance tests is given in Annex 3B. Please note that this information is regularly updated and available on the WHO website at [www.WHO.int/bct](http://www.WHO.int/bct) (follow the links to Key Initiatives, HIV Diagnostics, HIV Test Kit Bulk Procurement Scheme).

## 4. Sources & prices of medicines

Table 1. Anti-infective medicines

Antibacterials beta-lactam medicines	Manufacturer		Indicative prices, US\$						List prices, US\$	
	N° of manuf	N° of countries	unit	max	min	median	25th perc	No < than 25th perc	Brazil	Spain
<b>cefixime</b>										
paediatric oral suspension, 100 mg/ 5 ml	4	3	ml	0.201	0.016	0.028	0.023	1	none	1.422
paediatric oral suspension, 40 mg/ 5 ml	1	1	ml	0.108	0.108	0.108	0.108	1	none	n/a
tablet, 200 mg	4	3	tab	1.213	0.210	0.438	0.334	1	none	0.790
tablet, 400 mg	6	6	tab	0.460	0.064	0.103	0.075	2	none	n/a
<b>ceftriaxone</b>										
powder for injection, 250 mg (as sodium salt) in vial	11	7	vial	2.250	0.600	1.000	0.790	3	1.113	2.274
powder for injection, 1 g (as sodium salt) in vial	3	3	vial	1.820	0.679	1.000	0.839	1	none	n/a
<b>Other antibacterials</b>										
<b>azithromycin</b>										
capsule, 250 mg (dihydrate)	5	3	caps	0.532	0.120	0.200	0.146	2	none	1.251
capsule, 500 mg (dihydrate)	3	2	caps	2.812	0.180	0.300	0.240	1	1.106	3.861
<b>capreomycin</b>										
powder for injection, 1 g in vial	2	2	vial	5.000	5.000	5.000	5.000	1	none	2.361
<b>ciprofloxacin</b>										
tablet, 250 mg (as hydrochloride)	25	12	tab	0.792	0.011	0.047	0.017	3	0.026	0.303
tablet, 500 mg (as hydrochloride)	3	3	tab	0.170	0.024	0.054	0.039	1	none	n/a
<b>clarithromycin</b>										
tablet, 250 mg	12	8	tab	0.700	0.105	0.150	0.137	3	0.504 (as 500 mg)	0.568
<b>clindamycin</b>										
capsule, 150 mg	3	3	caps	0.311	0.036	0.113	0.074	1	0.118	n/a
injection, 150 mg (as phosphate)/ml	2	2	2 ml vial	1.592	0.191	0.891	0.541	1	0.4715 (600 mg/ 4 ml)	n/a
<b>cycloserine</b>										
capsule, 250 mg	2	1	caps	1.500	0.500	1.000	0.750	1	none	n/a

## SOURCES AND PRICES OF SELECTED DRUGS AND DIAGNOSTICS FOR PEOPLE LIVING WITH HIV/AIDS

	Manufacturer		Indicative prices, US\$						List prices, US\$	
	N° of manuf	N° of countries	unit	max	min	median	25th perc	No < than 25th perc	Brazil	Spain
<b>Other antibacterials</b>										
<b>erythromycin</b>										
powder for oral suspension, 125 mg	7	6	ml equivalent	0.018	0.002	0.009	0.006	2	0.006	n/a
tablet, 250 mg (as stearate)	17	8	tab	0.096	0.015	0.032	0.028	6	0.049	0.104
<b>ofloxacin</b>										
IV infusion, 2 mg/ml (hydrochloride)	1	1	ml	0.032	0.032	0.032	0.032	1	none	3.150
tablet, 200 mg	13	8	tab	1.620	0.021	0.040	0.030	4	none	0.718
<b>spectinomycin</b>										
powder for injection, 2 g (as hydrochloride) in vial	1	1	vial	4.000	4.000	4.000	4.000	1	none	2.275
<b>sulfadiazine</b>										
tablet, 500 mg	5	4	tab	0.257	0.022	0.036	0.028	2	0.037	0.054
<b>sulfamethoxazole+</b>										
<b>trimethoprim</b>										
oral suspension, 200+40 mg/5 ml	11	9	ml	0.009	0.001	0.006	0.005	4	none	n/a
tablet, 100+20 mg	10	5	tab	0.024	0.003	0.008	0.005	4	0.010	n/a
tablet, 400+80 mg	20	10	tab	0.035	0.006	0.009	0.008	7	0.010	n/a
tablet, 800+160 mg	2	2	tab	0.100	0.030	0.065	0.048	1	0.010	n/a
<b>Antifilarials</b>										
<b>crotamiton</b>										
cream/lotion 10%	1	1	ml	0.010	0.010	0.010	0.010	1	none	0.573
<b>ivermectin*</b>										
<b>lindane*</b>										
<b>Antifungal medicines</b>										
<b>amphotericine B</b>										
powder for injection, 50 mg in vial	2	2	vial	9.000	4.464	6.732	5.031	1	none	2.339
<b>fluconazole</b>										
capsule, 150 mg	2	2	caps	0.600	0.034	0.317	0.176	1	none	n/a
capsule, 200 mg	7	4	caps	0.600	0.038	0.200	0.126	2	none	6.346
solution for injection, 2mg/ml in 100 ml bottle	3	2	bottle	1.650	0.546	0.820	0.683	1	1.610	n/a
<b>itraconazole</b>										
capsule, 100 mg	3	2	caps	0.960	0.111	0.140	0.126	1	0.256	1.100
<b>ketoconazole</b>										
tablet, 200 mg	12	9	tab	0.150	0.024	0.042	0.037	5	0.041	0.304

\* No price information



#### 4. SOURCES & PRICES OF MEDICINES

	Manufacturer		Indicative prices, US\$						List prices, US\$	
	N° of manuf	N° of countries	unit	max	min	median	25th perc	No < than 25th perc	Brazil	Spain
<b>Antifungal medicines</b>										
<b>miconazole</b>										
cream, 2% in 15 g tube	4	4	tube	0.400	0.120	0.360	0.240	1	0.428	n/a
cream, 2% in 30 g tube	7	5	tube	1.245	0.333	0.560	0.435	2	none	n/a
<b>Anthelmintics</b>										
<b>albendazole</b>										
chewable tablet, 400 mg	9	6	tab	0.200	0.017	0.050	0.041	3	0.033	n/a
<b>Antiprotozoal medicines</b>										
<b>pentamidine</b>										
powder for injection, 300 mg (isetionate) in vial	3	3	vial	48.400	8.599	24.700	16.650	1	none	8.618
<b>pyrimethamine</b>										
tablet, 25 mg	4	3	tab	0.050	0.004	0.014	0.006	1	none	0.068
<b>tinidazole</b>										
tablet, 500 mg	4	3	tab	0.024	0.007	0.012	0.009	1	none	0.474
<b>Antiviral medicines</b>										
<b>aciclovir</b>										
powder for injection, 250 mg (as sodium salt) in vial	4	4	vial	14.286	1.650	2.487	1.913	1	1.246	4.873
tablet, 200 mg	14	10	tab	0.435	0.034	0.065	0.042	4	0.034	0.616
tablet, 400 mg	8	6	tab	0.500	0.008	0.069	0.060	4	0.093	n/a
tablet, 800 mg	9	6	tab	1.020	0.098	0.370	0.158	3	none	2.045
<b>cidofovir*</b>										
<b>fanciclovir*</b>										
<b>foscarnet sodium*</b>										
<b>ganciclovir</b>										
powder for injection, 500 mg in vial	1	1	vial	42.52	42.52	42.52	42.52	1	9.263	21.478
<b>imiquimod*</b>										
<b>podofilox*</b>										
<b>valacyclovir*</b>										
<b>valganciclovir*</b>										
<b>Antiretroviral medicines</b>										
<b>abacavir (ABC)</b>										
oral solution, 20 mg/ml	1	1	ml	0.145	0.145	0.145	0.145	1	0.156	n/a
tablet, 300 mg	1	1	tab	1.350	1.350	1.350	1.350	1	2.044	n/a

\* No price information

## SOURCES AND PRICES OF SELECTED DRUGS AND DIAGNOSTICS FOR PEOPLE LIVING WITH HIV/AIDS

	Manufacturer		Indicative prices, US\$						List prices, US\$	
	N° of manuf	N° of countries	unit	max	min	median	25th perc	No < than 25th perc	Brazil	Spain
<b>Antiretroviral medicines</b>										
<b>amprenavir (APV)*</b>										
<b>didanosine (ddI)</b>										
powder for syrup, 2 g	1	1	bottle	—	—	—	—	—	none	23.160
tablet, 25 mg	4	3	tab	0.130	0.058	0.081	0.059	2	none	0.252
tablet, 100 mg	6	5	tab	1.875	0.175	0.315	0.212	2	0.385	1.289
<b>efavirenz (EFZ)</b>										
capsule, 200 mg	6	3	caps	2.001	0.430	0.493	0.452	1	0.846	3.299
capsule, 600 mg	1	1	caps	0.950	0.950	0.950	0.950	1	none	n/a
<b>indinavir (IDV)</b>										
capsule, 400 mg	7	5	caps	1.058	0.274	0.320	0.317	2	none	1.67
<b>lamivudine (3TC)</b>										
oral solution, 50 mg/5 ml	1	1	bottle	5.070	5.070	5.070	5.070	1	10.181	n/a
tablet, 150 mg	8	5	tab	1.531	0.119	0.184	0.161	3	0.288	2.701
<b>nelfinavir (NFV)</b>										
capsule, 250 mg	4	4	caps	0.921	0.252	0.436	0.376	1	0.723	1.255
<b>nevirapine (NVP)</b>										
tablet, 200 mg	8	6	tab	1.984	0.208	0.247	0.222	3	none	3.822
suspension, 50 mg/5 ml	2	2	ml	0.025	0.014	0.019	0.017	1	none	0.194
<b>ritonavir (RTV)*</b>										
<b>saquinavir (SQV)</b>										
capsule, 200 mg	2	2	caps	0.483	0.265	0.374	0.319	1	none	1.147
<b>stavudine (d4T)</b>										
powder for syrup, 1 mg/ml	2	2	ml	0.013	0.011	0.012	0.011	1	none	0.144
capsule, 40 mg	10	7	caps	2.101	0.064	0.102	0.084	3	none	3.184
<b>zalcitabine (ddC)</b>										
tablet, 0.75 mg	2	2	tab	0.865	0.046	0.456	0.251	1	none	1.517
<b>zidovudine (AZT or ZDV)</b>										
capsule, 100 mg	13	8	caps	1.000	0.078	0.132	0.098	4	0.132	0.787
capsule, 250 mg	7	6	caps	1.450	0.255	0.430	0.363	2	none	1.921
capsule, 300 mg	6	4	caps	0.600	0.246	0.326	0.255	2	none	2.497
injection, 10 mg/ml in 20 ml vial	2	2	vial	9.330	2.140	5.735	3.938	1	none	n/a
oral solution, 50 mg/5 ml	5	4	ml	0.062	0.016	0.023	0.019	1	none	0.073

\* No price information

#### 4. SOURCES & PRICES OF MEDICINES

	Manufacturer		Indicative prices, US\$						List prices, US\$	
	N° of manuf	N° of countries	unit	max	min	median	25th perc	No < than 25th perc	Brazil	Spain
<b>Antiretroviral – combinations</b>										
<b>3TC/AZT</b>										
tablet, 150/300 mg	7	5	tab	2.951	0.063	0.433	0.362	1	0.564	5.558
<b>lopinavir (LPV)/RTV*</b>										
<b>3TC/ABC/ZDV</b>										
<b>3TC/D4T/NVP</b>										
tablet, 150/40/200 mg	3	2	tab	0.496	0.400	0.417	0.408	1	none	n/a

**Table 2. Antineoplastic medicines**

	Manufacturer		Indicative prices, US\$						List prices, US\$	
	N° of manuf	N° of countries	unit	max	min	median	25th perc	No < than 25th perc	Brazil	Spain
<b>Cytotoxic medicines</b>										
<b>bleomycin</b>										
powder for injection, 15 mg (as sulphate) in vial	3	3	vial	25.000	18.000	21.000	19.500	1	17.433	13.617
<b>calcium folinate (leucovorin)</b>										
tablet, 15 mg	4	4	tab	3.012	0.015	1.447	0.254	1	none	n/a
<b>doxorubicine HCl</b>										
powder for injection, 10 mg in vial	4	4	vial	20.438	3.000	7.035	4.125	1	2.896	6.456
powder for injection, 50 mg in vial	4	4	vial	95.737	14.000	30.075	18.500	1	10.930	30.817
liposomal, conc for IV infusion, 2mg/ml in vial1 *	—	—	vial	—	—	—	—	—	none	424.689
<b>etoposide</b>										
capsule, 100 mg	1	1	caps	2.000	2.000	2.000	2.000	1	none	11.590
injection, 20 mg/ ml in 5 ml ampoule	5	4	amp	25.000	5.000	8.000	5.000	2	2.659	7.772
<b>methotrexate</b>										
powder for injection, 50 mg (as sodium salt) in vial	4	4	vial	4.310	1.500	2.680	1.875	1	1.535	3.514
tablet, 2.5 mg	2	2	tab	0.188	0.080	0.134	0.107	1	0.109	0.048
<b>vinblastine</b>										
powder for injection, 10 mg (sulphate) in vial	3	3	vial	14.260	1.400	8.000	4.700	1	6.772	n/a
<b>vincristine</b>										
powder for injection, 1 mg (sulphate) in vial	4	3	vial	6.000	1.500	2.440	1.725	1	1.946	n/a
<b>vinorelbine</b>										
inj conc 10mg/ml in 1 ml vial	2	2	vial	38.000	16.480	27.240	21.860	1	none	18.434

\* No price information

Table 3. Psychotherapeutic medicines

	Manufacturer		Indicative prices, US\$						List prices, US\$	
	N° of manuf	N° of countries	unit	max	min	median	25th perc	No < than 25th perc	Brazil	Spain
<b>Medicines used in depressive disorders</b>										
<b>amitriptyline</b>										
tablet, 25 mg	4	3	tab	0.012	0.004	0.006	0.004	1	0.007	0.021
<b>fluoxetine</b>										
capsule, 20 mg	9	6	caps	0.150	0.019	0.056	0.021	3	0.039	0.298
<b>Medicines used in generalized anxiety and sleep disorders</b>										
<b>lorazepam</b>										
tablet, 1 mg	3	2	tab	0.325	0.012	0.019	0.015	1	0.100	0.016
<b>methotrimprazine/ levomepromazine*</b>										

Table 4. Analgesics

	Manufacturer		Indicative prices, US\$						List prices, US\$	
	N° of manuf	N° of countries	unit	max	min	median	25th perc	No < than 25th perc	Brazil	Spain
<b>Opioid analgesics</b>										
<b>codeine</b>										
tablet, 30 mg	5	4	tab	0.060	0.020	0.030	0.030	2	0.237	0.102
<b>morphine</b>										
injection, 10 mg (hydrochloride) in 1 ml ampoule	1	1	amp	0.2861	0.2861	0.2861	0.2861	1	none	n/a
oral solution (sulphate), 10 mg/5 ml in 100 ml bottle	1	1	bottle	2.7416	2.7416	2.7416	2.7416	1	none	n/a
<b>pethidine</b>										
inj, 50 mg (hydrochloride)/ml in 2-ml ampoule	4	4	amp	0.390	0.332	0.352	0.346	1	0.279	n/a
tablet, 50 mg	1	1	tab	0.130	0.130	0.130	0.130	1	none	n/a
<b>Medicines used in the treatment of opioid dependence</b>										
<b>buprenorphine*</b>										
sublingual tablet, 0.2 mg (hydrochloride)	1	1	tab	0.070	0.070	0.070	0.070	1	0.150	0.319
<b>naltrexone HCl</b>										
tablet, 50 mg	3	3	tab	1.434	1.000	1.100	1.050	1	none	2.319


\* No price information

Table 5. Gastrointestinal medicines

	Manufacturer		Indicative prices, US\$						List prices, US\$	
	N° of manuf	N° of countries	unit	max	min	median	25th perc	No < than 25th perc	Brazil	Spain
<b>Antacids and other antiulcer medicines</b>										
<b>omeprazole</b>										
capsule, 10 mg	4	2	caps	0.093	0.009	0.036	0.018	2	none	n/a
capsule, 20 mg	10	6	caps	0.216	0.013	0.099	0.030	4	0.026	0.152
capsule, 40 mg	3	3	caps	0.045	0.025	0.035	0.030	1	none	n/a
powder for injection, 40 mg in vial (as sodium salt)	1	1	vial	3.000	3.000	3.000	3.000	1	0.945	n/a
powder for IV infusion, 40 mg vial (sodium salt)	2	2	vial	3.000	1.950	2.475	2.213	1	none	n/a
<b>Antiemetic medicines</b>										
<b>dimenhydrinate</b>										
tablet, 50 mg	5	5	tab	0.056	0.004	0.032	0.029	2	none	0.104
<b>metoclopramide</b>										
injection 5 mg/ml in 2 ml ampoule	3	3	amp	0.133	0.055	0.084	0.070	1	0.045	n/a
tablet, 10 mg (as hydrochloride)	9	7	tab	0.033	0.002	0.008	0.008	5	0.003	0.016
<b>prochlorperazine</b>										
injection, 12.5 mg/ml	1	1	vial	1.763	1.763	1.763	1.763	1	none	n/a
tablet, 5 mg	3	3	tab	0.011	0.006	0.007	0.006	1	none	n/a
<b>Laxatives</b>										
<b>docusate sodium</b>										
capsule, 100 mg	1	1	caps	0.013	0.013	0.013	0.013	1	none	n/a

## 5. Variation in price between surveys

Figure 1. Variation in the maximum price quoted for ciprofloxacin and fluconazole between the 1st (2000) 2nd (2001) 3rd (2002) and 4th (2003) surveys



There is a considerable decrease in the price of fluconazole between surveys, as shown in Figure 1 above, whereas ciprofloxacin has only shown a very slight decrease in price.

Table 6. Variation in the price of ciprofloxacin and fluconazole

ciprofloxacin, tab, 250 mg	max	min	med	25th perc	no <25th perc
1st Survey	1.20	0.02	0.13	0.05	3
2nd Survey	0.95	0.02	0.10	0.04	5
3rd Survey	0.64	0.01	0.10	0.03	6
4th Survey	0.79	0.01	0.05	0.02	3
fluconazole, caps, 200 mg	max	min	med	25th perc	no <25th perc
1st Survey	15.24	8.42	14.10	11.26	1
2nd Survey	7.25	0.20	0.36	0.24	2
3rd Survey	1.25	0.20	0.39	0.27	2
4th Survey	0.60	0.04	0.20	0.13	2



## ANNEX 1A

# Registration status of products included in the sources and prices survey

(Listed in alphabetical order of International Non-proprietary Name (INN). n/a indicates data not available at the time of publication. Products marked in bold and with an asterisk (\*) are on the list of pre-qualified products, see section 3.)

International Non-Proprietary Name (INN)	Dosage form & strength	Manufacturer	Country	National Registration	Registration in other countries
aciclovir	powder for injection, 250 mg (as sodium salt)	Combino Pharm, S.L.	Spain	Yes	n/a
aciclovir	powder for injection, 250 mg (as sodium salt)	Lab. Filaxis International S.A.	Argentina	Yes	Mexico, Brazil, Costa Rica
aciclovir	powder for injection, 250 mg (as sodium salt)	Neon Antibiotics PVT. Ltd.	India	Yes	Ukraine, Sri Lanka in process
aciclovir	powder for injection, 250 mg (as sodium salt)	Samchully Pharm. Co., Ltd.	Korea, Republic of	Yes	Singapore, Vietnam
aciclovir	tablet, 200 mg	Alpharma	Indonesia	Yes	Denmark, UK, Netherlands, Norway, Spain, Saudi Arabia, United Arab Emirates
aciclovir	tablet, 200 mg	Apotex Protein, S.A. de C.V.	Mexico	Yes	Panama
aciclovir	tablet, 200 mg	Cipla Ltd.	India	Yes	Latvia
aciclovir	tablet, 200 mg	Genepharma SA	Greece	Yes	Cyprus
aciclovir	tablet, 200 mg	Sdn Bhd	Malaysia	Yes	Singapore, Hong Kong, Sri Lanka, Myanmar, Cambodia
aciclovir	tablet, 200 mg	IPCA Laboratories Limited	India	Yes	n/a
aciclovir	tablet, 200 mg	Korea United Pharm. Inc.	Korea, Republic of	Yes	n/a
aciclovir	tablet, 200 mg	Lab. Filaxis International S.A.	Argentina	Yes	n/a
aciclovir	tablet, 200 mg	Lomapharm	Germany	Yes	n/a
<b>*aciclovir</b>	tablet, 200 mg	Ranbaxy Laboratories Ltd	India	Yes	Algeria, Australia, Belarus, Brazil, Cameroon, China, Costa Rica, Czech Republic, Denmark, Dominican Republic, El Salvador, Finland, Ghana, Hong Kong, Iraq, Ireland, Ivory Coast, Jamaica, Kazakhstan, Kenya, Malawi, Malaysia, Mali, Moldova, Nepal, Netherlands, New Zealand, Nigeria, Norway, Panama, Poland, Romania, Russia, Singapore, South Africa, Sweden, Tanzania, Thailand, Uganda, UK, Ukraine, USA, Vietnam, Zimbabwe
aciclovir	tablet, 200 mg	Remedica Ltd.	Cyprus	Yes	Hong Kong, Kenya, Malawi, Myanmar, Singapore, Jordan
aciclovir	tablet, 200 mg	Samchully Pharm. Co., Ltd.	Korea, Republic of	Yes	Tanzania
aciclovir	tablet, 200 mg	Sanofi-Synthelabo Vietnam	Viet Nam	Yes	n/a
aciclovir	tablet, 200 mg	Sdn Bhd	Malaysia	Yes	Myanmar, Cambodia, Mauritius
aciclovir	tablet, 400 mg	Cipla Ltd.	India	Yes	Latvia
aciclovir	tablet, 400 mg	Ecobi Farmaceutici S.a.s.	Italy	Yes	Albania

SOURCES AND PRICES OF SELECTED DRUGS AND DIAGNOSTICS FOR PEOPLE LIVING WITH HIV/AIDS

International Non-Proprietary Name (INN)	Dosage form & strength	Manufacturer	Country	National Registration	Registration in other countries
aciclovir	tablet, 400 mg	Far Manguinhos	Brazil	Yes	n/a
aciclovir	tablet, 400 mg	Sdn Bhd	Malaysia	Yes	Singapore, Hong Kong, Sri Lanka, Myanmar, Cambodia, Yemen
aciclovir	tablet, 400 mg	IPCA Laboratories Limited	India	Yes	n/a
aciclovir	tablet, 400 mg	Korea United Pharm. Inc.	Korea, Republic of	Yes	n/a
<b>*aciclovir</b>	tablet, 400 mg	Ranbaxy Laboratories Ltd	India	Yes	Australia, Belarus, Brazil, Cameroon, Costa Rica, Czech Republic, Denmark, Dominican Republic, Egypt, Finland, Ivory Coast, Jamaica, Kazakhstan, Kenya, Malawi, Malaysia, Moldova, Myanmar, Netherlands, New Zealand, Norway, Panama, Poland, Romania, Russia, Singapore, South Africa, Sweden, Tanzania, Thailand, Uganda, UK, USA, Uzbekistan, Vietnam, Peru, Hong Kong
aciclovir	tablet, 400 mg	Remedica Ltd.	Cyprus	Yes	Zimbabwe, Hong Kong
aciclovir	tablet, 800 mg	Cipla Ltd.	India	Yes	n/a
aciclovir	tablet, 800 mg	Combino Pharm, S.L.	Spain	Yes	n/a
aciclovir	tablet, 800 mg	Ecobi Farmaceutici S.a.s.	Italy	Yes	Albania
aciclovir	tablet, 800 mg	IPCA Laboratories Limited	India	Yes	n/a
aciclovir	tablet, 800 mg	Korea United Pharm. Inc.	Korea, Republic of	Yes	n/a
aciclovir	tablet, 800 mg	Lab. Filaxis International S.A.	Argentina	Yes	n/a
aciclovir	tablet, 800 mg	Laboratorios Cinfa S.A.	Spain	Yes	n/a
<b>*aciclovir</b>	tablet, 800 mg	Ranbaxy Laboratories Ltd	India	Yes	Australia, Belarus, Brazil, Cameroon, Costa Rica, Czech Republic, Denmark, Finland, Ivory Coast, Kazakhstan, Malaysia, Moldova, Netherlands, New Zealand, Norway, Poland, Romania, Russia, Singapore, South Africa, Sweden, Thailand, UK, Ukraine, USA, Uzbekistan, Vietnam, El Salvador, Peru, Hong Kong
aciclovir	tablet, 800 mg	Remedica Ltd.	Cyprus	Yes	Guyana, Jordan
albendazole	chewable tablet, 400 mg	Artesan Pharma GmbH & Co.	Germany	No	n/a
albendazole	chewable tablet, 400 mg	Beltapharm SpA	Italy		Tanzania, Panama, Honduras, Guatemala
albendazole	chewable tablet, 400 mg	Gracure Pharmaceuticals Ltd.	India	Yes	n/a
albendazole	chewable tablet, 400 mg	Korea United Pharm. Inc.	Korea, Republic of	Yes	n/a
albendazole	chewable tablet, 400 mg	Lyka Labs Limited	India	Yes	n/a
albendazole	chewable tablet, 400 mg	Pharmadrug	Germany	No	n/a
albendazole	chewable tablet, 400 mg	Remedica Ltd.	Cyprus	No	Netherlands
albendazole	chewable tablet, 400 mg	Shiba Pharmaceuticals & Chemicals Ltd.	Yemen, Republic of	Yes	In process for: United Arab Emirates, Eritrea, Ethiopia, Iraq, Sudan, Tanzania
albendazole	chewable tablet, 400 mg	Strides Arcolab Limited	India	No	Vietnam
amitriptyline	tablet, 25 mg	Gracure Pharmaceuticals Ltd.	India	Yes	n/a
amitriptyline	tablet, 25 mg	Intas Pharmaceuticals Ltd	India		Tanzania, Mauritius, Sri Lanka, Peru, Malaysia, Uganda, Jamaica
amitriptyline	tablet, 25 mg	Pharmadrug	Germany	No	n/a
amitriptyline	tablet, 25 mg	Remedica Ltd.	Cyprus	Yes	Malawi

ANNEX 1A. REGISTRATION STATUS OF PRODUCTS INCLUDED IN THE SOURCES AND PRICES SURVEY

International Non-Proprietary Name (INN)	Dosage form & strength	Manufacturer	Country	National Registration	Registration in other countries
amphotericin B	powder for injection, 50 mg in vial	Combino Pharm, S.L.	Spain	Yes	n/a
amphotericin B	powder for injection, 50 mg in vial	Neon Antibiotics PVT. Ltd.	India	Yes	Sri Lanka in process
azithromycin	capsule, 250 mg (dihydrate)	Aleppo Pharmaceutical Industries (Alpha)	Syria	Yes	Lebanon, Yemen, Sudan, Iraq, Algeria
azithromycin	capsule, 250 mg (dihydrate)	Aurobindo Pharma Ltd.	India	Yes	n/a
azithromycin	capsule, 250 mg (dihydrate)	Lyka Labs Limited	India	Yes	Vietnam, Cambodia, DR Congo
azithromycin	capsule, 250 mg (dihydrate)	Shiba Pharmaceuticals & Chemicals Ltd.	Yemen, Republic of	Yes	In process for: United Arab Emirates, Eritrea, Ethiopia, Iraq, Sudan, Tanzania
azithromycin	capsule, 250 mg (dihydrate)	Strides Arcolab Limited	India	No	n/a
azithromycin	capsule, 500 mg (dihydrate)	Aurobindo Pharma Ltd.	India	Yes	n/a
azithromycin	capsule, 500 mg (dihydrate)	Lyka Labs Limited	India	Yes	n/a
azithromycin	tablet, 500 mg (dihydrate)	Tecnimed Sociedade Tecnico Medicinal, S.A.	Portugal	Yes	n/a
bleomycin	powder for injection, 15 mg (as sulfate) in vial	Aventis Pharma	France	Yes	Algeria, Belgium, France, Ivory Coast, Madagascar, Morocco, Romania, Tunisia
bleomycin	powder for injection, 15 mg (as sulfate) in vial	Korea United Pharm. Inc.	Korea, Republic of	Yes	n/a
bleomycin	powder for injection, 15 mg (as sulfate) in vial	Neon Antibiotics PVT. Ltd.	India	Yes	n/a
buprenorphine	sublingual tablet, 0.2 mg (hydrochloride)	ICN Hungary Co. Ltd.	Hungary	Yes	n/a
calcium folinate (leucovorin)	tablet, 15 mg	Ecobi Farmaceutici S.a.s.	Italy	Yes	Albania
calcium folinate (leucovorin)	tablet, 15 mg	Korea United Pharm. Inc.	Korea, Republic of	Yes	n/a
calcium folinate (leucovorin)	tablet, 15 mg	Lab. Filaxis International S.A.	Argentina	Yes	Uruguay, Mexico, Brazil
calcium folinate (leucovorin)	tablet, 15 mg	Medac GmbH, International Operations	Germany	Yes	China
capreomycin	powder for injection, 1 g in vial	Cheil Jedang Corp.	Korea, Republic of	Yes	Russia
capreomycin	powder for injection, 1 g in vial	Neon Antibiotics PVT. Ltd.	India	Yes	n/a
cefixime	paediatric oral suspension, 100 mg/5 ml	Aurobindo Pharma Ltd.	India	Yes	n/a
cefixime	paediatric oral suspension, 100 mg/5 ml	Aventis Pharma	France	Yes	Algeria, Burkina Faso, Benin, Cameroon, Central African Republic, DR Congo, France, Gabon, Guinea, Haiti, Ireland, Ivory Coast, Morocco, Madagascar, Mali, Mauritania, Mauritius, Niger, Senegal, Togo, Tunisia, UK
cefixime	paediatric oral suspension, 100 mg/5 ml	Bilim Pharmaceutical Ind.	Turkey	Yes	n/a
cefixime	paediatric oral suspension, 100 mg/5 ml	Lyka Labs Limited	India	Yes	n/a
cefixime	paediatric oral suspension, 40 mg/ 5 ml	Aventis Pharma	France	Yes	Algeria, Cameroon, Congo, France, Gabon, Guinea, Ivory Coast, Morocco, Madagascar, Mali, Mauritania, Mauritius, Niger, Senegal, Chad, Tunisia
cefixime	tablet, 200 mg	Aurobindo Pharma Ltd.	India	Yes	n/a
cefixime	tablet, 200 mg	Aventis Pharma	France	Yes	Algeria, Burkina Faso, Benin, Cameroon, Central African Republic, Congo, France, Gabon, Guinea, Haiti, Ireland, Ivory Coast, Morocco, Madagascar, Mali, Mauritania, Mauritius, Niger, Senegal, Togo, Tunisia, UK

## SOURCES AND PRICES OF SELECTED DRUGS AND DIAGNOSTICS FOR PEOPLE LIVING WITH HIV/AIDS

International Non-Proprietary Name (INN)	Dosage form & strength	Manufacturer	Country	National Registration	Registration in other countries
cefixime	tablet, 200 mg	Korea United Pharm. Inc.	Korea, Republic of	Yes	n/a
cefixime	tablet, 200 mg	Lyka Labs Ltd	India	Yes	Vietnam in process
cefixime	tablet, 400 mg	Alpharma	Indonesia	Yes	Denmark, UK, Netherlands, Norway, Spain, Saudi Arabia, United Arab Emirates
cefixime	tablet, 400 mg	Bilim Pharmaceutical Ind.	Turkey	Yes	n/a
cefixime	tablet, 400 mg	Genepharm SA	Greece	Yes	Cyprus
cefixime	tablet, 400 mg	Lomapharm	Germany		n/a
cefixime	tablet, 400 mg	Samchully Pharm. Co., Ltd.	Korea, Republic of	Yes	Vietnam
cefixime	tablet, 400 mg	Sdn Bhd	Malaysia	Yes	Myanmar, Cambodia
ceftriaxone	powder for injection, 1 g (as sodium salt) in vial	Neon Laboratories Ltd	India	Yes	n/a
ceftriaxone	powder for injection, 1 g (as sodium salt) in vial	Panpharma	France	Yes	n/a
ceftriaxone	powder for injection, 1 g (as sodium salt) in vial	Rekah Pharmaceutical Group	Israel	Yes	n/a
ceftriaxone	powder for injection, 250 mg (as sodium salt) in vial	Aleppo Pharmaceutical Industries (Alpha)	Syria	Yes	Lebanon, Yemen, Sudan, Iraq, Algeria
ceftriaxone	powder for injection, 250 mg (as sodium salt) in vial	Aventis Limited	Bangladesh	Yes	Sri Lanka
ceftriaxone	powder for injection, 250 mg (as sodium salt) in vial	Cheil Jedang Corp.	Korea, Republic of	Yes	Japan, Singapore, United Arab Emirates, Vietnam, Cambodia, Nicaragua, Honduras, Venezuela
ceftriaxone	powder for injection, 250 mg (as sodium salt) in vial	Combino Pharm, S.L.	Spain	Yes	n/a
ceftriaxone	powder for injection, 250 mg (as sodium salt) in vial	Demo S.A.	Greece	Yes	Yemen, Yugoslavia, Jordan
ceftriaxone	powder for injection, 250 mg (as sodium salt) in vial	Korea United Pharm. Inc.	Korea, Republic of	Yes	n/a
ceftriaxone	powder for injection, 250 mg (as sodium salt) in vial	Lupin Laboratories Ltd.	India	Yes	Bulgaria, China, Czech Republic, Ethiopia, Kenya, Romania, Russia, Slovakia
ceftriaxone	powder for injection, 250 mg (as sodium salt) in vial	Lyka Labs Limited	India	Yes	Philippines, Vietnam, Cambodia, DR Congo, Russia, Sudan, Sri Lanka
ceftriaxone	powder for injection, 250 mg (as sodium salt) in vial	Mepha Ltd	Switzerland	No	Benin, Brazil, Burkina Faso, Congo, El Salvador, Gabon, Guatemala, China, Ivory Coast, Kenya, Kuwait, Lithuania, Malaysia, Mali, Niger, Portugal, Senegal, Sudan, Tanzania, Togo, Turkmenistan
ceftriaxone	powder for injection, 250 mg (as sodium salt) in vial	Ranbaxy Laboratories Ltd	India	Yes	Bahrain, Belarus, Botswana, Cameroon, Chad, China, Congo, Gabon, Georgia, Guinea, Iraq, Ivory Coast, Kazakhstan, Kenya, Lithuania, Madagascar, Malawi, Mauritania, Mauritius, Myanmar, Nigeria, Oman, Russia, Singapore, Sri Lanka, Tanzania, Thailand, Trinidad & Tobago, Ukraine, Uzbekistan, Zimbabwe
ceftriaxone	powder for injection, 250 mg (as sodium salt) in vial	Strides Arcolab Limited	India	No	n/a
ciprofloxacin	tablet, 250 mg (as hydrochloride)	Alpharma	Indonesia	Yes	UK, Netherlands, Germany, Austria, Norway, Finland, Denmark, Portugal, Sweden, Malaysia, Philippines
ciprofloxacin	tablet, 250 mg (as hydrochloride)	Apotex Protein, S.A. de C.V.	Mexico	Yes	Panama, Nicaragua
ciprofloxacin	tablet, 250 mg (as hydrochloride)	Aurobindo Pharma Ltd.	India	Yes	Zambia, Malawi, Myanmar

ANNEX 1A. REGISTRATION STATUS OF PRODUCTS INCLUDED IN THE SOURCES AND PRICES SURVEY

International Non-Proprietary Name (INN)	Dosage form & strength	Manufacturer	Country	National Registration	Registration in other countries
ciprofloxacin	tablet, 250 mg (as hydrochloride)	Aventis Limited	Bangladesh	Yes	n/a
ciprofloxacin	tablet, 250 mg (as hydrochloride)	Bayer AG	Germany	Yes	n/a
<b>*ciprofloxacin</b>	tablet, 250 mg (as hydrochloride)	Cipla Ltd.	India	Yes	Myanmar, Russia, Yemen, Ghana, Sudan, Zambia, Belarus, Iraq, Sri Lanka, Armenia, Hong Kong, Kenya
ciprofloxacin	tablet, 250 mg (as hydrochloride)	Demo S.A.	Greece	Yes	n/a
ciprofloxacin	tablet, 250 mg (as hydrochloride)	Fourrts Laboratories Pvt. Ltd.	India	Yes	Sri Lanka
ciprofloxacin	tablet, 250 mg (as hydrochloride)	Genepharm SA	Greece	Yes	Romania
ciprofloxacin	tablet, 250 mg (as hydrochloride)	Glenmark Pharmaceuticals Ltd	India	Yes	n/a
ciprofloxacin	tablet, 250 mg (as hydrochloride)	Gracure Pharmaceuticals Ltd.	India	Yes	Kenya, Mali, Burma, Nepal
ciprofloxacin	tablet, 250 mg (as hydrochloride)	Intas Pharmaceuticals Ltd	India	Yes	Armenia, Belarus, Cambodia, Ethiopia, Georgia, Ghana, Hong Kong, Singapore, Sri Lanka, Uganda, Vietnam, Zimbabwe, Malaysia, Peru, Zambia
ciprofloxacin	tablet, 250 mg (as hydrochloride)	IPCA Laboratories Limited	India	Yes	Ethiopia, Kenya, Tanzania, UK, South Africa
ciprofloxacin	tablet, 250 mg (as hydrochloride)	IVAX Pharmaceuticals Mexico, S.A. de C.V.	Mexico	Yes	Costa Rica, El Salvador, Honduras, Nicaragua, Haiti, Dominican Republic, Guatemala, Chile
ciprofloxacin	tablet, 250 mg (as hydrochloride)	Korea United Pharm. Inc.	Korea, Republic of	Yes	n/a
ciprofloxacin	tablet, 250 mg (as hydrochloride)	Laboratorios Cinfa S.A.	Spain	Yes	Venezuela, Dominican Republic
ciprofloxacin	tablet, 250 mg (as hydrochloride)	Lupin Laboratories Ltd.	India	Yes	Bulgaria, China, Czech Republic, Ethiopia, Kenya, Romania, Russia, Slovakia
ciprofloxacin	tablet, 250 mg (as hydrochloride)	Lyka Labs Limited	India	Yes	Cambodia, Myanmar, Russia, DR Congo, Sri Lanka, Chile, Peru
ciprofloxacin	tablet, 250 mg (as hydrochloride)	Mepha Ltd	Switzerland	No	Benin, Brazil, Burkina Faso, Congo, El Salvador, Gabon, Guatemala, China, Ivory Coast, Kenya, Kuwait, Lithuania, Malaysia, Mali, Niger, Portugal, Senegal, Sudan, Tanzania, Togo, Turkmenistan
<b>*ciprofloxacin</b>	tablet, 250 mg (as hydrochloride)	Ranbaxy Laboratories Ltd	India	Yes	Austria, Bahrain, Belarus, Belgium, Brazil, Cambodia, Cameroon, China, Congo, Costa Rica, Czech Republic, Denmark, Egypt, Finland, Georgia, Germany, Guatemala, Hungary, Iraq, Jamaica, Kazakhstan, Kenya, Kyrgyzstan, PDR Lao, Latvia, Lithuania, Luxembourg, Madagascar, Malawi, Mali, Mauritius, Mexico, Moldova, Myanmar, Nigeria, Oman, Peru, Poland, Portugal, Romania, Russia, South Africa, Spain, Sri Lanka, Sweden, Tanzania, Thailand, Trinidad & Tobago, Uganda, UK, Ukraine, USA, Uzbekistan, Vietnam, Yemen, Zimbabwe
ciprofloxacin	tablet, 250 mg (as hydrochloride)	Remedica Ltd.	Cyprus	Yes	Myanmar, Pakistan
ciprofloxacin	tablet, 250 mg (as hydrochloride)	Samchully Pharm. Co., Ltd.	Korea, Republic of	yes	Vietnam, Tanzania
ciprofloxacin	tablet, 250 mg (as hydrochloride)	Shiba Pharmaceuticals & Chemicals Ltd.	Yemen, Republic of	Yes	United Arab Emirates, Eritrea, Ethiopia, Iraq, Sudan, Tanzania in process

SOURCES AND PRICES OF SELECTED DRUGS AND DIAGNOSTICS FOR PEOPLE LIVING WITH HIV/AIDS

International Non-Proprietary Name (INN)	Dosage form & strength	Manufacturer	Country	National Registration	Registration in other countries
ciprofloxacin	tablet, 250 mg (as hydrochloride)	Strides Arcolab Limited	India	No	Brazil
ciprofloxacin	tablet, 250 mg (as hydrochloride)	Tecnimede Sociedade Tecnico Medicinal, S.A.	Portugal	Yes	n/a
ciprofloxacin	tablet, 500 mg (as hydrochloride)	Aleppo Pharmaceutical Industries (Alpha)	Syria	Yes	Lebanon, Yemen, Sudan, Iraq, Algeria
ciprofloxacin	tablet, 500 mg (as hydrochloride)	Apotex Protein, S.A. de C.V.	Mexico	Yes	Panama, Nicaragua
ciprofloxacin	tablet, 500 mg (as hydrochloride)	Glenmark Pharmaceuticals Ltd	India	Yes	n/a
clarithromycin	tablet, 250 mg	Alpharma	Indonesia	Yes	UK, Netherlands, Germany, Austria, Norway, Finland, Denmark, Portugal, Sweden, Malaysia, Philippines
clarithromycin	tablet, 250 mg	Aurobindo Pharma Ltd.	India	Yes	Cambodia, Vietnam
clarithromycin	tablet, 250 mg	Bilim Pharmaceutical Ind.	Turkey	Yes	Azerbaijan, Cambodia, Ethiopia, Hong Kong, Macedonia, Malta, Mongolia, Moldova, Venezuela, Yemen, Dominican Republic, Kenya, Lithuania, Morocco, Romania
clarithromycin	tablet, 250 mg	Genepharm SA	Greece	Yes	n/a
clarithromycin	tablet, 250 mg	Intas Pharmaceuticals Ltd	India	Yes	Cambodia, Georgia, Hong Kong, Singapore, Kenya, Malaysia, Peru, Thailand, Paraguay, Kenya, Sri Lanka, Myanmar, Sudan, Vietnam, Mauritius
clarithromycin	tablet, 250 mg	IVAX Pharmaceuticals Mexico, S.A. de C.V.	Mexico	Yes	Costa Rica, El Salvador, Honduras, Nicaragua, Haiti, Dominican Republic, Guatemala, Chile
clarithromycin	tablet, 250 mg	Korea United Pharm. Inc.	Korea, Republic of	Yes	n/a
clarithromycin	tablet, 250 mg	Lyka Labs Limited	India	Yes	Vietnam, Cambodia, Myanmar, Sri Lanka, Romania
clarithromycin	tablet, 250 mg	Ranbaxy Laboratories Ltd	India	Yes	Brazil, Chile, Costa Rica, Dominican Republic, Jamaica, Myanmar, Russia, Tanzania, Trinidad & Tobago, Ukraine, Vietnam
clarithromycin	tablet, 250 mg	Remedica Ltd.	Cyprus	Yes	n/a
clarithromycin	tablet, 250 mg	Strides Arcolab Limited	India	No	Brazil
clarithromycin	tablet, 250 mg	The Government Pharmaceutical Organization	Thailand	Exempt	n/a
clindamycin	capsule, 150 mg	Bilim Pharmaceutical Ind.	Turkey	Yes	Mongolia, Ethiopia
clindamycin	capsule, 150 mg	Chephasaar, Chem.-pharm.Fabrick GmbH	Germany	Yes	n/a
clindamycin	capsule, 150 mg	Shiba Pharmaceuticals & Chemicals Ltd.	Yemen, Republic of	Yes	United Arab Emirates, Eritrea, Ethiopia, Iraq, Sudan, Tanzania in process
clindamycin	injection, 150 mg (as phosphate)/ml	Combino Pharm, S.L.	Spain	Yes	n/a
clindamycin	injection, 150 mg (as phosphate)/ml	Strides Arcolab Limited	India	No	Brazil
codeine	tablet, 30 mg	ICN Hungary Co. Ltd.	Hungary	Yes	n/a
codeine	tablet, 30 mg	Lomapharm	Germany	Yes	n/a
codeine	tablet, 30 mg	Pharmadrug	Germany	No	n/a
codeine	tablet, 30 mg	Rekah Pharmaceutical Group	Israel	Yes	n/a
codeine	tablet, 30 mg	Remedica Ltd.	Cyprus	Yes	n/a
crotamiton	cream/lotion 10%	Sdn Bhd	Malaysia	Yes	n/a



ANNEX 1A. REGISTRATION STATUS OF PRODUCTS INCLUDED IN THE SOURCES AND PRICES SURVEY

International Non-Proprietary Name (INN)	Dosage form & strength	Manufacturer	Country	National Registration	Registration in other countries
cycloserine	capsule 250 mg	Cheil Jedang Corp.	Korea, Republic of	Yes	n/a
cycloserine	capsule 250 mg	Korea United Pharm. Inc.	Korea, Republic of	Yes	India, Philippines
didanosine	syrup, 2 g	Aurobindo Pharma Ltd.	India	Yes	n/a
didanosine	tablet, 100 mg	Apotex Protein, S.A. de C.V.	Mexico	Yes	Panama, Nicaragua, Dominican Republic
didanosine	tablet, 100 mg	Aurobindo Pharma Ltd.	India	Yes	n/a
didanosine	tablet, 100 mg	Far Manguinhos	Brazil	Yes	n/a
didanosine	tablet, 100 mg	Lab. Filaxis International S.A.	Argentina	Yes	Brazil
didanosine	tablet, 100 mg	Laboratorio Dosa S.A.	US	Yes	Argentina, Uruguay, Paraguay, Chile, Bolivia
didanosine	tablet, 100 mg	Strides Arcolab Limited	India	No	n/a
didanosine	tablet, 25 mg	Apotex Protein, S.A. de C.V.	Mexico	Yes	Panama, Nicaragua, Dominican Republic
didanosine	tablet, 25 mg	Aurobindo Pharma Ltd.	India	Yes	n/a
didanosine	tablet, 25 mg	Far Manguinhos	Brazil	Yes	n/a
didanosine	tablet, 25 mg	Strides Arcolab Limited	India	No	n/a
dimenhydrinate	tablet, 50 mg	Apotex Protein, S.A. de C.V.	Mexico	Yes	Panama, Nicaragua, Dominican Republic
dimenhydrinate	tablet, 50 mg	Confab Laboratories Inc	Canada	No	n/a
dimenhydrinate	tablet, 50 mg	Laboratorios Cinfa S.A.	Spain	Yes	Bolivia, Guatemala, El Salvador
dimenhydrinate	tablet, 50 mg	Pharmadrug	Germany	Yes	n/a
dimenhydrinate	tablet, 50 mg	The Government Pharmaceutical Organization	Thailand	Exempt	n/a
docusate sodium	capsule, 100 mg	Banner Pharmacaps Ltd.	Canada	No	n/a
doxorubicine HCl	powder for injection, 10 mg in vial	Korea United Pharm. Inc.	Korea, Republic of	Yes	n/a
doxorubicine HCl	powder for injection, 10 mg in vial	Lab. Filaxis International S.A.	Argentina	Yes	Chile, Uruguay, Mexico, Brazil, Colombia, Dominican Republic, Costa Rica
doxorubicine HCl	powder for injection, 10 mg in vial	Medac GmbH, International Operations	Germany	Yes	UK
doxorubicine HCl	powder for injection, 10 mg in vial	Neon Antibiotics PVT. Ltd.	India	Yes	Sri Lanka in process
doxorubicine HCl	powder for injection, 50 mg in vial	Korea United Pharm. Inc.	Korea, Republic of	Yes	n/a
doxorubicine HCl	powder for injection, 50 mg in vial	Lab. Filaxis International S.A.	Argentina	Yes	Chile, Uruguay, Mexico, Brazil, Colombia, Dominican Republic, Costa Rica
doxorubicine HCl	powder for injection, 50 mg in vial	Medac GmbH, International Operations	Germany	Yes	UK
doxorubicine HCl	powder for injection, 50 mg in vial	Neon Antibiotics PVT. Ltd.	India	Yes	n/a
efavirenz	caps, 200 mg	Aurobindo Pharma Ltd.	India	Yes	n/a
efavirenz	caps, 200 mg	Cipla Ltd.	India	Yes	TBC
efavirenz	caps, 200 mg	Lab. Filaxis International S.A.	Argentina	Yes	n/a
efavirenz	caps, 200 mg	Merck & Co., Inc.	US		USA, UK, Germany, France, Italy, Spain, +70 developing countries
efavirenz	caps, 200 mg	Ranbaxy Laboratories Ltd	India	Yes	n/a
efavirenz	caps, 200 mg	Strides Arcolab Limited	India	No	n/a
efavirenz	caps, 600 mg	Merck & Co., Inc.	US		USA, UK, Germany, France, Italy, Spain, +70 developing countries
erythromycin	powder for oral suspension, 125 mg	Aventis Limited	Bangladesh	Yes	n/a

## SOURCES AND PRICES OF SELECTED DRUGS AND DIAGNOSTICS FOR PEOPLE LIVING WITH HIV/AIDS

International Non-Proprietary Name (INN)	Dosage form & strength	Manufacturer	Country	National Registration	Registration in other countries
erythromycin	powder for oral suspension, 125 mg	Beltapharm SpA	Italy	Yes	Cameroon, Panama, Costa Rica, Honduras
erythromycin	powder for oral suspension, 125 mg	Gracure Pharmaceuticals Ltd.	India	Yes	n/a
erythromycin	powder for oral suspension, 125 mg	Lachifarma, SRL	Italy	No	Yemen, Cameroon
erythromycin	powder for oral suspension, 125 mg	Purna Pharmaceuticals NV	Belgium	No	Macau
erythromycin	powder for oral suspension, 125 mg	Remedica Ltd.	Cyprus	Yes	Tanzania, Singapore, Sudan
erythromycin	powder for oral suspension, 125 mg	Shiba Pharmaceuticals & Chemicals Ltd.	Yemen, Republic of	No	United Arab Emirates, Eritrea, Ethiopia, Iraq, Sudan, Tanzania in process
erythromycin	tab, 250 mg (as stearate)	Artesan Pharma GmbH & Co.	Germany	No	n/a
erythromycin	tab, 250 mg (as stearate)	Aurobindo Pharma Ltd.	India	Yes	n/a
erythromycin	tab, 250 mg (as stearate)	Aventis Limited	Bangladesh	Yes	n/a
erythromycin	tab, 250 mg (as stearate)	Beltapharm SpA	Italy	Yes	Tanzania, Cameroon, Panama, Costa Rica
erythromycin	tab, 250 mg (as stearate)	Fourrts Laboratories Pvt. Ltd.	India	Yes	Sri Lanka
erythromycin	tab, 250 mg (as stearate)	Glenmark Pharmaceuticals Ltd	India	Yes	n/a
erythromycin	tab, 250 mg (as stearate)	Gracure Pharmaceuticals Ltd.	India	Yes	n/a
erythromycin	tab, 250 mg (as stearate)	Sdn Bhd	Malaysia	Yes	Singapore, Hong Kong, Sri Lanka, Myanmar, Yemen, Peru, Ghana, Botswana, Nigeria, Sudan, Zambia, Jordan, Haiti
erythromycin	tab, 250 mg (as stearate)	Lachifarma, SRL	Italy	No	Yemen, Cameroon
erythromycin	tab, 250 mg (as stearate)	Lyka Labs Limited	India	Yes	Cambodia, Myanmar, DR Congo
erythromycin	tab, 250 mg (as stearate)	Pharmadrug	Germany	Yes	n/a
erythromycin	tab, 250 mg (as stearate)	Phyto-Riker Pharmaceuticals Ltd.	Ghana	Yes	Benin, Cameroon, Togo, Mali, Senegal, Gambia, Ivory Coast, Niger
erythromycin	tab, 250 mg (as stearate)	Remedica Ltd.	Cyprus	Yes	Kenya, Myanmar, Oman, Sri Lanka, Sudan, Tanzania, Malawi, Botswana, Singapore
erythromycin	tab, 250 mg (as stearate)	Sanavita Aktiengesellschaft & Co.	Germany	No	Uzbekistan
erythromycin	tab, 250 mg (as stearate)	Shiba Pharmaceuticals & Chemicals Ltd.	Yemen, Republic of	Yes	United Arab Emirates, Eritrea, Ethiopia, Iraq, Sudan, Tanzania in process
erythromycin	tab, 250 mg (as stearate)	Sdn Bhd	Malaysia	Yes	Vietnam, Cambodia, Myanmar, Sri Lanka, South Africa, Mauritius, Hong Kong, Singapore
erythromycin	tab, 250 mg (as stearate)	Strides Arcolab Limited	India	No	n/a
etoposide	capsule, 100 mg	Korea United Pharm. Inc.	Korea, Republic of	Yes	n/a
etoposide	capsule, 100 mg	Medac GmbH, International Operations	Germany	Yes	n/a
etoposide	injection, 20 mg/ ml in 5 ml ampoule	Cipla Ltd.	India	Yes	Russia, Sri Lanka, Kenya, Malaysia, Ukraine, Ivory Coast
etoposide	injection, 20 mg/ ml in 5 ml ampoule	Korea United Pharm. Inc.	Korea, Republic of	Yes	n/a
etoposide	injection, 20 mg/ ml in 5 ml ampoule	Lab. Filaxis International S.A.	Argentina	Yes	Uruguay, Mexico, Brazil, Colombia, Dominican Republic, Guatemala, Costa Rica
etoposide	injection, 20 mg/ ml in 5 ml ampoule	Neon Antibiotics PVT. Ltd.	India	Yes	n/a

ANNEX 1A. REGISTRATION STATUS OF PRODUCTS INCLUDED IN THE SOURCES AND PRICES SURVEY

International Non-Proprietary Name (INN)	Dosage form & strength	Manufacturer	Country	National Registration	Registration in other countries
fluconazole	capsule, 150 mg	Bilim Pharmaceutical Ind.	Turkey	Yes	Dominican Republic, Malta, Mongolia, Moldova, Russia, Azerbaijan
fluconazole	capsule, 150 mg	Gracure Pharmaceuticals Ltd.	India	Yes	Vietnam, Cambodia
fluconazole	capsule, 200 mg	Cipla Ltd.	India	Yes	Russia, Vietnam, Belarus, Myanmar, Cambodia, Macau, Sri Lanka, Cameroon, Ukraine
fluconazole	capsule, 200 mg	Fourrts Laboratories Pvt. Ltd.	India	Yes	n/a
fluconazole	capsule, 200 mg	IPCA Laboratories Limited	India	Yes	Uganda, Zimbabwe, Tanzania, Ethiopia, Sudan, Kenya, Ukraine, Singapore, Malaysia, Ghana, Philippines, Thailand, Sri Lanka, Myanmar, South Africa, UK
*fluconazole	capsule, 200 mg	Ranbaxy Laboratories Ltd	India	Yes	Russia, Bulgaria, Cambodia, Croatia, Czech Republic, El Salvador, Hong Kong, Hungary, Jamaica, Peru, Poland, Romania, Slovak Republic, South Africa, Trinidad & Tobago, UK, USA, Venezuela
fluconazole	capsule, 200 mg	Remedica Ltd.	Cyprus		Malawi, Tanzania, Cambodia, Botswana
fluconazole	capsule, 200 mg	Shiba Pharmaceuticals & Chemicals Ltd.	Yemen, Republic of	Yes	United Arab Emirates, Eritrea, Ethiopia, Iraq, Sudan, Tanzania in process
fluconazole	capsule, 200 mg	The Government Pharmaceutical Organization	Thailand	Exempt	n/a
fluconazole	solution for injection, 2mg/ml in ampoule	CLARIS Life sciences Ltd.	India	Yes	Brazil, Chile, Mexico
fluconazole	solution for injection, 2mg/ml in ampoule	Geneparm SA	Greece	Yes	n/a
fluconazole	solution for injection, 2mg/ml in ampoule	Strides Arcolab Limited	India	No	Brazil
fluoxetine	caps, 20 mg	IPCA Laboratories Limited	India	Yes	Sri Lanka, Myanmar
fluoxetine	caps, 20 mg	Korea United Pharm. Inc.	Korea, Republic of	Yes	Vietnam, Philippines
fluoxetine	caps, 20 mg	Remedica Ltd.	Cyprus	Yes	Hong Kong, Malawi, Venezuela, Sudan
fluoxetine	tablet, 20 mg	Apotex Protein, S.A. de C.V.	Mexico	Yes	Panama, Costa Rica, Cameroon
fluoxetine	tablet, 20 mg	Combino Pharm, S.L.	Spain	Yes	n/a
fluoxetine	tablet, 20 mg	Geneparm SA	Greece	Yes	Cyprus
fluoxetine	tablet, 20 mg	IVAX Pharmaceuticals Mexico, S.A. de C.V.	Mexico	Yes	Costa Rica, El Salvador, Honduras, Nicaragua, Haiti, Dominican Republic, Guatemala, Chile
fluoxetine	tablet, 20 mg	Laboratorios Cinfa S.A.	Spain	Yes	Venezuela, Dominican Republic in process
fluoxetine	tablet, 20 mg	Ranbaxy Laboratories Ltd	India	Yes	Denmark, Finland, Germany, Ireland, Myanmar, Peru, Russia, UK, USA
ganciclovir	powder for injection, 500 mg in vial	Lab. Filaxis International S.A.	Argentina	Yes	n/a
indinavir	caps, 400 mg	Aurobindo Pharma Ltd.	India	Yes	n/a
indinavir	caps, 400 mg	Far Manguinhos	Brazil	Yes	n/a
indinavir	caps, 400 mg	Lab. Filaxis International S.A.	Argentina	Yes	n/a
indinavir	caps, 400 mg	Laboratorio Dosa S.A.	US	Yes	Argentina, Uruguay, Paraguay, Chile, Bolivia
indinavir	caps, 400 mg	Merck & Co., Inc.	US		USA, UK, Germany, France, Italy, Spain, +70 developing countries
indinavir	caps, 400 mg	Ranbaxy Laboratories Ltd	India	Yes	Brazil, Cambodia, Chad, Ethiopia, Guatemala, Mauritius, Nigeria, Peru
indinavir	caps, 400 mg	Strides Arcolab Limited	India	No	n/a

## SOURCES AND PRICES OF SELECTED DRUGS AND DIAGNOSTICS FOR PEOPLE LIVING WITH HIV/AIDS

International Non-Proprietary Name (INN)	Dosage form & strength	Manufacturer	Country	National Registration	Registration in other countries
itraconazole	capsule, 100 mg	Glenmark Pharmaceuticals Ltd	India	Yes	Ukraine
itraconazole	capsule, 100 mg	Intas Pharmaceuticals Ltd	India		Hong Kong, Macau, Trinidad & Tobago
itraconazole	capsule, 100 mg	IVAX Pharmaceuticals Mexico, S.A. de C.V.	Mexico	Yes	Costa Rica, El Salvador, Honduras, Nicaragua, Haiti, Dominican Republic, Guatemala, Chile
ketoconazole	tablet, 200 mg	Artesan Pharma GmbH & Co.	Germany	No	n/a
ketoconazole	tablet, 200 mg	Beltapharm SpA	Italy	Yes	Panama, Costa Rica, Cameroon
ketoconazole	tablet, 200 mg	Bilim Pharmaceutical Ind.	Turkey	Yes	Yemen, Trinidad & Tobago
ketoconazole	tablet, 200 mg	Gracure Pharmaceuticals Ltd.	India	Yes	n/a
ketoconazole	tablet, 200 mg	Sdn Bhd	Malaysia	Yes	Singapore, Hong Kong, Cambodia, Myanmar, Zambia, Sudan, Sri Lanka
ketoconazole	tablet, 200 mg	Intas Pharmaceuticals Ltd	India	Yes	Kenya, Mauritius, Peru, Tanzania, Uganda, Vietnam, West Indies, Armenia, Bolivia, Cambodia, Georgia, Hong Kong, Chile, Algeria, Zambia
ketoconazole	tablet, 200 mg	IVAX Pharmaceuticals Mexico, S.A. de C.V.	Mexico	Yes	Costa Rica, El Salvador, Honduras, Nicaragua, Haiti, Dominican Republic, Guatemala, Chile
ketoconazole	tablet, 200 mg	Korea United Pharm. Inc.	Korea, Republic of	Yes	n/a
ketoconazole	tablet, 200 mg	Remedica Ltd.	Cyprus	Yes	Albania, Cambodia, Ghana, Sudan, Tanzania, Uganda, Vietnam
ketoconazole	tablet, 200 mg	Sdn Bhd	Malaysia		Cambodia, Myanmar, Vietnam, Hong Kong, South Africa
ketoconazole	tablet, 200 mg	Strides Arcolab Limited	India	No	Brazil, Mexico, Venezuela
ketoconazole	tablet, 200 mg	The Government Pharmaceutical Organization	Thailand	Exempt	n/a
lamivudine	syrup, 50 mg/5 ml	Laboratorio Dosa S.A.	US	Yes	Argentina, Uruguay, Paraguay, Chile, Bolivia
<b>*lamivudine</b>	tablet, 150 mg	Cipla Ltd.	India	Yes	Ghana, Tanzania, Malawi, Iran, Cambodia, Macau, Burundi, Congo, Uganda, Myanmar, Syria, Cameroon, Central African Republic
lamivudine	tablet, 150 mg	Far Manguinhos	Brazil	Yes	n/a
lamivudine	tablet, 150 mg	IPCA Laboratories Limited	India	Yes	Ghana, Kenya, Tanzania, Uganda, Zaire, Zimbabwe
lamivudine	tablet, 150 mg	Lab. Filaxis International S.A.	Argentina	Yes	Peru, Colombia
lamivudine	tablet, 150 mg	Laboratorio Dosa S.A.	US	Yes	Argentina, Uruguay, Paraguay, Chile, Bolivia
<b>*lamivudine</b>	tablet, 150 mg	Ranbaxy Laboratories Ltd	India	Yes	Benin, Brazil, Cambodia, Central African Republic, Chad, Congo, Guatemala, Guinea, Mali, Mauritius, Nigeria, Peru, Senegal, Togo
lamivudine	tablet, 150 mg	Strides Arcolab Limited	India	No	n/a
lamivudine	tablet, 150 mg	The Government Pharmaceutical Organization	Thailand	Exempt	n/a
3TC/d4T/NVP	tablet, 150/40/200 mg	Cipla Ltd.	India	Yes	Congo, Guinea, Central African Republic, Malawi
3TC/d4T/NVP	tablet, 150/40/200 mg	Ranbaxy Laboratories Ltd	India	Yes	n/a
3TC/d4T/NVP	tablet, 150/40/200 mg	The Government Pharmaceutical Organization	Thailand	Exempt	n/a
lorazepam	tablet, 1 mg	Intas Pharmaceuticals Ltd	India	Yes	n/a
lorazepam	tablet, 1 mg	Lomapharm	Germany		n/a

ANNEX 1A. REGISTRATION STATUS OF PRODUCTS INCLUDED IN THE SOURCES AND PRICES SURVEY

International Non-Proprietary Name (INN)	Dosage form & strength	Manufacturer	Country	National Registration	Registration in other countries
lorazepam	tablet, 1 mg	Pharmadrug	Germany	No	n/a
methotrexate	powder for injection, 50 mg (as sodium salt) in vial	Aventis Pharma	France	Yes	Algeria, Argentina, Brazil, Colombia, Ecuador
methotrexate	powder for injection, 50 mg (as sodium salt) in vial	Korea United Pharm. Inc.	Korea, Republic of	Yes	n/a
methotrexate	powder for injection, 50 mg (as sodium salt) in vial	Lab. Filaxis International S.A.	Argentina	Yes	Uruguay, Mexico, Brazil, Dominican Republic, Costa Rica
methotrexate	powder for injection, 50 mg (as sodium salt) in vial	Neon Antibiotics PVT. Ltd.	India	Yes	n/a
methotrexate	tablet, 2.5 mg	Aventis Pharma	France	Yes	Algeria, Argentina, Bangladesh, Brazil, Cambodia, Colombia, Ecuador, Egypt, France, Croatia, Kazakhstan, Israel, Lithuania, Latvia, Madagascar, Malaysia, Mauritius, Peru, Romania, Russia, Slovakia, Serbia, Tunisia, Turkey, Ukraine, Uruguay, Uzbekistan
methotrexate	tablet, 2.5 mg	Korea United Pharm. Inc.	Korea, Republic of	Yes	n/a
metoclopramide	injection 5 mg/ml	Aventis Limited	Bangladesh	Yes	Myanmar
metoclopramide	injection 5 mg/ml	CLARIS Life sciences Ltd.	India	Yes	Brazil, Haiti, Chile
metoclopramide	injection 5 mg/ml	The Government Pharmaceutical Organization	Thailand	Exempt	n/a
metoclopramide	tablet, 10 mg (as hydrochloride)	Alpharma	Indonesia	Yes	n/a
metoclopramide	tablet, 10 mg (as hydrochloride)	Apotex Protein, S.A. de C.V.	Mexico	Yes	Dominican Republic
metoclopramide	tablet, 10 mg (as hydrochloride)	Aventis Limited	Bangladesh	Yes	Myanmar
metoclopramide	tablet, 10 mg (as hydrochloride)	Fourrts Laboratories Pvt. Ltd.	India	Yes	n/a
metoclopramide	tablet, 10 mg (as hydrochloride)	Genepharm SA	Greece	Yes	Peru, Macau
metoclopramide	tablet, 10 mg (as hydrochloride)	IPCA Laboratories Limited	India	Yes	n/a
metoclopramide	tablet, 10 mg (as hydrochloride)	Lomapharm	Germany		n/a
metoclopramide	tablet, 10 mg (as hydrochloride)	Pharmadrug	Germany	No	n/a
metoclopramide	tablet, 10 mg (as hydrochloride)	Remedica Ltd.	Cyprus	Yes	Kenya, Malawi, Myanmar, Singapore
miconazole	Cream 2% 15 g tube	Fourrts Laboratories Pvt. Ltd.	India	Yes	n/a
miconazole	Cream 2% 15 g tube	Sdn Bhd	Malaysia	Yes	Singapore, Hong Kong, Sri Lanka, Vietnam, Zambia, Myanmar
miconazole	Cream 2% 15 g tube	Lachifarma, SRL	Italy	No	Yemen, Cameroon
miconazole	Cream 2% 15 g tube	Pharmadrug	Germany	No	n/a
miconazole	Cream 2% 30 g tube	Apotex Protein, S.A. de C.V.	Mexico	Yes	Peru, Nicaragua, Dominican Republic
miconazole	Cream 2% 30 g tube	Beltapharm SpA	Italy	Yes	Cameroon, Honduras, Costa Rica, Panama
miconazole	Cream 2% 30 g tube	Confab Laboratories Inc	Canada	Yes	n/a
miconazole	Cream 2% 30 g tube	Ecobi Farmaceutici S.a.s.	Italy	Yes	Albania, Algeria, Senegal, Ivory Coast, Guinea, Togo, Burkina Faso, Gabon, Cameroon
miconazole	Cream 2% 30 g tube	IVAX Pharmaceuticals Mexico, S.A. de C.V.	Mexico	Yes	Costa Rica, El Salvador, Honduras, Nicaragua, Haiti, Dominican Republic, Guatemala, Chile
miconazole	Cream 2% 30 g tube	Lomapharm	Germany		n/a
miconazole	Cream 2% 30 g tube	Purna Pharmaceuticals NV	Belgium	No	Albania
morphine	injection, 10 mg (hydrochloride) in 1-ml ampoule	Lab. Renaudin	France	Yes	n/a
morphine	oral solution, 10 mg(sulfate)/5ml	Martindale Pharmaceuticals Ltd.	UK	Yes	n/a

## SOURCES AND PRICES OF SELECTED DRUGS AND DIAGNOSTICS FOR PEOPLE LIVING WITH HIV/AIDS

International Non-Proprietary Name (INN)	Dosage form & strength	Manufacturer	Country	National Registration	Registration in other countries
naltrexone HCl	tablet, 50 mg	Intas Pharmaceuticals Ltd	India	Yes	Mauritius, Malaysia, Jordan, Ukraine, Russia
naltrexone HCl	tablet, 50 mg	Lachifarma, SRL	Italy	No	Yemen, Cameroon
naltrexone HCl	tablet, 50 mg	Tecnimede Sociedade Tecnico Medicinal, S.A.	Portugal	Yes	n/a
nelfinavir	250mg, caps	Aurobindo Pharma Ltd.	India	Yes	n/a
<b>*nelfinavir</b>	250mg, caps	F. Hoffmann-La Roche Ltd.	Switzerland	Yes	Argentina, Aruba, Australia, Austria, Bahrain, Belgium, Belarus, Bolivia, Brazil, Bulgaria, Cambodia, Canada, Chile, Colombia, Costa Rica, Croatia, Curacao, Cyprus, Czech Republic, Denmark, Dominican Republic, Ecuador, Ireland, El Salvador, Estonia, Finland, France, Germany, Ghana, Greece, Guatemala, Honduras, Hong Kong, Hungary, Israel, Italy, Jamaica, Japan, Kenya, Kuwait, Latvia, Lithuania, Luxembourg, Malaysia, Malta, Mexico, Morocco, Netherlands, New Zealand, Nicaragua, Norway, Oman, Panama, Paraguay, Peru, Philippines, Poland, Portugal, Qatar, Romania, Russia, Singapore, Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, Taiwan, Tanzania, Thailand, Trinidad & Tobago, Tunisia, USA, United Arab Emirates, UK, Uruguay, Venezuela, Yugoslavia
nelfinavir	250mg, caps	Lab. Filaxis International S.A.	Argentina	Yes	n/a
nelfinavir	250mg, caps	Laboratorio Dosa S.A.	US	Yes	Argentina, Uruguay, Paraguay, Chile
nevirapine	200mg, tab	Aurobindo Pharma Ltd.	India	Yes	n/a
<b>*nevirapine</b>	200 mg, tab	Cipla Ltd.	India	Yes	Cambodia, Burundi, Congo, Uganda, Myanmar, Malawi, Guinea, Central African Republic
nevirapine	200mg, tab	Far Manguinhos	Brazil	Yes	n/a
nevirapine	200mg, tab	Lab. Filaxis International S.A.	Argentina	Yes	n/a
nevirapine	200mg, tab	Laboratorio Dosa S.A.	US	Yes	Argentina, Uruguay, Paraguay, Chile, Bolivia
<b>*nevirapine</b>	200 mg, tab	Ranbaxy Laboratories Ltd	India	Yes	Benin, Brazil, Cambodia, Central African Republic, Chad, Congo, Ethiopia, Guatemala, Guinea, Mali, Mauritius, Myanmar, Nigeria, Senegal, Togo
nevirapine	200mg, tab	Strides Arcolab Limited	India	No	n/a
nevirapine	200mg, tab	The Government Pharmaceutical Organization	Thailand	Exempt	n/a
nevirapine	50mg/5ml, syrup	Cipla Ltd.	India	Yes	Malawi
nevirapine	50mg/5ml, syrup	The Government Pharmaceutical Organization	Thailand	Exempt	n/a
ofloxacin	IV infusion, 2 mg/ml (hydrochloride)	Genepharma SA	Greece	Yes	n/a
ofloxacin	tablet, 200 mg	Aventis Pharma	France	yes	Algeria, Azerbaidjan, Benin, Burkina Faso, Cambodia, Cameroon, Congo, France, Gabon, Georgia, Guinea, Hungary, Israel, Ivory Coast, Kuwait, Jordan, Lebanon, Madagascar, Mali, Mauritania, Morocco, Niger, Romania, Russia, Senegal, Slovakia, South Africa, Sri Lanka, Togo, Tunisia, Turkey, Turkmenistan, Ukraine, United Arab Emirates, Uzbekistan, Zimbabwe
ofloxacin	tablet, 200 mg	Genepharma SA	Greece	Yes	Romania, Cyprus
ofloxacin	tablet, 200 mg	Glenmark Pharmaceuticals Ltd	India	Yes	n/a

ANNEX 1A. REGISTRATION STATUS OF PRODUCTS INCLUDED IN THE SOURCES AND PRICES SURVEY

International Non-Proprietary Name (INN)	Dosage form & strength	Manufacturer	Country	National Registration	Registration in other countries
ofloxacin	tablet, 200 mg	Gracure Pharmaceuticals Ltd.	India	Yes	n/a
ofloxacin	tablet, 200 mg	Sdn Bhd	Malaysia	Yes	Hong Kong, Myanmar, Yemen, Ethiopia
ofloxacin	tablet, 200 mg	Intas Pharmaceuticals Ltd	India	Yes	Malaysia, Armenia, Hong Kong, Singapore, Cambodia, Jamaica, Trinidad & Tobago
ofloxacin	tablet, 200 mg	IPCA Laboratories Limited	India	Yes	n/a
ofloxacin	tablet, 200 mg	Korea United Pharm. Inc.	Korea, Republic of	Yes	Brazil, Vietnam
ofloxacin	tablet, 200 mg	Lyka Labs Limited	India	Yes	n/a
ofloxacin	tablet, 200 mg	Ranbaxy Laboratories Ltd	India	Yes	Algeria, Belarus, Cambodia, China, Costa Rica, Czech Republic, Dominican Republic, Georgia, Germany, Guatemala, Guinea, Hungary, Indonesia, Iraq, Kazakhstan, Kyrgyzstan, Laos, Latvia, Lithuania, Mauritius, Moldova, Myanmar, Nigeria, Peru, Poland, Romania, Russia, Sri Lanka, UK, Ukraine, Uzbekistan, Vietnam
ofloxacin	tablet, 200 mg	Remedica Ltd.	Cyprus	Yes	Cambodia, Panama, Vietnam, Zimbabwe
ofloxacin	tablet, 200 mg	Shiba Pharmaceuticals & Chemicals Ltd.	Yemen, Republic of	Yes	In process for: United Arab Emirates, Eritrea, Ethiopia, Iraq, Sudan, Tanzania
ofloxacin	tablet, 200 mg	Tecnimed Sociedade Tecnico Medicinal, S.A.	Portugal	Yes	n/a
omeprazole	caps, 10 mg	Fourrts Laboratories Pvt. Ltd.	India	Yes	n/a
omeprazole	caps, 10 mg	Lyka Labs Limited	India	Yes	Rumania
omeprazole	caps, 10 mg	Sdn Bhd	Malaysia	Yes	Myanmar, Cambodia, Sri Lanka
omeprazole	caps, 10 mg	Strides Arcolab Limited	India	No	Brazil
omeprazole	caps, 20 mg	Apotex Protein, S.A. de C.V.	Mexico	Yes	Panama, Chile
omeprazole	caps, 20 mg	Aurobindo Pharma Ltd.	India	Yes	Malawi, Cambodia, Vietnam, Myanmar, Lao PDR
omeprazole	caps, 20 mg	Fourrts Laboratories Pvt. Ltd.	India	Yes	Poland
omeprazole	caps, 20 mg	Genepharm SA	Greece	Yes	Romania, Sudan, Iraq
omeprazole	caps, 20 mg	Intas Pharmaceuticals Ltd	India	Yes	Armenia, Georgia, Belarus, Hong Kong, Peru, Malaysia, Cambodia, Russia, Yugoslavia, Ukraine, Guyana, Dominican Republic, Vietnam
omeprazole	caps, 20 mg	IVAX Pharmaceuticals Mexico, S.A. de C.V.	Mexico	Yes	Costa Rica, El Salvador, Honduras, Nicaragua, Haiti, Dominican Republic, Guatemala, Chile
omeprazole	caps, 20 mg	Laboratorios Cinfa S.A.	Spain	Yes	Dominican Republic Pending in Venezuela and Macau
omeprazole	caps, 20 mg	Mepha Ltd	Switzerland	No	n/a
omeprazole	caps, 20 mg	Strides Arcolab Limited	India	No	Brazil
omeprazole	caps, 20 mg	Tecnimed Sociedade Tecnico Medicinal, S.A.	Portugal	Yes	n/a
omeprazole	caps, 40 mg	Aurobindo Pharma Ltd.	India	Yes	n/a
omeprazole	caps, 40 mg	Strides Arcolab Limited	India	No	Brazil
omeprazole	caps, 40 mg	Tecnimed Sociedade Tecnico Medicinal, S.A.	Portugal	Yes	n/a
omeprazole	powder for injection, 40 mg in vial (as sodium salt)	Neon Antibiotics PVT. Ltd.	India	Yes	n/a
omeprazole	powder for IV infusion, 40 mg vial (sodium salt)	Genepharm SA	Greece	Yes	n/a
omeprazole	powder for IV infusion, 40 mg vial (sodium salt)	Neon Antibiotics PVT. Ltd.	India	Yes	n/a

SOURCES AND PRICES OF SELECTED DRUGS AND DIAGNOSTICS FOR PEOPLE LIVING WITH HIV/AIDS

International Non-Proprietary Name (INN)	Dosage form & strength	Manufacturer	Country	National Registration	Registration in other countries
pentamidine	powder for injection, 300 mg (isetionate) in vial	Aventis Pharma	France	yes	Argentina, Australia, Azerbaidjan, Belgium Brazil, Canada, Colombia, Chile, Croatia, Denmark, Finland, France, Germany, Greece, Israel, Hong Kong, Ireland, Italy, Japan, Luxembourg, Madagascar, Malaysia, Mexico, Netherlands, New Zealand, Peru, Portugal, Romania, Russia, Singapore, Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, Thailand, UK, USA Uruguay
pentamidine	powder for injection, 300 mg (isetionate) in vial	Combino Pharm, S.L.	Spain	Yes	n/a
pentamidine	powder for injection, 300 mg (isetionate) in vial	Lab. Filaxis International S.A.	Argentina	Yes	Uruguay, Mexico, Brazil, Colombia
pethidine	inj, 50 mg (hydrochloride)/ml in 1 ml ampoule	Martindale Pharmaceuticals Ltd.	UK	Yes	Ireland, Cyprus, El Salvador, Oman, Jordan
pethidine	inj, 50 mg (hydrochloride)/ml in 1-ml ampoule	Neon Laboratories Ltd	India	Yes	n/a
pethidine	inj, 50 mg (hydrochloride)/ml in 1-ml ampoule	Pharmadrug	Germany	No	n/a
pethidine	inj, 50 mg (hydrochloride)/ml in 2-ml ampoule	Lab. Renaudin	France	Yes	Lebanon, Madagascar, Romania
pethidine	tablet, 50 mg	Martindale Pharmaceuticals Ltd.	UK	Yes	Ireland, Nepal
prochlorperazine	injection, 12.5 mg/ml	Aventis Limited	Bangladesh	Yes	Myanmar, Sri Lanka
prochlorperazine	tablet, 5 mg	Aventis Limited	Bangladesh	Yes	Myanmar, Sri Lanka
prochlorperazine	tablet, 5 mg	Pharmadrug	Germany	No	n/a
prochlorperazine	tablet, 5 mg	Remedica Ltd.	Cyprus	Yes	Yemen, Netherlands
pyrimethamine	tablet, 25 mg	Artesan Pharma GmbH & Co.	Germany	No	n/a
pyrimethamine	tablet, 25 mg	Far Manguinhos	Brazil	Yes	n/a
pyrimethamine	tablet, 25 mg	Pharmadrug	Germany	No	n/a
pyrimethamine	tablet, 25 mg	Shiba Pharmaceuticals & Chemicals Ltd.	Yemen, Republic of	Yes	In process for: United Arab Emirates, Eritrea, Ethiopia, Iraq, Sudan, Tanzania
rifabutin	capsule, 150 mg	Lupin Laboratories Ltd.	India	Yes	Bulgaria, China, Czech Rep, Ethiopia, Kenya, Romania, Russia, Slovakia
saquinavir	200mg,caps	Aurobindo Pharma Ltd.	India	Yes	n/a
<b>*saquinavir</b>	200 mg,caps	F. Hoffmann-La Roche Ltd.	Switzerland	Yes	Argentina, Australia, Austria, Bahrain, Bangladesh, Belgium, Brazil, Bulgaria, Cambodia, Canada, Chile, Colombia, Costa Rica, Curacao, Cyprus, Czech Republic, Denmark, Ecuador, Ireland, El Salvador, Estonia, Ethiopia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kazakhstan, Kenya, Kuwait, Latvia, Lithuania, Luxembourg, Malaysia, Mexico, Morocco, Nepal, Netherlands, New Zealand, Norway, Oman, Panama, Peru, Philippines, Poland, Portugal, Qatar, Romania, Russia, Slovakia, South Africa, Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, USA, United Arab Emirates, UK, Uruguay, Venezuela, Vietnam, Yugoslavia
spectinomycin	powder for injection, 2 g (as hydrochloride) in vial	Neon Antibiotics PVT. Ltd.	India	Yes	n/a
stavudine	1mg/ml, syrup	Laboratorio Dosa S.A.	US	Yes	Argentina, Uruguay, Paraguay, Bolivia, Chile



ANNEX 1A. REGISTRATION STATUS OF PRODUCTS INCLUDED IN THE SOURCES AND PRICES SURVEY

International Non-Proprietary Name (INN)	Dosage form & strength	Manufacturer	Country	National Registration	Registration in other countries
stavudine	1mg/ml, syrup	The Government Pharmaceutical Organization	Thailand	Exempt	n/a
stavudine	40 mg caps	Apotex Protein, S.A. de C.V.	Mexico	Yes	Panama, Nicaragua, Dominican Republic
stavudine	40 mg caps	Aurobindo Pharma Ltd.	India	Yes	Ethiopia
stavudine	40 mg caps	Cipla Ltd.	India	Yes	Ghana, Ivory Coast, Cameroon, Myanmar, Tanzania, Cambodia, Burundi, Congo, Uganda, Malawi, Guinea, Central African Republic
stavudine	40 mg caps	Far Manguinhos	Brazil	Yes	n/a
stavudine	40 mg caps	Lab. Filaxis International S.A.	Argentina	Yes	n/a
stavudine	40 mg caps	Laboratorio Dosa S.A.	US	Yes	Argentina, Uruguay, Paraguay, Chile, Bolivia
stavudine	40 mg caps	Ranbaxy Laboratories Ltd	India	Yes	Brazil, Cambodia, Chad, Ethiopia, Guatemala, Guinea, Mali, Mauritius, Myanmar, Nigeria, Senegal, Togo
stavudine	40 mg caps	Samchully Pharm. Co., Ltd.	Korea, Republic of	In process	n/a
stavudine	40 mg caps	Strides Arcolab Limited	India	No	n/a
stavudine	40 mg caps	The Government Pharmaceutical Organization	Thailand	Exempt	n/a
sulfadiazine	tablet, 500 mg	Ecobi Farmaceutici S.a.s.	Italy	Yes	n/a
sulfadiazine	tablet, 500 mg	Far Manguinhos	Brazil	Yes	n/a
sulfadiazine	tablet, 500 mg	Heyl Chem.-pharm. Fabrik GmbH KG	Germany	Yes	n/a
sulfadiazine	tablet, 500 mg	Laboratorio Reig Jofre S.A.	Spain	Yes	n/a
sulfadiazine	tablet, 500 mg	Pharmadrug	Germany	No	n/a
sulfamethoxazole+ trimethoprim	oral suspension, 200+40 mg/5 ml	Apotex Protein, S.A. de C.V.	Mexico	Yes	Peru, Dominican Republic
sulfamethoxazole+ trimethoprim	oral suspension, 200+40 mg/5 ml	Aventis Limited	Bangladesh	Yes	Myanmar
sulfamethoxazole+ trimethoprim	oral suspension, 200+40 mg/5 ml	Ecobi Farmaceutici S.a.s.	Italy	Yes	Albania, Algeria, Senegal
sulfamethoxazole+ trimethoprim	oral suspension, 200+40 mg/5 ml	Fourrts Laboratories Pvt. Ltd.	India	Yes	Uganda, Sri Lanka
sulfamethoxazole+ trimethoprim	oral suspension, 200+40 mg/5 ml	Sdn Bhd	Malaysia	Yes	Singapore, Hong Kong, Sri Lanka, Myanmar, Yemen, Cambodia, Ghana, Kenya, Mali, Haiti, Papua New Guinea
sulfamethoxazole+ trimethoprim	oral suspension, 200+40 mg/5 ml	Lachifarma, SRL	Italy	No	Yemen, Cameroon
sulfamethoxazole+ trimethoprim	oral suspension, 200+40 mg/5 ml	Purna Pharmaceuticals NV	Belgium	No	El Salvador
sulfamethoxazole+ trimethoprim	oral suspension, 200+40 mg/5 ml	Rekah Pharmaceutical Group	Israel	Yes	n/a
sulfamethoxazole+ trimethoprim	oral suspension, 200+40 mg/5 ml	Remedica Ltd.	Cyprus	Yes	Oman, Yemen, Albania
sulfamethoxazole+ trimethoprim	oral suspension, 200+40 mg/5 ml	Shiba Pharmaceuticals & Chemicals Ltd.	Yemen, Republic of	Yes	In process for: United Arab Emirates, Eritrea, Ethiopia, Iraq, Sudan, Tanzania
sulfamethoxazole+ trimethoprim	oral suspension, 200+40 mg/5 ml	Sdn Bhd	Malaysia	Yes	Cambodia, Myanmar, Papua New Guinea
sulfamethoxazole+ trimethoprim	tab, 120 mg	Lomapharm	Germany		n/a
sulfamethoxazole+ trimethoprim	tablet, 100+20 mg	Artesan Pharma GmbH & Co.	Germany	No	n/a
sulfamethoxazole+ trimethoprim	tablet, 100+20 mg	Aurobindo Pharma Ltd.	India	Yes	Zambia, Malawi, Tanzania, Cambodia, Lao PDR, Costa Rica, Honduras

SOURCES AND PRICES OF SELECTED DRUGS AND DIAGNOSTICS FOR PEOPLE LIVING WITH HIV/AIDS

International Non-Proprietary Name (INN)	Dosage form & strength	Manufacturer	Country	National Registration	Registration in other countries
sulfamethoxazole+ trimethoprim	tablet, 100+20 mg	Ecobi Farmaceutici S.a.s.	Italy	Yes	Albania
sulfamethoxazole+ trimethoprim	tablet, 100+20 mg	Fourrts Laboratories Pvt. Ltd.	India	Yes	n/a
sulfamethoxazole+ trimethoprim	tablet, 100+20 mg	Gracure Pharmaceuticals Ltd.	India	Yes	n/a
sulfamethoxazole+ trimethoprim	tablet, 100+20 mg	Lachifarma, SRL	Italy	No	Yemen, Cameroon
sulfamethoxazole+ trimethoprim	tablet, 100+20 mg	Lyka Labs Limited	India	Yes	DR Congo, Cambodia, Chile, Peru
sulfamethoxazole+ trimethoprim	tablet, 100+20 mg	Rekah Pharmaceutical Group	Israel	Yes	Kazakhstan
sulfamethoxazole+ trimethoprim	tablet, 100+20 mg	The Government Pharmaceutical Organization	Thailand	Exempt	n/a
sulfamethoxazole+ trimethoprim	tablet, 400+80 mg	Alpharma	Indonesia	Yes	Netherlands, Germany, UK
sulfamethoxazole+ trimethoprim	tablet, 400+80 mg	Apotex Protein, S.A. de C.V.	Mexico	Yes	Panama, Nicaragua, Dominican Republic
sulfamethoxazole+ trimethoprim	tablet, 400+80 mg	Artesan Pharma GmbH & Co.	Germany	No	n/a
sulfamethoxazole+ trimethoprim	tablet, 400+80 mg	Aurobindo Pharma Ltd.	India	Yes	Zambia, Malawi, Tanzania, Cambodia, Lao PDR, Costa Rica, Honduras
sulfamethoxazole+ trimethoprim	tablet, 400+80 mg	Ecobi Farmaceutici S.a.s.	Italy	Yes	Albania, Algeria
sulfamethoxazole+ trimethoprim	tablet, 400+80 mg	Far Manguinhos	Brazil	Yes	n/a
sulfamethoxazole+ trimethoprim	tablet, 400+80 mg	Fourrts Laboratories Pvt. Ltd.	India	Yes	Myanmar, Uganda, Sri Lanka
sulfamethoxazole+ trimethoprim	tablet, 400+80 mg	Gracure Pharmaceuticals Ltd.	India	Yes	n/a
sulfamethoxazole+ trimethoprim	tablet, 400+80 mg	Sdn Bhd	Malaysia	Yes	Singapore, Hong Kong, Sri Lanka, Myanmar, Yemen, El Salvador, Mali,
sulfamethoxazole+ trimethoprim	tablet, 400+80 mg	Intas Pharmaceuticals Ltd	India	Yes	Haiti, Singapore, Zimbabwe, Armenia, Zambia, Belarus, Costa Rica, Nicaragua
sulfamethoxazole+ trimethoprim	tablet, 400+80 mg	Intas Pharmaceuticals Ltd	India	Yes	Myanmar
sulfamethoxazole+ trimethoprim	tablet, 400+80 mg	IPCA Laboratories Limited	India	Yes	Ethiopia, Kazakhstan, Malawi, Myanmar, Nigeria, Russia, Sri Lanka, Tanzania, Trinidad & Tobago, Uganda, Ukraine, Yemen, Zimbabwe, Afghanistan, Mali, Sudan
sulfamethoxazole+ trimethoprim	tablet, 400+80 mg	IVAX Pharmaceuticals Mexico, S.A. de C.V.	Mexico	Yes	Costa Rica, El Salvador, Honduras, Nicaragua, Haiti, Dominican Republic, Guatemala, Chile
sulfamethoxazole+ trimethoprim	tablet, 400+80 mg	Pharmadrug	Germany	Yes	n/a
sulfamethoxazole+ trimethoprim	tablet, 400+80 mg	Ranbaxy Laboratories Ltd	India	Yes	Belarus, Burkina Faso, Cameroon, Kazakhstan, Lithuania, Malawi, Malaysia, Moldova, Myanmar, Russia, Senegal, Sri Lanka, Thailand, Trinidad & Tobago, Uganda, Ukraine, Yemen
sulfamethoxazole+ trimethoprim	tablet, 400+80 mg	Remedica Ltd.	Cyprus	Yes	Ethiopia, Hong Kong, Malawi, Myanmar, Oman, Sudan
sulfamethoxazole+ trimethoprim	tablet, 400+80 mg	Sanavita Aktiengesellschaft & Co.	Germany	Yes	Russia, Madagascar, Armenia, Kazakhstan, Uzbekistan
sulfamethoxazole+ trimethoprim	tablet, 400+80 mg	Sanofi-Synthelabo Vietnam	Viet Nam	Yes	Myanmar

ANNEX 1A. REGISTRATION STATUS OF PRODUCTS INCLUDED IN THE SOURCES AND PRICES SURVEY

International Non-Proprietary Name (INN)	Dosage form & strength	Manufacturer	Country	National Registration	Registration in other countries
sulfamethoxazole+ trimethoprim	tablet, 400+80 mg	Shiba Pharmaceuticals & Chemicals Ltd.	Yemen, Republic of	Yes	In process for: United Arab Emirates, Eritrea, Ethiopia, Iraq, Sudan, Tanzania
sulfamethoxazole+ trimethoprim	tablet, 400+80 mg	Strides Arcolab Limited	India	No	Sri Lanka
sulfamethoxazole+ trimethoprim	tablet, 400+80 mg	Lomapharm	Germany	Yes	n/a
sulfamethoxazole+ trimethoprim	tablet, 800+160 mg	Apotex Protein, S.A. de C.V.	Mexico	Yes	Panama, Nicaragua, Dominican Republic
sulfamethoxazole+ trimethoprim	tablet, 800+160 mg	Rekah Pharmaceutical Group	Israel	Yes	n/a
tinidazole	tablet, 500 mg	Fourrts Laboratories Pvt. Ltd.	India	Yes	n/a
tinidazole	tablet, 500 mg	Gracure Pharmaceuticals Ltd.	India	Yes	n/a
tinidazole	tablet, 500 mg	Pharmadrug	Germany	No	n/a
tinidazole	tablet, 500 mg	Remedica Ltd.	Cyprus	Yes	Ethiopia, Kenya, Malaysia, Sudan
vinblastine	powder for injection, 10 mg (sulfate) in vial	Korea United Pharm. Inc.	Korea, Republic of	Yes	n/a
vinblastine	powder for injection, 10 mg (sulfate) in vial	Lab. Filaxis International S.A.	Argentina	Yes	Uruguay, Mexico, Brazil
vinblastine	powder for injection, 10 mg (sulfate) in vial	Neon Antibiotics PVT. Ltd.	India	Yes	n/a
vincristine	injection, 1 mg (sulfate)/ ml in vial	Neon Antibiotics PVT. Ltd.	India	Yes	n/a
vincristine	powder for injection, 1 mg (sulfate) in vial	Korea United Pharm. Inc.	Korea, Republic of	Yes	n/a
vincristine	powder for injection, 1 mg (sulfate) in vial	Lab. Filaxis International S.A.	Argentina	Yes	Chile, Uruguay, Mexico, Brazil, Colombia
vincristine	powder for injection, 5 mg (sulfate) in vial	Korea United Pharm. Inc.	Korea, Republic of	Yes	n/a
vinorelbine	injection concentrate 10mg/ml in vial	Lab. Filaxis International S.A.	Argentina	Yes	Uruguay, Brazil
vinorelbine	injection concentrate 10mg/ml in vial	Pierre Fabre Laboratory	France	Yes	Iraq, Algeria
zalcitabine	0.75mg, tab	Far Manguinhos	Brazil	Yes	n/a
zalcitabine	0.75mg, tab	Lab. Filaxis International S.A.	Argentina	Yes	Colombia
<b>*ZDV/3TC</b>	300mg/150mg, tab	Cipla Ltd.	India	Yes	Tanzania, Cambodia, Burundi, Congo, Uganda, Myanmar, Syria, Ghana, Guinea, Central African Republic
ZDV/3TC	300mg/150mg, tab	Far Manguinhos	Brazil	Yes	n/a
ZDV/3TC	300mg/150mg, tab	Lab. Filaxis International S.A.	Argentina	Yes	n/a
ZDV/3TC	300mg/150mg, tab	Laboratorio Dosa S.A.	US	Yes	Argentina, Uruguay, Paraguay, Chile, Bolivia
<b>*ZDV/3TC</b>	300mg/150mg, tab	Ranbaxy Laboratories Ltd	India	Yes	Benin, Brazil, Cambodia, Central African Republic, Chad, Ethiopia, Guatemala, Guinea, Mali, Mauritius, Myanmar, Nigeria, Senegal, Togo
ZDV/3TC	300mg/150mg, tab	Strides Arcolab Limited	India	No	n/a
ZDV/3TC	300mg/150mg, tab	The Government Pharmaceutical Organization	Thailand	Exempt	n/a
zidovudine (AZT)	capsule, 100 mg	Apotex Protein, S.A. de C.V.	Mexico	Yes	Panama, Nicaragua, Dominican Republic
zidovudine (AZT)	capsule, 100 mg	Aurobindo Pharma Ltd.	India	Yes	Cambodia
<b>*zidovudine (AZT)</b>	capsule, 100 mg	Cipla Ltd.	India	Yes	Uganda, Iran, Zambia, Ghana, Malawi, Cambodia, Congo, Myanmar, Guinea, Tanzania
<b>*zidovudine (AZT)</b>	capsule, 100 mg	Combino Pharm, S.L.	Spain	Yes	Ivory Coast, Gabon
zidovudine (AZT)	capsule, 100 mg	Far Manguinhos	Brazil	Yes	n/a

SOURCES AND PRICES OF SELECTED DRUGS AND DIAGNOSTICS FOR PEOPLE LIVING WITH HIV/AIDS

International Non-Proprietary Name (INN)	Dosage form & strength	Manufacturer	Country	National Registration	Registration in other countries
zidovudine (AZT)	capsule, 100 mg	IPCA Laboratories Limited	India	Yes	Ghana, Kenya, Tanzania, Uganda, Zaire, Zimbabwe
zidovudine (AZT)	capsule, 100 mg	Korea United Pharm. Inc.	Korea, Republic of	Yes	List to be provided. Vietnam, Cambodia
zidovudine (AZT)	capsule, 100 mg	Lab. Filaxis International S.A.	Argentina	Yes	Chile, Uruguay, Mexico, Brazil, Venezuela, Rep. Dominican
zidovudine (AZT)	capsule, 100 mg	Laboratorio Dosa S.A.	US	Yes	Argentina, Uruguay, Paraguay, Chile, Bolivia
<b>*zidovudine (AZT)</b>	capsule, 100 mg	Ranbaxy Laboratories Ltd	India	Yes	Nigeria
zidovudine (AZT)	capsule, 100 mg	Samchully Pharm. Co., Ltd.	Korea, Republic of	Yes	Vietnam, Guinea
zidovudine (AZT)	capsule, 100 mg	Strides Arcolab Limited	India	No	n/a
zidovudine (AZT)	capsule, 100 mg	The Government Pharmaceutical Organization	Thailand	Exempt	Cambodia
zidovudine (AZT)	capsule, 250 mg	Apotex Protein, S.A. de C.V.	Mexico	Yes	Panama, Nicaragua, Dominican Republic
<b>*zidovudine (AZT)</b>	capsule, 250 mg	Combino Pharm, S.L.	Spain	Yes	Ivory Coast, Gabon
zidovudine (AZT)	capsule, 250 mg	Lab. Filaxis International S.A.	Argentina	Yes	Mexico, Brazil, Colombia
zidovudine (AZT)	capsule, 250 mg	Laboratorio Dosa S.A.	US	Yes	Argentina, Uruguay, Paraguay, Chile, Bolivia
zidovudine (AZT)	capsule, 250 mg	Samchully Pharm. Co., Ltd.	Korea, Republic of	Yes	Nigeria
zidovudine (AZT)	capsule, 250 mg	Strides Arcolab Limited	India	No	n/a
zidovudine (AZT)	capsule, 300 mg	Aurobindo Pharma Ltd.	India	Yes	Cambodia, Haiti
<b>*zidovudine (AZT)</b>	capsule, 300 mg	Cipla Ltd.	India	Yes	Malawi, Cameroon, Iran, Burundi, Congo, Uganda, Myanmar, Guinea, Tanzania
zidovudine (AZT)	capsule, 300 mg	Combino Pharm, S.L.	Spain	Yes	Ivory Coast
<b>*zidovudine (AZT)</b>	capsule, 300 mg	Ranbaxy Laboratories Ltd	India	Yes	Benin, Cambodia, Central African Republic, Chad, Congo, Guatemala, Guinea, Mali, Mauritius, Myanmar, Nigeria, Peru, Senegal, Togo
zidovudine (AZT)	capsule, 300 mg	Samchully Pharm. Co., Ltd.	Korea, Republic of	No	n/a
zidovudine (AZT)	capsule, 300 mg	The Government Pharmaceutical Organization	Thailand	Exempt	Cambodia
zidovudine (AZT)	injection, 10 mg/ml in 20-ml vial	Lab. Filaxis International S.A.	Argentina	Yes	Mexico, Brazil
zidovudine (AZT)	injection, 10 mg/ml in 20-ml vial	Laboratorio Dosa S.A.	US	Yes	Argentina, Uruguay, Paraguay, Chile, Bolivia
zidovudine (AZT)	oral solution, 50 mg/5 ml	Aurobindo Pharma Ltd.	India	Yes	n/a
<b>*zidovudine (AZT)</b>	oral solution, 50 mg/5 ml	Cipla Ltd.	India	Yes	Burundi, Congo, Uganda
zidovudine (AZT)	oral solution, 50 mg/5 ml	Combino Pharm, S.L.	Spain	Yes	n/a
zidovudine (AZT)	oral solution, 50 mg/5 ml	Lab. Filaxis International S.A.	Argentina	Yes	Uruguay, Mexico, Brazil, Colombia
zidovudine (AZT)	oral solution, 50 mg/5 ml	Laboratorio Dosa S.A.	US	Yes	Argentina, Uruguay, Paraguay, Chile, Bolivia

## ANNEX 1B

# Index of manufacturers

Manufacturer	Address	Telephone	Fax	E-mail/ Website	Products
Aleppo Pharmaceutical Industries (Alpha)	PO Box 517 Aleppo Syria	+963 21 224 4100	+963 21 221 4288	alphasyr@net.sy www.alpha-syria.com	azithromycin, ceftriaxone, ciprofloxacin
Alpharma	Jl. Raya Bogor km 28 P.O. Box 1044 JAT Jakarta 13710 Indonesia	+62 21 871 0311	+62 21 871 0044	herry.prasetya@alpharma.no	aciclovir, cefixime, ciprofloxacin, clarithromycin, metoclopramide, sulfamethoxazole+trimethoprim
Apotex Protein, S.A. de C.V.	Anil No. 865 Granjas Mexico, Iztacalco Mexico 08400	+52 5556 570888	+52 5556 570986	protein3@ibm.net www.apotex.com.mx	aciclovir, ciprofloxacin, didanosine, dimenhydrinate, fluoxetine, metoclopramide, miconazole, omeprazole, stavudine, sulfamethoxazole+trimethoprim, zidovudine (AZT)
Artesan Pharma GmbH & Co.	Osterbrooksweg 15 Schnefeld 22869 Germany	+49 40 542270	+49 40 542270	j.ahlers@pharma-aid.de http://www.pharma-aid.de	albandazole, amitrityline, erythromycin, ketoconazole, pyrimethamine, sulfamethoxazole+trimethoprim
Aventis Limited	6/2/A, Segun Bagicha Dhaka 1000 Bangladesh	+880 2 9562893	+880 2 9550009	khan-md.tarique@aventis.com http://www.aventis.com	ceftriaxone, ciprofloxacin, erythromycin, metoclopramide, prochlorperazine, sulfamethoxazole+trimethoprim
Aventis Pharma	20, Avenue Raymond Aron/ Tri E1/360 Antony Cedex 92165 France	+33 1 5571 7637	+33-1 5571 7447	sandrine.girardot@aventis.com http://www.aventis.com	bleomycin, cefixime, methotrexate, ofloxacin, pentamidine
Banner Pharmacaps Ltd.	5807 -47th Avenue Olds T4H 1S7 Canada	+1 403 556 2531	+1 403 556 8596	dmrichardson@banpharm.com http://www.banpharm.com	docusate sodium
Bayer AG	Pharma Division Leverkusen 51368 Germany	+49 214 30 24558	+49 214 30 58075	michaela.oxfort.mp@bayer-ag.de http://www.bayer.de	ciprofloxacin

Manufacturer	Address	Telephone	Fax	E-mail/ Website	Products
Beltapharm SpA	Via Stelvio, 66 Cusano Milanino 20095 Italy	+39 02 66401216	+39 02 6196714	f.pansera@beltapharm.com	albendazole, erythromycin, ketoconazole, miconazole
Bilim Pharmaceutical Ind.	Ayazaga Koyu Yolu G 42, Sok Maslak 34398 Turkey	+90 212 2852290	+90 212 2869472	info@bilimpharma.com http://www.bilimpharma.com	cefixime, clarithromycin, clindamycin, fluconazole, ketoconazole
Cheil Jedang Corp	CJ Bldg. 500, 5-Ga, Namdajeon-Ro, Jung-Gu Seoul 100 802 Korea	+82 2 726 8410	+82 2 726 8429	040100@cj.net http://www.cj.net	capreomycin, ceftriaxone, cycloserine
Chephasaar, Chem.- Pharm.Fabrick GmbH	Postfach 4249, Mühlstraße 50 St. Ingbert , 66386 Germany	+49 68 94 9710	+49 6894 971 199	sabine.itt@chephasaar.de http://www.clinda-saar.de	clindamycin
Cipla Ltd.	289, Bellasis Road Mumbai Central 400 008 India	+91 22 2308 2891	+9122 2307 0013	exports@cipla.com www.cipla.com	aciclovir, ciprofloxacin, efavirenz, etoposide, fluconazole, lamivudine, lamivudine/stavudine/nevirapine, nevirapine, stavudine, ZDV/3TC, zidovudine (AZT)
CLARIS Lifesciences Ltd	Corporate Towers, Near Parimal Crossing, Ellisbridge Ahmedabad 380 006 India	+91 79 656 3331	+91 79 6565 879	claris@clarislifesciences.com http://www.clarislifesciences.com	fluconazole, metoclopramide
Combino Pharm, S.L.	Carrer Fructuos Gelabert, 6-8 Edificio Conata 2 Sant Joan Despi 08970 Spain	+34 93 480 8833	+34 93 480 8832	info@combino-pharm.es www.combino-pharm.es	aciclovir, amphotericine B, ceftriaxone, clindamycin, fluoxetine, pentamidine, zidovudine (AZT)
Demo S.A.	21st km National Road Athens – Lamia Athens 145 68 Greece	+30 210 8161802	+30 210 8161587	lxenitos@demo.gr http://www.demo.gr	ceftriaxone, ciprofloxacin
Ecobi Farmaceutici S.a.s.	Via Enrico Bazzano, 26 Ronco Scrivia 16019 Italy	+39 010 935280	+39 010 9350679	ecobi@aleph.it www.ecobi.com	aciclovir, calcium folinate (leucovorin), miconazole, sulfadiazine, sulfamethoxazole+trimethoprim

Manufacturer	Address	Telephone	Fax	E-mail/ Website	Products
F. Hoffmann-La Roche Ltd	Pharma Development Drug Regulatory Affairs Bldg 74 Basel 4070 Switzerland	+41 61 688 1111	+41 61 691 9391	hans-ruedi.wiedmer@roche.com http://www.roche.com	nelfinavir, saquinavir
Far Manguinhos	Rua Sizenando Nabuco, 100 Manguinhos, C.P. 926 Rio de Janeiro 21041-250 Brazil	+55 21 3977 2424	+55 21 2290 1297	robertopatricio@far.fiocruz.br http://www.far.fiocruz.br	aciclovir, AZT/3TC, didanosine, indinavir, lamivudine, nevirapine, pyrimethamine, stavudine, sulfadiazine, sulfamethoxazole+trimethoprim, zalcitabine, zidovudine (AZT)
Genepharma SA	18th Km. Marathon Ave. Pallini 15351 Greece	+30 210 6039336/8	+30 210 6039402	info@genepharma.gr http://www.genepharma.gr	aciclovir, cefixime, ciprofloxacin, clarithromycin, fluconazole, fluoxetine, metoclopramide, ofloxacin, omeprazole
Glenmark Pharmaceuticals Ltd	L-82 & L-83 Verna Industrial Estate Verna 403 722 India	+91 22 2657 1060	+91 22 2657 2677	glenmarklab@vsnl.net www.glenmarkindia.com	ciprofloxacin, erythromycin, itraconazole, ofloxacin
Gracure Pharmaceuticals Ltd.	107, Magnum House -1, Karampura Complex, Shivaji Marg New Delhi 110 015 India	+91 11 25920344	+91 11 259 20747	gracure@vsnl.com	albendazole, amitriptyline, ciprofloxacin, erythromycin, fluconazole, ofloxacin, tinidazole, sulfamethoxazole+trimethoprim,
Heyl Chem.-pharm. Fabrik GmbH KG	Goerzallee 253 Berlin 14167 Germany	+49 30 8 16960	+49 308174049	info@heyhl-berlin.de http://www.heyhl-berlin.de	sulfadiazine
Hovid SDN. BHN.	121 Jalan Kuala Kangsar Ipoh 30010 Malaysia	+605 506 0690	+605 506 1215	info@hovid.com http://www.hovid.com/	aciclovir, erythromycin, ketoconazole, micronazole ofloxacin, sulfamethoxazole+trimethoprim
ICN Hungary Co. Ltd.	Tiszavasvari, Kabay J.u.29 4440 Hungary	+36 13455916	+36 13455923	gkeresztury@icnpharm.com http://www.icnpharm.com	buprenorphine, codeine
Intas Pharmaceuticals Ltd	2nd floor, Chinubhai Centre, Ashram Road Ahmedabad 380 009 India	+91 79 657 6655	+91 79 657 8862	alkesh_shah@intaspharma.com www.intaspharma.com	amitriptyline, ciprofloxacin, clarithromycin, itraconazole, ketoconazole, lorazepam, naltrexone HCl, ofloxacin, omeprazole, sulfamethoxazole+trimethoprim

Manufacturer	Address	Telephone	Fax	E-mail/ Website	Products
IPCA Laboratories Limited	48, Kandivli Industrial Estate Kandivli (West) 400067 India	+91 22 28684241/ 9390/2030	+91 22 2868 6613	ipca@ipca.co.in http://www.ipca.co.in	aciclovir, ciprofloxacin, fluconazole, fluoxetine, lamivudine, metoclopramide, ofloxacin, sulfamethoxazole+trimethoprim, zidovudine (AZT)
IVAX Pharmaceuticals Mexico, S.A. de C.V	Calz. De Tlalpan 3007 Col. Santa Ursula Coapa 04650 Mexico	+52 5555 990000	+52 5556 178164	jpeniche@ivaxpharma.com.mx	ciprofloxacin, clarithromycin, fluoxetine, itraconazole, ketoconazole, miconazole, omeprazole
Korea United Pharm. Inc.	154-8, Nonhyn-Dong Kangnam-Ku Seoul Korea	+82 2 512 9982	+82 2 512 0144	trade@kup.co.kr www.kup.co.kr	aciclovir, albendazole, bleomycin, calcium folinate (leucovorin), cefixime, ceftriaxone, ciprofloxacin, clarithromycin, cycloserine, doxorubicine HCl, etoposide, fluoxetine, ketoconazole, methotrexate, ofloxacin, vinblastine, vincristine, zidovudine (AZT)
Lab. Filaxis International S.A.	Panama 2121 Martinez B1640DK Argentina	+54 11 4513 8009	+54 11 4513 8008	liliana.b.mendez@filaxis.com http://www.filaxis.com	aciclovir, calcium folinate (leucovorin), didanosine, docusate sodium, doxorubicine HCl, efavirenz, etoposide, ganciclovir, indinavir, lamivudine, methotrexate, nelfinavir, nevirapine, pentamidine, vinblastine, vincristine, vinorelbine, zalcitabine, stavudine, ZDV/3TC, zidovudine (AZT)
Lab. Renaudin	125, Bureaux de la Colline Saint-Cloud Cedex 92213 France	+33 1 4112 0382	+33 1 4112 0377		morphine, pethidine
Laboratorio Dosa S.A.	2818 NW 79th Avenue Miami 33122 USA	+1 305 591 9449	+1 305 591 7773	hisham@hishamal-fayed.com	didanosine, indinavir, lamivudine, nelfinavir, nevirapine, stavudine, ZDV/3TC, zidovudine (AZT)
Laboratorio Reig Jofre S.A.	C/ Gran Capitan 10 Sant Joan Despi 08970 Barcelona Spain	+34 91 4153801	+34 91 5191849	rjexport@reigjofre.com www.reigjofre.com	sulfadiazine
Laboratorios Cinfa S.A.	Olaz-Chipi, 10 Poligono Areta Huarte-Pamplona 31620 Spain	+34 948 33 51 02	+34 948 33 03 67	bsanado@cinfa.com www.cinfa.com	aciclovir, ciprofloxacin, dimenhydrinate, fluoxetine, omeprazole
Lachifarma, SRL	S.S. 16 Zona Industriale Zollino Zollino (LE) 73010 Italy	+39 0836 600 661	+39 0836 600 662	info@lachifarma.com http://www.lachifarma.com	erythromycin, miconazole, naltrexone HCl, sulfamethoxazole+trimethoprim




Manufacturer	Address	Telephone	Fax	E-mail/ Website	Products
Lomapharm	Postfach 1210 Langes Feld 5 Emmerthal, 31860 Germany	+49 5155 63200	+49 5155 63240	lomapharm@t-online.de http://www.lomapharm.de	aciclovir, cefixime, codeine, lorazepam, metoclopramide, miconazole, sulfamethoxazole+trimethoprim
Lupin Laboratories Ltd.	159, C.S.T. Road, Kalina Santacruz East Mumbai 400 098 India	+91 22 2652 8257	+91 22 2652 8321	lupin@bom5.vsnl.net.in	ceftriaxone, ciprofloxacin, rifabutin
Lyka Labs Limited	77, Nehru Road, Vile Parle (East) Mumbai 400 099 India	+91 22 2610 6754	+91 22 2611 1024	lykaexports@rediffmail.com www.lykalabs.com	albendazole, azithromycin, cefixime, ceftriaxone, ciprofloxacin, clarithromycin, erythromycin, ofloxacin, omeprazole, sulfamethoxazole+trimethoprim
Martindale Pharmaceuticals Ltd.	Hubert Road Brentwood CM14 4LZ United Kingdom	+44 1277 266600	+44 1277 266688	matt.bartlett@ martindalepharma.co.uk http://www.martindalepharma. co.uk	morphine, pethidine
Medac GmbH, International Operations	Theaterstraße 6 Wedel 22880 Germany	+49 4103 8006 0	+49 4103 8006 100	d.rehder@medac.de www.medac.de	calcium folinate (leucovorin), doxorubicine HCl, etoposide
Mepha Ltd	Dornacherstrasse 114 Aesch 41147 Switzerland	+41 61 705 4343	+41 61 705 4338	hanspeter.baumann@mepha.ch www.mepha.com	ceftriaxone, ciprofloxacin, omeprazole
Merck & Co., Inc.	One Merck Drive P.O. Box 100 Whitehouse Station NJ 08889-010 USA	+1 908 423 3981	+1 908 735 1704	jeffrey_sturchio@merck.com http://www.merck.com	efavirenz, indinavir, ivermectin
Neon Antibiotics PVT. Ltd.	146A, Damji Shamji Industrial Complex M. Caves Road 28 Mahal Ind. Estate Andheri (East) 400 093 India	+91 22 2687 5366/ 67/68/69	+91 22 2687 3502	neon@bom1.vsnl.net.in www.neongroup.com	amphotericine B, aciclovir, bleomycin, capreomycin, doxorubicine HCl, etoposide, methotrexate, omeprazole, spectinomycin, vinblastine, vincristine

Manufacturer	Address	Telephone	Fax	E-mail/ Website	Products
Neon Laboratories Ltd.	146A, Damji Shamji Industrial Complex M. Caves Road 28 Mahal Ind. Estate Andheri (East) 400 093 India	+91 22 2687 5366/ 67/68/69	+91 22 2687 3502	neon@bom1.vsnl.net.in www.neongroup.com	ceftriaxone, pethidine
Panpharma	Z.I. du Clairay Luitre 35133 France	+33 2 99979127	+33 2 99979983	mlebellego@panpharma.fr http://www.panpharma.fr	ceftriaxone
Pharmadrug	Saseler Chausee 191a Hamburg 22393 Germany	+49 40 601 79 37	+49 40 601 63 58	info@pharmadrug.de	albendazole, amitriptyline, codeine, dimenhydrinate, erythromycin, lorazepam, metoclopramide, miconazole, pethidine, prochlorperazine, pyrimethamine, sulfadiazine, sulfamethoxazole+trimethoprim, tinidazole
Phyto-Riker Pharmaceuticals Ltd.	P.O. Box 5266 Accra-North Ghana	+233 21 760316	+233 21 760316	info@phyto-riker.com http://www.phyto-riker.com	erythromycin
Pierre Fabre Laboratory	45, place Abel Gance Boulogne, 92654 France	+33 450 353555	+33 450 353590	f.porte@pierre-fabre.com http://www.pierre-fabre.com	vinorelbine
Purna Pharmaceuticals NV	K.M.O. Zone "Pullaar" Rijksweg 17 Puurs 2870 Belgium	+32 388 60085	+32 388 62538	info@purna.be http://www.purna.be	erythromycin, miconazole, sulfamethoxazole+trimethoprim
Ranbaxy Laboratories Ltd	13th Floor, 6 Devika Towers New Delhi 110 019 India	+91 11 2600 20 21	+91 11 124 234 31 24	sandeep.juneja@ranbaxy.com www.ranbaxy.com	aciclovir, ceftriaxone, ciprofloxacin, clarithromycin, efavirenz, fluconazole, fluoxetine, lamivudine, lamivudine/stavudine/nevirapine, ofloxacin, stavudine, sulfamethoxazole+trimethoprim, ZDV/3TC, zidovudine (AZT)
Rekah Pharmaceutical Group	30 Hamelacha Street Holon 58859 Israel	+972 3 558 1233	+972 3 556 5919	rite@rekah.co.il http://www.rekah.co.il	ceftriaxone, codeine, sulfamethoxazole+trimethoprim
Remedica Ltd.	Acharmon Street Ypsonas Industrial Estate, PO Box 51706 Limassol 3508 Cyprus	+357 25 393444	+357 5 390192	remedica@cytanet.com.cy www.cyprus-services.com/ remedica	aciclovir, albendazole, amitriptyline, ciprofloxacin, clarithromycin, codeine, erythromycin, fluconazole, fluoxetine, ketoconazole, metoclopramide, ofloxacin, prochlorperazine, sulfamethoxazole+trimethoprim, tinidazole

Manufacturer	Address	Telephone	Fax	E-mail/ Website	Products
Samchully Pharm. Co., Ltd.	947-7, Daechi-Dong, Gangnam-Gu Seoul 135-735 Korea	+82 2 527 6300	+82 2 561 6006	chem@samchullypharm.com http://www.samchullypharm.com	aciclovir, cefixime, ciprofloxacin, stavudine, zidovudine (AZT)
Sanavita Aktiengesellschaft & Co.	Am Bahnhof 1-3 Werne 59368 Germany	+49 2389 79720	+49 2389 797259	info@sanavita.net www.sanavita.net	erythromycin, sulfamethoxazole+trimethoprim
Sanofi-Synthelabo Vietnam	440 Nguyen Thi Minh Khai, D.3 Ho Chi Minh City Vietnam	+84 8 8341440	+84 8 8341884	hong-thinh.nguyen@sanofi-synthelabo.com www.sanofi-synthelabo.com	aciclovir, amoxicillin, sulfamethoxazole+trimethoprim
Scanpharm A/S	Topstykket, 12 Birkerød, 3460 Denmark	+45 45822022	+45 45823033	sh@scanpharm.dk http://www.scanpharm.dk	sulfamethoxazole+trimethoprim
Shiba Pharmaceuticals & Chemicals Ltd.	P.O. Box 4265 Seif Street 9th Branch Bldg. No. 7 Sana'a Yemen	+967 1 218 451/2/3	+967 1 218 454	ahiba@y.net.ye	albendazole, azithromycin, ciprofloxacin, clindamycin, erythromycin, fluconazole, ofloxacin, pyrimethamine, sulfamethoxazole+trimethoprim
SM Pharmaceuticals Sdn Bhd	Lot 88, Sungai Petani Industrial Estate Sungai Petani 08000 Malaysia	+604 4411801	+604 4411341	smformu@po.jaring.my	aciclovir, cefixime, crotamiton, erythromycin, ketoconazole, omeprazole, sulfamethoxazole+trimethoprim
Strides Arcolab Limited	Strides House Bilekahalli Opp. IIMB Bannerghatta Rd. Bangalore 560 076 India	+91 80 6581 343	+91 80 6584 330	info@stridesarco.com www.stridesarco.com	albendazole, azithromycin, ceftriaxone, ciprofloxacin, clarithromycin, clindamycin, didanosine, efavirenz, erythromycin, fluconazole, indinavir, ketoconazole, lamivudine, nevirapine, omeprazole, stavudine, sulfamethoxazole+trimethoprim, ZDV/3TC, zidovudine (AZT)
Tecnimed Sociedade Tecnico Medicinal, S.A.	Rua. Prof. Henrique de Barros Edificio Sagres, 3 A Prior Vehlho 2685-338 Portugal	+351 21 942 0081	+351 21 941 0839	tecnimede@mail.telepac.pt	azithromycin, ciprofloxacin, naltrexone HCl, ofloxacin, omeprazole
The Government Pharmaceutical Organization	75/1 Rama VI Rd. Ratchathewi Bangkok, 10 400 Thailand	+662 248 1482	+662 248 1488	sukhum@health.moph.go.th www.moph.go.th/gpo	clarithromycin, dimenthydrinate, fluconazole, ketoconazole, lamivudine, lamivudine/stavudine/nevirapine, nevirapine, metoclopramide, stavudine, sulfamethoxazole+trimethoprim, ZDV/3TC, zidovudine (AZT)

## ANNEX 1C

# Geographical distribution of participating manufacturers



## ANNEX 2

# WHO Bulk Procurement Scheme 2003

Specifications of HIV test kits

### SIMPLE/RAPID ASSAYS

Assay name (Manufacturer)	Company's Order Code	No. of tests per kit	HIV type	Assay type Antigen	Sample type	Equipment requirements	Cost/test' €/¥	Cost/test' US \$
CAPILLUS HIV-1/HIV-2 (Trinity Biotech plc)	6058G 6048G	20 100	HIV-1+2	agglutination recombinant proteins	whole blood serum/plasma	G		1.10
DETERMINE™ HIV-1/2 (Abbott)	7023-13	100	HIV 1+2	lateral flow recombinant protein, synthetic peptide	whole blood serum/plasma	D, G		Access countries: 0.80 Elsewhere: 1.00
Genie II HIV-1/HIV-2 <sup>2</sup> (BioRad)	72323	40	HIV-1 HIV-2	lateral flow recombinant proteins synthetic peptides	serum/plasma	D, G	€2.58	(2.78)
HIV 1&2 DOUBLECHECK (Organics Ltd)	60332000	40	HIV-1+2	lateral flow recombinant proteins, synthetic peptides	serum/plasma	G		1.00
HIV TRIDOT <sup>2</sup> (Mitra & Co., India)	IR130010 IR130050 IR130100 IR130200	10 50 100 200	HIV-1 HIV-2	flow through recombinant proteins	serum/plasma	G	€1.20 €1.10 €1.00 €0.90	(1.29) (1.18) (1.08) (0.97)
IMMUNOCOMB II BISPOT <sup>2</sup> HIV-1&2 (Organics Ltd)	60432002	36	HIV-1 HIV-2	dipstick synthetic peptides	serum/plasma	D, G		1.00
InstantScreen Rapid HIV-1/2 Assay (Gaifar GmbH)	GA101 GA102 GA104	20 200 1	HIV-1+2	flow through epitope-combi antigens	whole blood serum/plasma	G D, G		4.10 2.90 6.00
SERODIA HIV-1/2 (Fujirebio)	220658 226063	100 220	HIV-1+2	agglutination recombinant proteins	serum/plasma	D, G	¥130 ¥130	(1.11) (1.11)
UNI-GOLD™ HIV (Trinity Biotech plc)	1206502	20	HIV-1+2	lateral flow recombinant proteins	whole blood serum/plasma	G		1.25

Assay name (Manufacturer)	Company's Order Code	No. of tests per kit	HIV type	Assay type Antigen	Sample type	Equipment requirements	Cost/test' €/¥	Cost/test' US \$
ADVANCED QUALITY™ RAPID HIV TEST (InTec Products Inc.) (SEAR & WPR only)	ITP02002-TC40	40	HIV-1+2	lateral flow recombinant proteins	whole blood serum/plasma	D, G		0.50
FIRST RESPONSE™ HIV-1/ HIV-2 WB Card Test (Premier Medical Corporation) (SEAR & WPR only)	DD/138	30	HIV-1+2	lateral flow recombinant proteins	whole blood serum/plasma	D, G		0.70
INSTANTCHEK™ HIV 1+2 RAPID TEST (EY Laboratories) (SEAR & WPR only)	8-1003-40 8-1003-100	40 100	HIV-1+2	lateral flow	whole blood serum/plasma	G		1.07 1.00
SD BIOLINE HIV 1/2 3.02 (Standard Diagnostics Inc.) (SEAR & WPR only)	03FK10	30	HIV-1 HIV-2	lateral flow recombinant proteins	whole blood serum/plasma	D, G		0.92
<b>ELISA ASSAYS</b>								
ENZYGNOST ANTHIV 1/2 plus (Dade Behring AG) Enzygnost/TMB reagent kit	OQFK13 OQFK21 OQFK17	2 x 96 10 x 96	HIV-1+2+0	recombinant proteins	450 nm	A, B, C, D, E, F		0.99 0.75
GENSCREEN HIV Ag-Ab (BioRad)	72375 72376	96 480	HIV-1+2+0 HIV Ag	recombinant proteins, synthetic peptides	450 nm 620 nm	A, B, C, D, E, F	€0.55 €0.50	(0.59) (0.54)
HIV-1/HIV-2 gO EIA (Abbott)	1D89-24 1D89-32	100 1000	HIV-1+2+0	recombinant proteins	492 nm	A, B, C, D, E, F		0.85 0.60
HIV EIA (Anilabsystems Ltd OY)	6111011 6111012 6111013	96 480 960	HIV-1+2	synthetic peptides	450 nm	A, B, C, D, E, F	€0.40 €0.36 €0.34	(0.43) (0.39) (0.37)
RECOMBIGEN HIV-1/2 EIA (Trinity Biotech plc)	960401A	192	HIV-1+2	recombinant proteins	492 nm	A, B, C, D, E, F		0.45
UBI HIV-1/2 EIA (United Biomedical)	680328	192	HIV-1+2	synthetic peptides	492 nm	A, B, C, D, E, F		0.40
VIRONOSTIKA HIV UNIFORM II PLUS O (Biomérieux BV)	284017 284018	192 576	HIV-1+2+0	recombinant proteins, synthetic peptides	450 nm	A, B, C, D, E, F	€0.63 €0.25	(0.69) (0.49)

## SUPPLEMENTAL ASSAYS

Assay name (Manufacturer)	Company's Order Code	No. of tests per kit	HIV type	Assay type Antigen	Sample type	Equipment requirements	Cost/test <sup>1</sup> €/¥	Cost/test <sup>1</sup> US \$
HIV BLOT 2.2 <sup>2</sup> (GeneLabs Diagnostics)	11031-018 11031-036	36	HIV-1+2	viral lysate + synthetic peptide	NA	C, D, E		10.97
INNO-LIA HIV-1/HIV-2 Ab <sup>2</sup> (Innogenetics)	80007	20	HIV-1+2	recombinant + synthetic peptide	NA	D, E	€12.00	(12.92)
PEPTI-LAV 1-2 <sup>2</sup> (BioRad)	72253	10	HIV-1, HIV-2	synthetic peptides	NA	C, D, E	€15.00	(16.15)
NEW LAV BLOT II (BioRad)	72252	18	HIV-2		NA	D, E	€13.00	(13.99)

## Notes

<sup>1</sup> Please note that this price does not include freight nor other charges.

<sup>2</sup> These assays can discriminate between HIV-1 and HIV-2.

Equipment requirements: **A:** ELISA reader; **B:** ELISA washer; **C:** Consumables; **D:** Pipette; **E:** Power supply; **F:** For large volume testing more than 40 samples daily; **G:** For small volume testing 1 to 40 samples daily.

## ANNEX 3A

# Summary of main characteristics of methods for CD4/CD8 lymphocyte determination

	Flow cytometry	FACSCount <sup>tm</sup>	Coulter manual CD4+ count kit	Zymune	Capcellia	Dynabeads <sup>R</sup>	Immunoalkaline Phosphatase
<b>Manufacturer</b>	Becton Dickinson Coulter Corp. Ortho Diagnostic Syst.	Becton Dickinson	Coulter Corp.	Zynaxis Inc.	Sanofi Diagnostics Pasteur	Dynal A/S	Reagents available commercially
<b>Instrument</b>	Flow cytometer and computer assisted analysis. Preparation can be automated. May need use of cell counter.	Automated special instrument	Automated or light microscope and hematocytometer.	Microtiter EIA	Microtiter EIA	Magnet and counting equipment* alt. light or fluorescence microscope	Light microscope
<b>Detection system</b>	Fluorescence labelled MAB against cell surface molecules.	Fluorescence labelled anti-CD3, CD4 and CD8 MAB	anti-CD4 MAB conjugated to beads	Anti-CD4 and CD8 MAB	Anti-CD4 and CD8 MAB	Anti-CD4 and CD8 conjugated to magnetic beads.	Staining of blood smears with anti-CD3, CD4 and CD8 MAB
<b>Specimen</b>	Whole blood with RBC lysis	Whole blood	Whole blood	Whole blood	PBMC	Whole blood	Blood smear
<b>Results</b>	Double, triple or quadruple stainings of any cell surface marker where MAB are available.	CD3, CD4 and CD8 counts	CD4 counts	CD4 and CD8 counts	pmol CD4/L and CD8/L	CD4 and CD8 counts	CD3, CD4 and CD8 counts (or any MAB of interest)
<b>Correlation with flow cytometry (corr coeff)</b>	NA	0.93-0.98 (several international studies)	0.74-0.91 (several international studies)	0.92-0.94 (two studies in USA)	NA	0.94 (one study)	0.96 (one study)
<b>Cost (Instruments, USD)</b>	40-80 000	25 000	2000	15 000 (standard equipment for EIA)	15 000 (standard equipment for EIA)	2000-10 000	2000



	Flow cytometry	FACSCount™	Coulter manual CD4+ count kit	Zymmune	Capcellia	Dynabeads®	Immunoalkaline Phosphatase
<b>Cost/test (reagents only; USD, approx.)</b>	10–15	20	8		28	5	3
<b>Advantages</b>	Powerful and flexible, allows for double, triple or quadruple stainings. Can be used for examination of difficult samples where alternative techniques often are insufficient.	Few steps, less human error. Low biohazard risk. Quick results. Gives CD3, CD4 and CD8 counts.	Simple and rapid	Simple. Can process many samples at a time. Gives CD4 and CD8 counts.	Gives CD4 and CD8 counts.	Gives CD4 and CD8 counts. Simple and rapid. Flexible, small sample volume. Robust.	Low cost. Long specimen shelf life. Small sample volume.
<b>Disadvantages</b>	Expensive equipment and reagents. Complex, requires highly trained personnel.	Expensive equipment and reagents. Work station allows only 8 samples at a time.	Short shelf life. Gives only CD4 counts.	Many pipetting steps.	PBMC isolation by density centrifugation. Does not give results as a cell number, i.e. difficult to compare results with e.g. flow cytometry. Expensive.	Few samples processed at a time. Subjectivity in visual counting. Short specimen shelf life. Not yet available as a kit.	Fairly complicated staining process. Laborious manual counting. Not available as a kit.

Precision (coeff of variation) similar for all assays as given by the manufacturers: <5–10%.

\* Automated cell counter or hemacytometer

**PBMC:** peripheral blood mononuclear cells; **MAB:** monoclonal antibodies; **EIA:** enzyme immunoassay; **RBC:** red blood cells; **NA:** not applicable

## ANNEX 3B

# Summary of main characteristics of Viral Load Technologies

(nucleic acid based)

Company	Abbott	Roche	Bayer	bioMérieux	bioMérieux	Primigen
Assay Name	LcX® HIV RNA Quantitative	Amplacor HIV-1 Monitor® Test	Versant® HIV-1 RNA 3.0 Assay	NucLiSens® HIV-1-QT	NucLiSens EasyQ® HIV-1	Retina™ Rainbow
Type of assay	RT-PCR	RT-PCR	bDNA	NASBA	NASBA	NASBA
Dynamic Range (copies/ml)	50–1 000 000	50–750 000	75–500 000	50–1 000 000	50–3 000 000	500–50 000 000
Specimen Type	Plasma	Plasma, dried blood spots	Plasma	Plasma, serum, dried blood spots	Plasma, serum, dried blood spots	Plasma, serum, whole blood, dried blood spots
Specimen volume	200–1 000 µl	100–500 µl	1 000–2 000 µl	10–2 000 µl	10–2 000 µl	200 µl
Area of HIV genome amplified	Pol	Gag	Pol	Gag	Gag	LTR
HIV-1 subtypes amplified	Group M (subtypes A-G) and Group O	All, plus some HIV-2	Group M (subtypes A-G)	All	All	All
Time for result	5 hours	6–7 hours	22 hours	2 hours	2 hours	1.5 hours
Cost/test	\$40	\$119	\$125	\$96	\$60	\$20
Number of samples/run	21 (+3 controls)	9–48	12–168	50	48	96
Equipment required <sup>14</sup>	Vacuum pump Centrifuge (x2) Heat block LCx Analyser Thermal cycler	COBAS Ampliprep Dead-air box Computer/printer Safety hood Heat block (x2) Centrifuge (x2)	Bayer System 340 (bDNA Analyzer, Data Management Software, and computer system) Centrifuge Heatblock Waterbath Vacuum system	EasyQ Extractor Fume hood Waterbath Heat block (x4) EasyQ Reader Centrifuge (x3) Shaker	EasyQ Extractor EasyQ Analyser	RetinAlyser Heatblock Computer Centrifuge

<sup>14</sup> All assays require pipettes, vortex mixers (& refrigerator for all but Primigen)

<b>Company</b>	<b>Abbott</b>	<b>Roche</b>	<b>Bayer</b>	<b>bioMérieux</b>	<b>bioMérieux</b>	<b>Primagen</b>
<b>Equipment Cost (\$US)</b>	8 500 + LCx Analyser 25 000	10 000 + COBAS Ampliprep 30 000	10 000 + Bayer System Analyzer	140 000	130 000	23 000
<b>(non-nucleic acid based)</b>						
<b>Company</b>	<b>Cavidi</b>	<b>Perkin Elmer</b>	<b>Innogenetics</b>			
<b>Assay Name</b>	<b>ExaVir™ Load Quantitative HIV-RT Load Kit</b>	<b>HIV-1 p24 Ultra ELISA ELAST ELISA amplification system</b>	<b>Innotest™</b>			
<b>Type of Assay</b>	Enzyme immunoassay for quantitation of RT activity	Enzyme immunoassay for quantitation of p24 antigen	Enzyme immunoassay for quantitation of p24 antigen	Enzyme immunoassay for quantitation of p24 antigen		
<b>Dynamic Range</b>	750–over 50 000 copies/ml	400 copies/ml	7 pg/ml –250	(50–200 000 copies/ml)		
<b>Specimen Type</b>	Plasma	Plasma, serum or cell culture supernatant	Plasma, serum or cell culture supernatant			
<b>Specimen Volume</b>	1 000 µl	100 µl	100 µl			
<b>Area of HIV Genome Selected for Amplification</b>	RT activity	p24 antigen	p24 antigen			
<b>HIV-1 Subtypes Amplified</b>	All, plus HIV-2	HIV-1	All, plus HIV-2			
<b>Time for Result</b>	24 hours	2.30 hours	2 hours			
<b>Cost/Test</b>	\$13–15	\$ 10	\$10			
<b>Number of Samples/Run</b>	30	96	96			
<b>Equipment Required<sup>15</sup></b>	Incubator (33deg), Freezer, ELISA reader, computer	Incubator, ELISA reader Refrigerator	Incubator (37deg), ELISA reader, refrigerator			
<b>Equipment Cost (\$US)</b>	9 000–10 000 (start up pack includes other necessary equipment and 3 kits)	7 000–9 000	7 000–9 000	7 000–9 000		

<sup>15</sup> All tests require pipettes and vortex mixers

## ANNEX 4

# Further reading, references, and contacts

- *Handbook on access to HIV/AIDS-related treatment. A collection of information, tools and resources for NGOs, CBOs and PLWA groups.* Joint publication UNAIDS, WHO and International AIDS Alliance, Geneva, 2003.  
<http://www.unaids.org/publications/documents/health/access/NGOtoolkit/index.html>  
[http://www.who.int/hiv/pub/prev\\_care/pub29/en/](http://www.who.int/hiv/pub/prev_care/pub29/en/)
- *Policy and programming options for reducing the procurement costs of essential medication in developing countries.* Levison, L., Boston University School of Public Health, 2003.  
[http://dcc2.bumc.bu.edu/richardl/IH820/Resource\\_materials/Web\\_Resources/Levison-hiddencosts.doc](http://dcc2.bumc.bu.edu/richardl/IH820/Resource_materials/Web_Resources/Levison-hiddencosts.doc)
- *A Commitment to Action for Expanded Access to HIV/AIDS Treatment. International HIV Treatment Access Coalition.* WHO, Geneva, 2002 (WHO/HIV/2002.24).  
[http://www.who.int/hiv/pub/prev\\_care/who\\_hiv\\_2002\\_24.pdf](http://www.who.int/hiv/pub/prev_care/who_hiv_2002_24.pdf)
- *Report on the Global HIV/AIDS Epidemic 2002.* UNAIDS/WHO, Geneva, 2002 (UNAIDS/02.46E).  
[http://www.unaids.org/worldaidsday/2002/press/update/epiupdate2002\\_en.doc](http://www.unaids.org/worldaidsday/2002/press/update/epiupdate2002_en.doc)
- *Guidelines on interaction with commercial enterprises to achieve health outcomes* (Annex to Guidelines on working with the private sector to achieve health outcomes). WHO, Geneva, 2000 (EB107/20).  
[http://www.who.int/gb/EB\\_WHA/PDF/EB107/ee20.pdf](http://www.who.int/gb/EB_WHA/PDF/EB107/ee20.pdf)
- *Guidelines for Drug Donations* (interagency document). WHO, Geneva, 1999 (WHO/EDM/PAR/99.4).  
<http://www.who.int/medicines/docs/pagespublications/supplypub.htm>
- *Ethical & Social Issues Relating to Antiretroviral Treatments, Module 9.* WHO/UNAIDS, Geneva, 1998 (WHO/ASD/98.1–UNAIDS/98.7).
- *Managing Drug Supply.* MSH/WHO, Second Edition, 1997.  
[http://www.msh.org/what\\_MSH\\_does/cpm/resources.html#top](http://www.msh.org/what_MSH_does/cpm/resources.html#top)

## Treatment guidelines

- Web version only: *The Selection and Use of Essential Medicines. Report of the WHO Expert Committee, 2003 (including the 13th Model List of Essential Medicines).* WHO, Geneva, 2003.  
<http://www.who.int/medicines/organization/par/edl/expertcomm.shtml>
- *The Selection and Use of Essential Medicines. Report of the WHO Expert Committee, 2002 (including the 12th Model List of Essential Medicines).* WHO, Geneva, 2003 (WHO Technical Report Series, No. 914).  
<http://www.who.int/medicines/organization/par/edl/expertcomm.shtml>
- *WHO Model Formulary 2002.* World Health Organization, Geneva, 2002.  
<http://mednet3.who.int/mf/intro.asp>
- *Scaling up antiretroviral therapy in resource-limited settings: Guidelines for a public health approach.* WHO, Geneva, 2002.  
[http://www.who.int/hiv/pub/prev\\_care/ScalingUp\\_E.pdf](http://www.who.int/hiv/pub/prev_care/ScalingUp_E.pdf)
- *Guidelines for the management of sexually transmitted infections.* WHO, Geneva, 2001 (WHO HIV/AIDS/2001.01).  
<http://www.who.int/hiv/pub/sti/pub6/en/>
- *AIDS: Palliative Care. UNAIDS Technical Update.* UNAIDS, Geneva, 2000.  
<http://www.unaids.org/publications/documents/care/general/JC-PalliCare-TU-E.pdf>
- *Safe and effective use of antiretroviral treatments in adults, with particular reference to resource limited settings.* WHO/UNAIDS/International AIDS Society, Geneva, 2000 (WHO/HSI/2000.04).  
<http://www.paho.org/english/hcp/hca/useARVadults.pdf>
- *WHO Model Prescribing Information: Drugs Used in HIV-related Illnesses.* WHO, Geneva, 1999 (WHO/DMP/DSI/99.2).  
<http://www.who.int/medicines/library/qsm/who-dmp-dsi-99-2/who-dmp-dsi-99-2.htm>

## Intellectual Property rights and pharmaceuticals

- *Drug patents under the spotlight: sharing practical knowledge about pharmaceutical patents*. MSF, Geneva, 2003.  
<http://www.accessmed-msf.org/prod/publications.asp?scntid=2252003114784&contenttype=PARA&>
- *Globalization, patents and drugs. An annotated bibliography*. Health Economics and Drugs EDM Series No. 9. WHO, Geneva, 2002 (EDM/PAR/2002.1).  
<http://www.who.int/medicines/library/par/who-edm-par-2001-1/who-edm-par-2001-1.htm>
- *Implications of the DOHA Declaration on the TRIPS Agreement and public health*. WHO, Geneva, 2002 (WHO/EDM/PAR/2002.3).  
[http://www.who.int/medicines/library/docseng\\_from\\_a\\_to\\_z.shtml#p](http://www.who.int/medicines/library/docseng_from_a_to_z.shtml#p)
- *Network for monitoring the impact of globalization and TRIPS on Access to Medicines. Meeting report*. 2001. Health Economics and Drugs EDM Series No. 11 (WHO/EDM/PAR/2002.1)
- *Globalization, TRIPS and Access to Pharmaceuticals*. WHO Policy Perspectives on Medicines, No.3. WHO, Geneva, 2001.  
<http://www.who.int/medicines/organization/ood/ood6pagars.shtml>
- *Patent situation of HIV/AIDS-related drugs in 80 countries*. UNAIDS/WHO, Geneva, 2000.  
[http://www.who.int/medicines/library/docseng\\_from\\_a\\_to\\_z.shtml#g](http://www.who.int/medicines/library/docseng_from_a_to_z.shtml#g)
- *Globalization and Access to Drugs. Perspectives on the WTO/TRIPS Agreement*. Health Economics and Drugs EDM Series No. 7 Revised (WHO/DAP/98.9)

## Pricing strategies

- *Cost-containment mechanisms for Essential Medicines, including antiretrovirals, in China*. WHO, Geneva, 2003 (WHO/EDM/PAR/2003.6).  
<http://www.who.int/medicines/>
- *Medicine Prices: a new approach to measurement, 2003 edition*. Joint WHO and HAI publication, Geneva, 2003 (WHO/EDM/PAR/2003.2).  
<http://www.who.int/medicines/library/prices.shtml>
- *Public-Private Roles in the pharmaceutical sector. Implications for equitable access and rational drug use*.

Drug Action Programme on Essential Drugs, WHO, Geneva, 1997 (WHO/DAP/97.2).

<http://www.who.int/medicines/library/dap/who-dap-97-12/who-dap-97-12.htm>

- *Overview of pharmaceutical pricing and reimbursement regulation in Europe*. Panos Kanavos, LSE Health and Social Care, 2001
- *Annex: Comparative Review of Drug Prices. Policies on Pricing and Reimbursement of Medicines in Europe, Networking for Information Exchange among policy Makers*. WHO Regional Office for Europe, Copenhagen, 2000.

## Websites

### Partner sites

UNAIDS: [www.unaids.org](http://www.unaids.org)

UNICEF: [www.unicef.org](http://www.unicef.org)

WHO: [www.who.int](http://www.who.int)

MSF: [www.msf.org](http://www.msf.org)

### Public drug prices

#### Spain:

<http://www.cof.es>

<http://www.canaldefarmacia.com>

#### UK:

<http://www.drugtariff.com>

<http://www.doh.gov.uk/generics>

#### Brazil:

<http://bpreco.saude.gov.br/pls/BPREFD/consulta.inicio>

#### Latin America & Caribbean:

[http://www.paho.org/English/HCP/HCA/antiretrovirals\\_HP.htm](http://www.paho.org/English/HCP/HCA/antiretrovirals_HP.htm)

#### Canada:

<http://www.pmprb-cepmb.gc.ca>

#### WHO:

<http://www.who.int/medicines/organization/par/ipc/drugpriceinfo.shtml>

#### Other:

<http://cptech.org/ip/health/econ/pricingstudies.html>

## Treatment & testing guidelines

### Taken from

[http://www.who.int/HIV\\_AIDS/first.html#HIV/AIDS%20Care%20and%20Antiretrovirals](http://www.who.int/HIV_AIDS/first.html#HIV/AIDS%20Care%20and%20Antiretrovirals)

- Safe and effective use of antiretroviral therapy in adults with reference to resource poor settings 2000
- Key elements in HIV/AIDS care and support 2000
- Fact Sheets on HIV/AIDS for nurses and midwives
- Nine Guidance Modules on Antiretroviral Treatments, 1998
- WHO-UNAIDS HIV Vaccine Initiative
- Voluntary Counselling and Testing for HIV Infection in Antenatal Care Practical considerations for implementation
- Guidelines for the Management of Sexually Transmitted Infections
- Report of the WHO consultative meeting on ARV use in resource limited settings, May 2001

### Other websites for general information on HIV/AIDS related issues

<http://www.globalfundatm.org>

<http://www.genericsnow.org>

<http://www.avert.org>

<http://www.aegis.com>

<http://www.msh.org/>

<http://www.haiweb.org>

<http://www.phrma.org>

<http://www.ims-global.com/insight/report/global/report.htm>

## Contacts

For further information about suppliers or products, please contact:

- Pharmaceutical and Micronutrient Group, Sources of Medicines for HIV/AIDS Survey, UNICEF Supply Division  
Supply@unicef.org  
Fax +45 35 269421

For further information on HIV test kit evaluations or the bulk procurement scheme, contact

- Blood Safety and Clinical Technology (BCT)  
World Health Organization  
Fax +41 22 791 4836

**For any comments on this document, or additional information that could be useful to this project, please contact:**

- Sources of medicines for HIV/AIDS Survey  
Pharmaceutical and Micronutrient Group, UNICEF, Supply Division  
Fax: +45 35 269421
- Essential Drugs and Medicines Policy (EDM)  
World Health Organization  
Fax: +41 22 7914167
- Department of Social Mobilization and Information, UNAIDS  
Fax: +41 22 7914741
- Campaign for Access to Essential Drugs, MSF  
Fax: +41 22 8498404

**Alternatively, please complete the feedback form, Annex VI, and return it to:**

- Sources of medicines for HIV/AIDS Survey  
Pharmaceutical and Micronutrient Group  
UNICEF Supply Division  
Unicef plads  
Freeport DK-2100  
Copenhagen Ø  
Denmark  
Fax: +45 35 269421  
Email: supply@unicef.org

## ANNEX 5

# Feedback and enquiry form

Please fill out this form and fax it to UNICEF Supply Division +45 35 26 94 21 or post it to:  
UNICEF SD, Pharmaceutical and Micronutrient Group – HIV/AIDS Survey, Freeport DK-2100 Copenhagen Ø, Denmark

### 1. GENERAL INFORMATION

Your name

Occupation

Company name/Organization name

Address

Telephone

Fax

Email (required)

Internet address

### 2. FEEDBACK

**What did you think of the publication in general?**

Excellent, very useful    Good, quite useful    Satisfactory, reasonably useful

Poor, not useful—please indicate why: \_\_\_\_\_

**What did you think of the medicines included in the publication?**

Good selection of medicines

More medicines required, for example: \_\_\_\_\_

Fewer medicines required, remove: \_\_\_\_\_

**What did you think of the pricing information?**

Good, enough information on the prices of drugs of interest

Poor, not enough information

**Have you contacted any of the manufacturers listed?**

Yes    No

**Other comments:**

---

---

### 3. ENQUIRY

I would like to participate in the next Survey (Manufacturing companies only)

I would like to receive more copies of the Publication

Other enquiry:

---





---

**ANNEX 6**

# Untangling the web of price reductions







# Table of contents

<b>3</b>	Table of contents
<b>4</b>	General background and objectives
<b>4</b>	Methodology
<b>5</b>	Limitations of the current system
<b>5</b>	The challenge of paediatric formulations
<b>6</b>	Research and development for HIV/AIDS
<b>7</b>	The effects of generic competition
<b>8</b>	Guide to reading and using tables
<b>9</b>	<b>Tables</b>
<b>9</b>	<b>Table 1: Summary of selected pharmaceutical companies' best ARV price offers for eligible developing countries</b>
<b>9</b>	Table 1a – Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
<b>10</b>	Table 1b – Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
<b>11</b>	Table 1c – Nucleotide Reverse Transcriptase Inhibitors (NtRTIs)
<b>12</b>	Table 1d – Protease Inhibitors (PIs)
<b>13</b>	Table 1e – Fixed Dose Combinations (FDCs)
<b>14</b>	Table 1f – Paediatric Formulations
<b>15</b>	<b>Table 2: Company ARV offers and restrictions for developing countries, adult and paediatric formulations</b>
<b>15</b>	Table 2a – Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
<b>18</b>	Table 2b – Non-Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
<b>19</b>	Table 2c – Nucleotide Reverse Transcriptase Inhibitors (NtRTIs)
<b>20</b>	Table 2d – Protease Inhibitors (PIs)
<b>23</b>	Table 2e – Fixed Dose Combinations (FDCs)
<b>25</b>	Table 2f – Selected Generic companies' ARV offers and restrictions for developing countries
<b>26</b>	<b>Annexes</b>
<b>26</b>	Annex 1: Least Developed Countries (LDCs)
<b>26</b>	Annex 2: Human Development Index (HDI)
<b>27</b>	Annex 3: Sub-Saharan countries
<b>27</b>	Annex 4: World Bank low-income countries
<b>27</b>	Annex 5: Company contacts
<b>29</b>	Glossary
<b>31</b>	References

## General background and objectives

Lack of clear information on pharmaceutical prices on the international market is a significant barrier to improving access to essential medicines in developing countries. The situation is particularly complex in the case of antiretrovirals (ARVs).

The data in this guide on ARV prices offered by originator companies and some generic companies in low- and middle-income countries are meant to provide potential buyers with clear verified data. This information is intended for use by government and non-profit procurement agencies, as well as other bulk purchasers of ARVs, including health facilities and non governmental organisations (NGOs).

This document includes both adult and paediatric formulations, and is meant to be used in tandem with the report of “*Pilot Procurement, Quality and Sourcing Project: Access to HIV/AIDS Drugs and Diagnostics of Acceptable Quality*”, a project initiated by WHO and developed in collaboration with other United Nations Organisations (UNAIDS, UNICEF, UNFPA). This project evaluates

pharmaceutical manufacturers and products according to WHO recommended standards of quality and compliance with Good Manufacturing Practices. It is part of an ongoing process that will expand as the participation of suppliers increases. An updated list of products is regularly posted on the websites of WHO and other UN-collaborating agencies; products on this list are commonly referred to as “WHO pre-qualified.” This list of “pre-qualified” drugs is not exhaustive.

Pricing information on other essential drugs and diagnostics used for HIV/AIDS can be found in the 4th edition of the report “*Sources and Prices of Selected Drugs and Diagnostics for People Living with HIV/AIDS*” May 2003<sup>2</sup>.

This is the fourth edition of “*Accessing Antiretrovirals: Untangling the Web of Price Reductions for Developing Countries*”, the first edition was published in October 2001<sup>3</sup>.

## Methodology

In order to obtain accurate information on discounted price offers by both originator and generic companies, companies were

## This fourth edition provides:

- **updated information** on prices for eligible countries, including both price per unit and price per patient per year for adult and paediatric formulations
- **updated information and clarifications** on the conditions and restrictions applying to these offers

contacted and asked to verify their offers. The list of generic producers included in this report is by no means exhaustive<sup>4</sup>. All generic drugs included in this pricing guide have made price offers for developing countries and have at least been cleared for marketing in their countries of origin.

Manufacturers were asked to provide the following information:

- drug, dosage and pharmaceutical form
- price per unit (or daily dose) of different price offers
- restrictions that apply to the offers, including:
  - i. country eligibility
  - ii. potential beneficiaries of the offer
  - iii. additional comments on conditions or procedures, such as quantity restrictions, how to access discounts, bureaucratic procedures

such as memoranda of understanding or special agreement

- iv. delivery of goods in relation to payment (FOB, CIF etc.)<sup>5</sup>

Information is presented in a table format to facilitate comparison. However, comparison is difficult because of the lack of standardisation among different companies on eligibility, terms and conditions, and pricing. For products for which complete information was available, the annual cost of therapy was calculated according to the dosing schedules reported in WHO “*Scaling-up Antiretroviral Therapy in Resource Limited Settings*:

*Guidelines for a Public Health Approach*”<sup>6</sup>, 2002, or the Centres for Disease Control and Prevention (CDC), “*Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents*”, by the Panel on Clinical Practices for the Treatment of HIV, 2002<sup>7</sup>.

All prices are quoted in US dollars and conversions were made on the day the price was received.

All prices were checked and verified by companies.

**It is important to note that these prices may not correspond to end-user prices (prices to patients), which may be further influenced by other factors such as national distribution and handling charges, mark-up rates, and national and/or import and sales taxes. Information concerning the patent status of ARVs was not included in the present analysis, and will differ between countries. Some information about patent status of ARVs in some countries can be found in “Patent Situation of HIV/AIDS related drugs in 80 countries”, WHO/UNAIDS, 2000<sup>8</sup>.**

**Practical information on patents can also be found in the new MSF report “Drug patents under the spotlight: sharing practical knowledge about pharmaceutical patents”, May 2003<sup>9</sup>.**

**Inclusion in the report does not constitute pre-qualification or approval by MSF. National regulatory authorities are ultimately responsible**

**for approving use of a given drug from a given manufacturer. Products that were “WHO pre-qualified” at the time of writing are indicated with an asterisk (\*)<sup>1</sup>.**

### Limitations of the current system

The lack of a uniform preferential pricing system has resulted in each company defining a unique series of terms and criteria. For instance, whereas Merck & Co., Inc. takes into account criteria related to resources (Human Development Index) and epidemiology (HIV/AIDS prevalence<sup>10</sup>) to determine national eligibility (theoretically, nearly 120 countries benefit from these offers), GlaxoSmithKline (GSK) uses the classification of Least Developed Countries and the geographical classification of sub-Saharan countries (a total of 63 countries).

Most of the originator companies, apart from Merck & Co., Inc. and Roche, do not have a policy for countries outside sub-Saharan Africa, or are not classified by UNCTAD as Least Developed Countries. For example, Bristol-Myers Squibb (BMS) applies discounts to wholesale and retail purchasers in sub-Saharan Africa (theoretically, 48 countries

benefit from this offer) but not in Central America where prices are negotiated on a case-by-case basis through the Accelerated Access Initiative.

Even when a given country is eligible, all institutions within the country may not be eligible for reduced prices. Again, eligibility is currently at the companies' discretion. It does not mean that the drugs are registered and a distribution system exists in these countries.

In actual practice, MSF has observed that the most powerful downward pressure on prices has been a system of equity pricing. Equity pricing is composed of a series of simultaneous strategies: a)

stimulating generic competition; b) differential pricing which addresses all developing countries, according to clearly defined policies, or voluntary licensing of proprietary products; and c) readiness on the part of national governments to override patents by issuing compulsory licenses or making government use of a patent when affordable prices are not offered for patented products. Since the adoption of the *Doha declaration on TRIPS and Public Health* least

developed countries (LDC's) are not obligated to patent drugs until 2016<sup>11</sup>.

Although generic competition is a critical factor in reducing prices (see Graph 1, where the prices trend of a sample ARV triple therapy combination is shown over the period May 2000-April 2003), it cannot be a stand-alone strategy as newer drugs may not be available in generic form immediately. There is an urgent need to develop a more systematic, transparent approach to differential pricing of originator products in addition to stimulating generic competition.

### The challenge of paediatric formulations

Children living with HIV/AIDS are one of the most neglected populations: paediatric formulations are lacking and/or formulations do not meet children's and caregivers' needs (unpleasant tasting syrup, tablets too big to swallow, need to refrigerate some products, unbreakable tablets, lack of fixed dose combinations (FDCs), and non-adapted dosages. For example there are currently no fixed dose combinations for paediatric use.

---

## Research and development for HIV/AIDS

Paediatric formulations is not the only area where there is a need for R&D. For both adults and children, new drugs and diagnostic tools, as well as vaccines are needed for HIV/AIDS. Pharmaceutical investment in research and development largely corresponds to developed country patient needs, where the epidemic has more or less stabilized. We need to ensure that there is a strong focus on the needs of patients in developing and least developed countries and that the R&D momentum is not lost.




## The Effects of Generic Competition


Sample of ARV triple-combination: stavudine (d4T) + lamivudine (3TC) + nevirapine (NVP). Lowest world prices per patient per year.

Generic competition has shown to be the most effective means of lowering drug prices. During the last three years, originator companies have often responded to generic competition.

May 2000-April 2003



January 2001-April 2003



## Guide to reading and using tables

## Guide to reading and using tables

**Quality:** This document strictly relates to prices: products from specific manufacturers have not necessarily been assessed for quality standards. Therefore, procurement agencies should follow their own procedure in this respect.

**Prices:** table 1 shows the best price offers of some generic manufacturers and originator producers for each antiretroviral drug, including fixed-dose combinations. Figures within brackets indicate price in US\$ per unit (capsules, tablets etc.). Prices per patient per year have been calculated according to daily doses given either in WHO guidelines or in CDC guidelines (for those products not recommended in WHO guidelines). Prices can be used as a reference with suppliers.

**Restrictions:** tables 2a) and 2b) show restrictions imposed by generic and originator companies and provide indications about the availability of offers in individual countries. There is no uniform differential pricing system and each company sets geographical limits to their programmes.

**Access:** since ARVs are not always registered and/or available in 'selected countries', many offers from pharmaceutical companies may remain 'theoretical' until the companies are challenged to follow through on their offers, by registering the products and creating proper distribution channels at national or regional level.

Please refer to Annexes 1, 2 and 4 for updated country classification by UNCTAD (Least Developed Countries), UNDP (Human Development Index) and World Bank (Low income Countries). Annex 3 lists sub-Saharan countries.

This document is also available in French and Spanish on [www.accessmed-msf.org](http://www.accessmed-msf.org)

**Table 1: Summary of selected pharmaceutical companies' best ARV price offers for eligible developing countries**

**Table 1a – Nucleoside Reverse Transcriptase Inhibitors (NRTIs)**

All prices are in US\$. Prices are given both for a yearly adult dose and by unit.

For details on eligibility and offer restrictions for countries and institutions, please refer to table 2a.

NRTI (Abbreviation)	abacavir (ABC)	didanosine (ddI)	didanosine (ddI)	didanosine (ddI)	lamivudine (3TC)	lamivudine (3TC)	stavudine (d4T)	stavudine (d4T)	stavudine (d4T)	zidovudine (ZDV or AZT)
Strength (mg)	300	100 (\$)	EC 400	150	300	300	40	30	40	300
Trade name Europe/US	Ziagen® (GSK)	Videx® (BMS)	Videx® (BMS)	Epivir® (GSK)	Epivir® (GSK)	Epivir® (GSK)	Zerit® (BMS)	Zerit® (BMS)	Zerit® (BMS)	Retrovir® (GSK)
Daily dose	2	4	1	2	1	2	2	2	2	2
BMS (US)		<b>310*</b> (0.212/unit)	Not applicable				<b>55*</b> (0.075/unit)	<b>49*</b> (0.066/unit)		
GSK (UK)	<b>986*</b> (1.350/unit)			<b>128*</b> (0.175/unit)						<b>274*</b> (0.375/unit)
Aurobindo (India)		197 (0.135/unit)		66 (0.090/unit)			<b>31</b> (0.043/unit)			<b>140</b> (0.192/unit)
Cipla (India)	<b>821</b> (1.125/unit)	426 (0.292/unit)	<b>271</b> (0.741/unit)	<b>126*</b> (0.172/unit)	<b>124</b> (0.340/unit)		53 (0.072/unit)	48 (0.065/unit)		<b>198*</b> (0.271/unit)
GPO (Thailand)		650 (0.445/unit)		163 (0.223/unit)			73 (0.100/unit)			277 (0.380/unit)
Hetero (India)	1325 (1.815/unit)	<b>185</b> (0.127/unit)		<b>65</b> (0.089/unit)			<b>31</b> (0.042/unit)			175 (0.240/unit)
Ranbaxy (India)			335 (0.917/Unit)	<b>100*</b> (0.137/unit)			47 (0.064/unit)	<b>36</b> (0.049/unit)		<b>180*</b> (0.246/unit)
Combinopharm (Spain)										<b>292*</b> (0.400/unit)

(\$) BMS sells ddI (Videx®) in other doses (per mg price remains the same)

Products on the WHO list of Pilot Procurement, Quality and Sourcing Project: Access to HIV/AIDS drugs and diagnostics of acceptable quality (Sixth edition, 5th May 2003) are in **bold** and have an **asterisk** \* next to the price. Always check website for most recently updated list. Best prices are in **bold & underlined**. Incoterms vary according to manufacturers.

Annual cost is calculated according to the daily doses given in the WHO 'Scaling-up Antiretroviral Therapy in Resource Limited Settings: Guidelines for a Public Health Approach' (June 2002) and/or the 'Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents' from the Panel on Clinical Practices for the Treatment of HIV (2002).

**Table 1b – Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)**

All prices are in US\$. Prices are given both for a yearly adult dose and by unit.

For details on eligibility and offer restrictions for countries and institutions, please refer to table 2b.

Products on the WHO list of Pilot Procurement, Quality and Sourcing Project: Access to HIV/AIDS drugs and diagnostics of acceptable quality (Sixth edition, 5th May 2003) are in **bold** and have an **asterisk** \* next to the price. Always check website for most recently updated list. Best prices are in **bold & underlined**. Incoterms vary according to manufacturers.

Annual cost is calculated according to the daily doses given in the WHO ‘Scaling-up Antiretroviral Therapy in Resource Limited Settings: Guidelines for a Public Health Approach’ (June 2002) and/or the ‘Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents’ from the Panel on Clinical Practices for the Treatment of HIV (2002).

NNRTI (Abbreviation)	efavirenz (EFV)	efavirenz (EFV)	efavirenz (EFV)	nevirapine (NVP)
Strength (mg)	200	600	200	200
Trade name in Europe/US	Stocrin® or Sustiva® (Merck & Co., Inc.)(**)	Stocrin® or Sustiva® (Merck & Co., Inc.)(**)	Viramune® (Boehringer-Ingelheim)	
Daily dose	3	1	2	
Boehringer-Ingelheim (Germany)			<b>438*</b> <b>(0.600/unit)</b>	
Merck & Co., Inc. (US)	500 (0.457/unit)(†)	<b>346.75</b> <b>(0.950/unit)(†)</b>		
Aurobindo (India)	<b>438</b> <b>(0.400/unit)</b>		112 (0.153/unit)	
Cipla (India)	462 (0.422/unit)	462 (1.267/unit)	<b>208*</b> <b>(0.285/unit)</b>	
GPO (Thailand)			244 (0.334/unit)	
Hetero (India)	548 (0.500/unit)		<b>105</b> <b>(0.144/unit)</b>	
Ranbaxy (India)		578 (1.583/unit)	<b>166*</b> <b>(0.228/unit)</b>	

(\*\*) *Known as Sustiva® (BMS) in US, Canada, UK, Republic of Ireland, France, Spain, Italy and Germany.*

(†) Prices given in this table are for Low Human Development Index (HDI) countries plus medium HDI countries with adult HIV prevalence of 1% or greater.

In table 2b, prices for medium HDI countries with adult HIV prevalence less than 1%, are given.

**Table 1c - Nucleotide Reverse Transcriptase Inhibitors (NRTIs)**

Price is in US\$. Price is given both for a yearly adult dose and by unit.

For details on eligibility, offer restrictions for countries and institutions, Incoterm and ways to apply, please refer to table 2c.

NRTI	tenofovir (TDF)
Strength (mg)	300 mg
Trade name in Europe/US	Viread® (Gilead)
Daily dose	1
Gilead (US)	<b>475</b> <b><u>(1.30/unit)</u></b>

Products on the WHO list of Pilot Procurement, Quality and Sourcing Project: Access to HIV/AIDS drugs and diagnostics of acceptable quality (Sixth edition, 5th May 2003) are in **bold** and have an **asterisk \*** next to the price. Always check website for most recently updated list. Best prices are in **bold & underlined**. Incoterms vary according to manufacturers.

Annual cost is calculated according to the daily doses given in the WHO 'Scaling-up Antiretroviral Therapy in Resource Limited Settings: Guidelines for a Public Health Approach' (June 2002) and/or the 'Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents' from the Panel on Clinical Practices for the Treatment of HIV (2002).

**Table 1d - Protease Inhibitors (PIs)**

All prices are in US\$. Prices are given both for a yearly adult dose and by unit.

For details on eligibility and offer restrictions for countries and institutions, please refer to tables 2d.

Products on the WHO list of Pilot Procurement, Quality and Sourcing Project: Access to HIV/AIDS drugs and diagnostics of acceptable quality (Sixth edition, 5th May 2003) are in **bold** and have an **asterisk \*** next to the price. Always check website for most recently updated list. Best prices are in **bold & underlined**. Incoterms vary according to manufacturers.

Annual cost is calculated according to the daily doses given in the WHO 'Scaling-up Antiretroviral Therapy in Resource Limited Settings: Guidelines for a Public Health Approach' (June 2002) and/or the 'Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents' from the Panel on Clinical Practices for the Treatment of HIV (2002).

For Roche, prices are given in Swiss Francs and were converted in US\$ (1 US\$ = 1.40 CHF on 15 April 2003)

PI (Abbreviation)	indinavir (IDV)	nelfinavir (NFV)	ritonavir (r)	saquinavir hard gel capsules (SQV hgc)
Strength (mg)	400	250	100	200
Trade name in Europe/US	Crixivan® (Merck & Co. Inc.)	Viracept® (Roche)	Norvir® (Abbott)	Invirase® (Roche)
Daily dose	4 (**)	10 (***)	2 (§)	10 (#)
Abbott (US)			<b>83*</b> <u>(0.114/unit)</u>	
Merck & Co., Inc. (US)	400 (0.274/unit)			
Roche (Switzerland)		<b>880*</b> <u>0.241/unit(t)</u>		<b>920*</b> <u>0.252/unit(t)</u>
Aurobindo (India)	393 (0.269/unit)	1533 (0.420/unit)	336 (0.460/unit)	
Cipla (India)	406 (0.278/unit)	2026 (0.555/unit)	1084 (1.485/unit)	
Hetero (India)	<b>387</b> <u>(0.265/unit)</u>	1500 (0.411/unit)	219 (0.300/unit)	1335 (0.366/unit)
Ranbaxy (India)	467 (0.320/unit)			

(\*\*) The daily dose referred to is 800mg IDV twice daily with ritonavir 100mg twice daily as booster. The prescribing information given by the manufacturer is 800mg three times daily

(\*\*\*) The daily dose referred to is 1250 mg twice daily although the dosage of 9 tablets (3 tablets three times a day) can also be used.

(§) The daily dose referred to is 100mg twice daily, for use as booster medication. This dose is not indicated in the manufacturer's label.

(#) Invirase should be used in combination with low-dose ritonavir as Saquinavir/Ritonavir 1000mg/100mg twice daily

(t) Prices given in this table are for sub-Saharan Africa and Least Developed Countries as UN defined. In table 2d, also prices for Low Income and Lower Middle Income Countries, as classified by the World Bank, are given.

**Table 1e – Fixed Dose Combinations (FDCs)**

All prices are in US\$. Prices are given both for a yearly adult dose and by unit. For details on eligibility and offer restrictions for countries and institutions, please refer to tables 2.

Combination	lopinavir+ ritonavir (LPV/r)	3TC+d4T	3TC+d4T	ZDV+3TC	ZDV+3TC+NVP	ABC+3TC+ZDV	3TC+d4T+NVP	3TC+d4T+NVP
Strength (mg)	133.3 + 33.3	150 + 30	150 + 40	300+150	300 + 150 + 200	300+150+300	150 +30+200	150 +40+200
Therapeutic class(es)	PI	NRTI	NRTI	NRTI	NRTI + NNRTI	NRTI	NRTIs + NNRTI	NRTI + NNRTI
Trade name in Europe/US	Kaletra® (Abbott)		Combivir® (GSK)			Trizivir® (GSK)		
Daily dose	6	2	2	2	2	2	2	2
Abbott (US)	<b>500*</b> <b>(0.228/unit)</b>							
GSK (UK)				<b>329*</b> <b>(0.450/unit)</b>		<b>1241*</b> <b>(1.700/unit)</b>		
Aurobindo (India)				<b>204</b> <b>(0.280/unit)</b>				
Cipla (India)	162 (0.222/unit)	172 (0.236/unit)		<b>292*</b> <b>(0.400/unit)</b>	418 (0.573/unit)		304 (0.417/unit)	304 (0.417/unit)
GPO (Thailand)				407 (0.558/unit)			325 (0.445/unit)	358 (0.490/unit)
Hetero (India)	3833 (1.750/unit)	135 (0.185/unit)	141 (0.193/unit)	276 (0.378/unit)	<b>383</b> <b>(0.525/unit)</b>	1648 (2.258/unit)	<b>281</b> <b>(0.385/unit)</b>	<b>286</b> <b>(0.392/unit)</b>
Ranbaxy (India)		<b>125*</b> <b>(0.171/unit)</b>	<b>135</b> <b>(0.185/unit)</b>	<b>265*</b> <b>(0.363/unit)</b>			285 (0.390/unit)	292 (0.400/unit)

Products on the WHO list of Pilot Procurement, Quality and Sourcing Project: Access to HIV/AIDS drugs and diagnostics of acceptable quality (Sixth edition, 5th May 2003) are in **bold** and have an **asterisk (\*)** next to the price. Always check website for most recently updated list. Best prices are in **bold & underlined**. Incoterms vary according to manufacturers.

Annual cost is calculated according to the daily doses given in the WHO ‘Scaling-up Antiretroviral Therapy in Resource Limited Settings: Guidelines for a Public Health Approach’ (June 2002) and/or the ‘Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents’ from the Panel on Clinical Practices for the Treatment of HIV (2002).



**Table 1f – Paediatric Formulations**

For details on eligibility and offer restrictions for countries and institutions, please refer to tables 2.

ARV (Abbreviation)	Company (trade name)	Strength/Dosage form	Presentation	Price per pack	Additional information
<b>zidovudine</b>	GSK (Retrovir®)	10mg/ml oral solution	200ml	<b>US\$ 7.90*</b>	Cost per day as indicated by the manufacturer (average paediatric dosage based on 25kg average weight): US\$ 1.58.
	Cipla (Zidovir®)	50mg/5ml oral solution	100ml	<b>US\$ 1.53*</b>	
	GPO (Antivir®)	10mg/ml syrup	60ml/200ml	US\$ 1.17/3.40	
	Combimopharm	50mg/5ml oral solution	200ml	US\$ 4.20	
<b>lamivudine</b>	GSK (Epirivir®)	10mg/ml oral solution	240ml	<b>US\$ 7.45*</b>	Cost per day as indicated by the manufacturer (average paediatric dosage based on 25kg average weight): US\$ 0.62.
	Cipla (Lamivir®)	10mg/ml oral solution	100ml	<b>US\$ 2.00*</b>	
<b>didanosine</b>	GPO (Lamivir®)	10mg/ml syrup	60ml	US\$ 1.40	
	BMS (Videx®)	powder: 2g of active principle sold as a bottle for re-constitution with water and with antacids		US\$ 16.61 (16.61 Euro) (**)	Sold in local currency in Southern Africa – Rand and East Africa - shillings. Sold in Euro to West African countries.
	Merck&Co.Inc (Stocrin®)	50mg capsules	Bottle of 30	US\$ 3.47	US\$ 0.116/unit.
<b>efavirenz</b>					
<b>abacavir</b>	GSK (Ziagen®)	20mg/ml oral solution	240ml	<b>US\$ 34.80*</b>	Cost per day as indicated by manufacturer: US\$ 2.90.
	BMS (Zerit®)	1mg/ml powder for syrup	200ml	US\$ 10.71 (10.71 Euro) (**)	Sold in local currency in Southern Africa - Rand and East Africa - shillings. Sold in Euro to West African countries.
<b>stavudine</b>	BMS (Zerit®)	15mg capsules	Blister pack of 56	<b>Not available*</b>	
	BMS (Zerit®)	20mg capsules	Blister pack of 56	<b>US\$ 5.25*</b>	US\$ 0.094/unit.
	GPO (Stavir®)	15mg capsules	Box of 60	US\$ 3.50	US\$ 0.058/capsule.
	GPO (Stavir®)	20mg capsules	Box of 60	US\$ 4.20	US\$ 0.070/capsule.
<b>nevirapine</b>	GPO (Stavir®)	1mg/ml dry syrup	60ml	US\$ 0.65	
	GPO (Stavir®)	5mg/ml dry syrup	60ml	US\$ 0.85	
	BI (Viramune®)	10mg/ml suspension	240ml	<b>US\$ 17.50*</b>	
	Cipla (Nevimune®)	50mg/5ml suspension	100ml & 25ml (PMTCT)	US\$ 2.45 & US\$ 2.00 (PMTCT)	PMTCT dose: 25ml.
<b>ritonavir</b>	Abbott (Norvir®)	80mg/ml oral solution	450ml(5x90ml)	<b>US\$ 41.67*</b>	
<b>ritonavir + lopinavir</b>	Abbott (Kaletra®)	20mg + 80mg/ml oral solution	300ml(5x60ml)	<b>US\$ 41.67*</b>	
	Roche (Viracept®)	50mg/g. powder for suspension	144g	<b>US\$ 35*</b> (**) (f)	

(\*\*) on 15 April 2003, 1 US\$ =1.40 CHF and on 15 April 2003, 1Euro = 1\$US. (f) All prices of Roche products are in Swiss francs (CHF). Prices given in this table are for sub-Saharan Africa and Least Developed Countries as UN defined. In table 2c, also prices for Low Income and Lower Middle Income Countries, as classified by the World Bank, are given. Products on the WHO list of Pilot Procurement, Quality and Sourcing Project. Access to HIV/AIDS drugs and diagnostics of acceptable quality (Sixth edition, 5th May 2003) are in **bold** and have an **asterisk (\*)** next to the price. Always check website for most recently updated list. Best prices are in **bold & underlined**. Intotems vary according to manufacturers.



**Table 2 Company ARV offers and restrictions for developing countries, adult and paediatric formulations**  
**Table 2a Nucleoside Reverse Transcriptase Inhibitors (NRTIs)**

Product	Company	Eligibility (countries)	Eligibility (body)	Price in US\$	Additional comments	Delivery of goods <sup>(5)</sup>
<b>abacavir 300mg tablets (Ziagen®)</b>	GlaxoSmithKline	Least Developed Countries (LDCs) plus sub-Saharan Africa. All projects fully financed by the Global Fund to fight AIDS, TB and Malaria. <i>(For middle income developing countries public sector prices negotiated on a case-by-case basis or bilaterally or through the AAI).</i>	Governments, aid organisations, charities, international, UN agencies, other not-for-profit organisations and international purchase funds such as the Global Fund to fight AIDS, TB and Malaria. In sub-Saharan Africa employers there who offer HIV/AIDS care and treatment directly to their staff through workplace clinics or similar arrangements are also eligible. All organisations must supply the preferentially priced products on a not for profit basis.	US\$ 986/year 1.350/unit	Supply Agreement required (For NGOs requiring less than 10 patient packs per month, this requirement may be waived). The manufacturer recommends that 'prescribers must ensure that patients are fully informed regarding hypersensitivity reaction to abacavir. Patients developing signs or symptoms must contact their doctor immediately for advice.'	CIP
<b>abacavir 20mg/ml oral solution 240ml (Ziagen®)</b>	GlaxoSmithKline	Least Developed Countries (LDCs) plus sub-Saharan Africa. All projects fully financed by the Global Fund to fight AIDS, TB and Malaria. <i>(For middle income developing countries public sector prices negotiated on a case-by-case basis or bilaterally or through the AAI).</i>	Governments, aid organisations, charities, international, UN agencies, other not-for-profit organisations and international purchase funds such as the Global Fund to fight AIDS, TB and Malaria. In sub-Saharan Africa employers there who offer HIV/AIDS care and treatment directly to their staff through workplace clinics or similar arrangements are also eligible. All organisations must supply the preferentially priced products on a not for profit basis.	US\$ 34.80 per bottle	Supply Agreement required (For NGOs requiring less than 10 patient packs per month, this requirement may be waived). The manufacturer recommends that 'prescribers must ensure that patients are fully informed regarding hypersensitivity reaction to abacavir. Patients developing signs or symptoms must contact their doctor immediately for advice.'	CIP

Product	Company	Eligibility (countries)	Eligibility (body)	Price in US\$	Additional comments	Delivery of goods <sup>51</sup>
<b>didanosine 100mg (Videx®)</b>	Bristol-Myers Squibb Co.	Sub-Saharan Africa. <i>(For other developing countries, prices negotiated on a case by case basis through the AAI.)</i>	Both private and public sector organisations that are able to provide effective, sustainable and medically sound care and treatment of HIV/AIDS are eligible.	US\$ 310/year US\$ 0.212/unit Lower tablet dosages prices in line with this offer		DDU to government purchasing entities.
<b>lamivudine 150mg tablet (EpiVir®)</b>	GlaxoSmithKline	LDCs plus sub-Saharan Africa. All projects fully financed by the Global Fund to fight AIDS, TB and Malaria. <i>(For middle income developing countries public sector prices negotiated on a case-by-case basis or bilaterally or through the AAI.)</i>	Governments, aid organisations, charities, international, UN agencies, other not-for-profit organisations and international purchase funds such as the Global Fund to fight AIDS, TB and Malaria. In sub-Saharan Africa employers there who offer HIV/AIDS care and treatment directly to their staff through workplace clinics or similar arrangements are also eligible. All organisations must supply the preferentially priced products on a not for profit basis.	US\$ 128/year US\$ 0.175/unit	Supply Agreement required (For NGOs requiring less than 10 patient packs per month, this requirement may be waived).	CIP
<b>lamivudine 10mg/ml oral solution 240ml (EpiVir®)</b>	GlaxoSmithKline	LDCs plus sub-Saharan Africa. All projects fully financed by the Global Fund to fight AIDS, TB and Malaria. <i>(For middle income developing countries public sector prices negotiated on a case-by-case basis or bilaterally or through the AAI.)</i>	Governments, aid organisations, charities, international, UN agencies, other not-for-profit organisations and international purchase funds such as the Global Fund to fight AIDS, TB and Malaria. In sub-Saharan Africa employers there who offer HIV/AIDS care and treatment directly to their staff through workplace clinics or similar arrangements are also eligible. All organisations must supply the preferentially priced products on a not for profit basis.	US\$ 7.45 per bottle	Supply Agreement required (For NGOs requiring less than 10 patient packs per month, this requirement may be waived).	CIP

Product	Company	Eligibility (countries)	Eligibility (body)	Price in US\$	Additional comments	Delivery of goods <sup>(5)</sup>
<b>stavudine 30mg and 40mg caps (Zerit®)</b>	Bristol-Myers Squibb Co.	Sub-Saharan Africa. <i>(For other developing countries, prices negotiated on a case-by-case basis through the AAI.)</i>	Both private and public sector organisations that are able to provide effective, sustainable and medically sound care and treatment of HIV/AIDS are eligible.	30mg: US\$ 49/year (US\$0.066/unit) 40mg: US\$ 55/year (US\$0.075/unit)		DDU to government purchasing entities
<b>zidovudine 300mg tablets (Retrovir®)</b>	GlaxoSmithKline	LDCs plus sub-Saharan Africa. All projects fully financed by the Global Fund to fight AIDS, TB and Malaria. <i>(For middle income developing countries public sector prices negotiated on a case-by-case basis or bilaterally or through the AAI.)</i>	Governments, aid organisations, charities, international, UN agencies, other not-for-profit organisations and international purchase funds such as the Global Fund to fight AIDS, TB and Malaria. In sub-Saharan Africa, employers there who offer HIV/AIDS care and treatment directly to their staff through workplace clinics or similar arrangements are also eligible. All organisations must supply the preferentially priced products on a not for profit basis.	US\$ 274/year (US\$ 0.375/unit)	Supply Agreement required.  (For NGOs requiring less than 10 patients packs per month, this requirement may be waived.)	CIP
<b>zidovudine 10mg/ml oral solution 200ml (Retrovir®)</b>	GlaxoSmithKline	LDCs plus sub-Saharan Africa. All projects fully financed by the Global Fund to fight AIDS, TB and Malaria. <i>(For middle income developing countries public sector prices negotiated on a case-by-case basis or bilaterally or through the AAI.)</i>	Governments, aid organisations, charities, international, UN agencies, other not-for-profit organisations and international purchase funds such as the Global Fund to fight AIDS, TB and Malaria. In sub-Saharan Africa, employers there who offer HIV/AIDS care and treatment directly to their staff through workplace clinics or similar arrangements are also eligible. All organisations must supply the preferentially priced products on a not for profit basis.	US\$7.90 per bottle	Supply Agreement required.  (For NGOs requiring less than 10 patients packs per month, this requirement may be waived.)	CIP

**Table 2b Non-Nucleoside Reverse Transcriptase Inhibitors (NRTIs)**

Product	Company	Eligibility (countries)	Eligibility (body)	Price in US\$	Additional comments	Delivery of goods <sup>[5]</sup>
<b>efavirenz (Stocrin®)</b>	Merck & Co., Inc.	Low Human Development Index (HDI) countries plus medium HDI countries with adult HIV prevalence of 1% or greater <sup>10</sup> .	Governments, international organisations, NGOs, private sector hospitals and insurers).  Merck & Co., Inc. does not rule out supplying ARVs to patients through retail pharmacies.	600mg tablet: US\$ 346.75/year (US\$ 0.950/unit)  200mg capsule: US\$ 500/year (US\$ 0.457/unit)  50mg capsule: US\$ 0.116/unit US\$ 3.47 per bottle of 30	Although Romania does not fall under these categories it also benefits from these prices due to a government commitment to a programme of universal access.	CIF
<b>efavirenz (Stocrin®)</b>	Merck & Co., Inc.	Medium HDI countries with adult HIV prevalence less than 1% <sup>10</sup> .	Governments, international organisations, NGOs, private sector hospitals and insurers).  Merck & Co., Inc. does not rule out supplying ARVs to patients through retail pharmacies.	600mg tablet: US\$ 767/year (US\$ 2.10/unit)  200mg capsule: US\$ 920/year (US\$ 0.840/unit)  50mg capsule US\$ 0.213 per unit US\$ 6.39 per bottle of 30		CIF
<b>nevirapine 200mg tablets (Viramune®)</b>	Boehringer Ingelheim	All World Bank low-income countries and sub-Saharan Africa. <i>(Other countries on a case-by-case basis.)</i>	Governments, NGOs and other partners who can guarantee that the programme is run in a responsible manner.	US\$ 438/year (US\$ 0.600/unit)		CIF
<b>nevirapine 10mg/ml suspension 240ml (Viramune®)</b>	Boehringer Ingelheim	All World Bank low-income countries and sub-Saharan Africa. <i>(Other countries on a case-by-case basis.)</i>	Governments, NGOs and other partners who can guarantee that the programme is run in a responsible manner.	US\$ 17.50 per unit		CIF

**Table 2c Nucleotide Reverse Transcriptase Inhibitors (NRTIs)**

Product	Company	Eligibility (countries)	Eligibility (body)	Price in US\$	Additional comments	Delivery of goods <sup>(5)</sup>
<b>tenofovir 300mg (Viread®)</b>	Gilead	53 nations in Africa and 15 other UN-designated 'least developed' countries.	Organisations that provide HIV treatment in the 68 countries covered by the Viread Access programme will be able to receive Viread at the access price. Applications will go through a review process.	US\$ 475/year (US\$ 1.30/unit)	The programmes will be managed through Axios.	FOB

**Table 2d Protease Inhibitors (PIs)**

<b>Product</b>	<b>Company</b>	<b>Eligibility (countries)</b>	<b>Eligibility (body)</b>	<b>Price in US\$</b>	<b>Additional comments</b>	<b>Delivery of goods<sup>(5)</sup></b>
<b>indinavir (400mg caps) (Crixivan®)</b>	Merck & Co., Inc.	Low Human Development Index (HDI) countries plus medium HDI countries with adult HIV prevalence of 1% or greater <sup>o</sup> .	Governments, international organisations, NGOs, private sector organisations (e.g. employers, hospitals and insurers). Merck & Co., Inc. does not rule out supplying ARVs to patients through retail pharmacies.	US\$ 400/year (US\$ 0.274/unit)	Although Romania does not fall under these categories it also benefits from these prices due to a government commitment to a programme of universal access.	CIP
<b>indinavir (400mg caps) (Crixivan®)</b>	Merck & Co., Inc.	Medium HDI countries with adult HIV prevalence less than 1% <sup>o</sup> .	Governments, international organisations, NGOs, private sector organisations (e.g. employers, hospitals and insurers). Merck & Co., Inc. does not rule out supplying ARVs to patients through retail pharmacies.	US\$ 686/year (US\$ 0.470/unit)		CIP
<b>nelfinavir 250mg tablets (Viracept®)</b>	Roche	Low income countries and lower middle income countries - as classified by the World Bank.	Governments, Non Profit Institutional Providers of HIV care, NGOs.	Bottle of 270 tablets: CHF 300.00 US\$ 214.29 US\$ 2898/year (US\$ 0.794/unit)		Terms and conditions: Effective date 1st March 2003. FCA Basel (Switzerland), CAD (Cash Against Documents) 30 days at sight. Minimum order and delivery amount per shipment is CHF 10,000 (US\$ 7143)

Product	Company	Eligibility (countries)	Eligibility (body)	Price in US\$	Additional comments	Delivery of goods <sup>151</sup>
<b>nelfinavir 250mg tablets (Viracept®)</b>	Roche	All countries in sub-Saharan Africa and all UN defined Least Developed Countries.	Governments, Non Profit Institutional Providers of HIV care, NGOs.	Bottle of 270 tablets CHF 90.90 (US\$ 64.93) US\$ 880/year (US\$ 0.241/unit)		Terms and conditions: Effective date 1st March 2003. FCA Basel (Switzerland), CAD (Cash Against Documents) 30 days at sight. Minimum order amount per shipment is CHF 10,000 (US\$ 7143)
<b>nelfinavir powder for oral solution 144g 50mg/g (Viracept®)</b>	Roche	Low income countries and Lower middle income countries - as classified by the World Bank.	Governments, Non Profit Institutional Providers of HIV care, NGOs.	CHF 55.00 per bottle (US\$ 32.29)		Terms and conditions: Effective date 1st March 2003. FCA Basel (Switzerland), CAD (Cash Against Documents) 30 days at sight. Minimum order amount per shipment is CHF 10,000 (US\$ 7143)
<b>nelfinavir powder for oral solution 144g 50mg/g (Viracept®)</b>	Roche	All countries in sub-Saharan Africa and all UN defined Least Developed Countries.	Governments, Non Profit Institutional Providers of HIV care, NGOs.	CHF 49.00 per bottle (US\$ 35.00)		

Product	Company	Eligibility (countries)	Eligibility (body)	Price in US\$	Additional comments	Delivery of goods <sup>(5)</sup>
<b>ritonavir 100mg caps (Norvir®)</b>	Abbott	All African countries and the LDCs outside of Africa.	Governments, NGOs, UN system organisations and other national and international health institutions.	“Booster dose”: US\$ 83/year (US\$ 0.114/unit)		FOB
<b>ritonavir oral solution 450ml (Norvir®)</b>	Abbott	All African countries and the LDCs outside of Africa.	Governments, NGOs, UN system organisations and other national and international health institutions.	US\$ 41.67 per bottle		FOB
<b>saquinavir 200mg hard gel capsules (Invirase®)</b>	Roche	Low income countries and lower middle income countries - as classified by the World Bank.	Governments, Non Profit Institutional Providers of HIV care, NGOs.	Bottle of 270 capsules: CHF 300.00 (US\$ 214.29)  US\$ 2898/year (US\$ 0.794/unit)		Terms and conditions: Effective date 1st March 2003. FCA Basel (Switzerland), CAD (Cash Against Documents) 30 days at sight. Minimum order and delivery amount per shipment is CHF 10,000 (US\$ 7143)
<b>saquinavir 200mg hard gel capsules (Invirase®)</b>	Roche	All countries in sub-Saharan Africa and all UN defined Least Developed Countries.	Governments, Non Profit Institutional Providers of HIV care, NGOs.	Bottle of 270 capsules: CHF 95.40 (US\$ 68.14)  US\$ 920/year (US\$ 0.252/unit)		Terms and conditions: Effective date 1st March 2003. FCA Basel (Switzerland), CAD (Cash Against Documents) 30 days at sight. Minimum order and delivery amount per shipment is CHF 10,000 (US\$ 7143)



Table 2e Fixed Dose Combinations

Product	Company	Eligibility (countries)	Eligibility (body)	Price in US\$	Additional comments	Delivery of goods <sup>(5)</sup>
<b>lopinavir/ ritonavir 133.33 + 33.3 mg capsules (Kaletra®)</b>	Abbott	All African countries and the Least Developed Countries (LDCs) outside of Africa.	Governments, NGOs, UN system organisations, and other national and international health institutions.	US\$ 500/year (0.228/unit)		FOB
<b>lopinavir/ ritonavir oral solution 300ml (Kaletra®)</b>	Abbott	All African countries and the Least Developed Countries (LDCs) outside of Africa.	Governments, NGOs, UN system organisations, and other national and international health institutions.	US\$ 41.67 per bottle		FOB
<b>3TC + ZDV 300mg + 150mg tablets (Combivir®)</b>	GlaxoSmithKline	LDCs plus sub-Saharan Africa. All projects fully financed by the Global Fund to fight AIDS, TB and Malaria. <i>(For middle income developing countries public case-by-case basis bilaterally or through the AAI.)</i>	Governments, aid organisations, charities, international, UN agencies, other not-for-profit organisations and international purchase funds such as the Global Fund to fight AIDS, TB & Malaria. In sub-Saharan Africa, employers there who offer HIV/AIDS care and treatment directly to their staff through workplace clinics or similar arrangements are also eligible. All organisations must supply the preferentially priced products on a not for profit basis.	US\$ 329/year (US\$ 0.450/unit)	Supply Agreement required. <i>(For NGOs requiring less than 10 patients packs per month, this requirement may be waived.)</i>	CIP

Product	Company	Eligibility (countries)	Eligibility (body)	Price in US\$	Additional comments	Delivery of goods <sup>(5)</sup>
<b>abacavir + 3TC + ZDV 300 + 150 + 300mg tablets (Trizivir®)</b>	GlaxoSmithKline	LDCs plus sub-Saharan Africa. All projects fully financed by the Global Fund to fight AIDS, TB and Malaria. <i>(For middle income developing countries public sector prices negotiated on a case-by-case basis bilaterally or through the AAI.</i>	Governments, aid organisations, charities, international, UN agencies, other not-for-profit organisations and international purchase funds such as the Global Fund to fight AIDS, TB & Malaria. In sub-Saharan Africa, employers there who offer HIV/AIDS care and treatment directly to their staff through workplace clinics or similar arrangements are also eligible. All organisations must supply the preferentially priced products on a not for profit basis.	US\$ 1241/year (US\$ 1.700/unit)	Supply Agreement required. (For NGOs requiring less than 10 patients packs per month, this requirement may be waived.) The manufacturer recommends that 'prescribers must ensure that patients are fully informed regarding hypersensitivity reaction to abacavir. Patients developing signs or symptoms of hypersensitivity must contact their doctor immediately for advice.'	CIP

**Table 2f Selected generic companies' ARV offers and restrictions for developing countries**

<b>Company</b>	<b>Eligibility (countries)</b>	<b>Eligibility (body)</b>	<b>Price in US\$</b>	<b>Additional comments</b>	<b>Delivery of goods<sup>(5)</sup></b>
<b>Aurobindo</b>	No restriction	NGOs and Governmental Organizations.	See Table 1.	Prices available for at least 1,000,000 units for each product per single shipment. Payment by letter of credit.	FOB Hyderabad (India)
<b>Cipla</b>	No restriction	NGOs and Governmental Organizations.	See Table 1.	Payment at the confirmation of the order. Only available directly through Cipla HQ Mumbai. No quantity related conditions. Prices are as per table 1 however for larger quantities the prices are negotiable.	FOB Mumbai (India)
<b>GPO</b>	No restriction	Not-for-profit organizations and governments.	See Table 1.	Payment by signed letter of credit.	FOB Bangkok (Thailand)
<b>Hetero</b>	No restriction	Private sector, Public sector and NGO's.	See Table 1.	Prices could be negotiated on individual basis according commercial terms.	FOB Mumbai (India)
<b>Ranbaxy</b>	No restriction	NGO's and Governments or Programs supported by them.	Prices given in Table 1 apply to orders for a minimum of 1.5 million units. Different prices are offered for smaller quantities (500 000 or 1 million units).	Signed letter of credit.	FOB Delhi/Mumbai (India)
<b>Combinopharm</b>	No restriction	No restriction.	See Table 1.	Delivery terms 120 days. No minimum order required unless any special labelling is required (standard labelling is in Spanish): order of a complete batch. Pack of 60 or 300 capsules available for ZDV.	FOB Barcelona (Spain)

Other generic manufacturers producing ARVs exist but are not included in this summary of offers

## Annex 1: Least Developed Countries (LDCs)

Source: UNCTAD  
<http://www.unctad.org/Templates/WebFlyer.asp?intItemID=2161&lang=1>  
 Forty-nine countries are currently designated least developed countries (LDCs). The list is reviewed every three years.

Afghanistan; Angola; Bangladesh; Benin; Bhutan; Burkina Faso; Burundi; Cambodia; Cape Verde; Central African Republic; Chad; Comoros; Democratic Republic of Congo; Djibouti; Equatorial Guinea; Eritrea; Ethiopia; Gambia; Guinea; Guinea Bissau; Haiti; Kiribati; Lao People's Democratic Republic; Lesotho; Liberia; Madagascar; Malawi; Maldives; Mali; Mauritania; Mozambique; Myanmar; Nepal; Niger; Rwanda; Samoa, Sao Tome and Principe; Senegal; Sierra Leone; Solomon Islands; Somalia; Sudan; Togo; Tuvalu; Uganda; United Republic of Tanzania; Vanuatu; Yemen; Zambia.

## Annex 2: Human Development Index (HDI)

Source: Human Development Report 2002, Making new technologies work for human development UNDP. For full list of Human Development Index ranking see  
<http://hdr.undp.org/reports/global/2002/en/pdf/backbone.pdf>

### Medium human development

Albania; Algeria; Armenia; Azerbaijan; Belarus; Belize; Bolivia; Botswana; Brazil; Bulgaria; Cambodia; Cameroon; Cape Verde; China; Colombia; Comoros; Congo; Cuba; Dominica; Dominican Republic; Ecuador; Egypt; El Salvador; Equatorial Guinea; Fiji; Gabon; Georgia; Grenada; Ghana; Guatemala; Guyana; Honduras; India; Indonesia; Iran (Islamic Rep. of); Jamaica; Jordan; Kazakhstan; Kenya; Kyrgyzstan; Lebanon; Lesotho; Libyan Arab Jamahiriyah; Macedonia (TFYR); Malaysia; Maldives; Mauritius; Mexico; Moldova (Rep. of); Mongolia; Morocco; Myanmar; Namibia; Nicaragua; Oman; Panama; Papua New Guinea; Paraguay; Peru; Philippines; Romania; Russian Federation; Saint Lucia; Saint Vincent & the Grenadines; Samoa (Western); São Tomé & Príncipe; Saudi Arabia; Solomon Islands; South Africa; Sri Lanka; Suriname; Swaziland; Syrian

Arab Republic; Tajikistan; Thailand; Tunisia; Turkey; Turkmenistan; Ukraine; Uzbekistan; Vanuatu; Venezuela; Viet Nam; Zimbabwe.

### Low human development

Angola; Bangladesh; Benin; Bhutan; Burkina Faso; Burundi; Central African Republic; Chad; Congo (Dem. Rep. of the); Côte d'Ivoire; Djibouti; Eritrea; Ethiopia; Gambia; Guinea; Guinea-Bissau; Haiti; Lao People's Dem. Rep.; Madagascar Malawi; Mali; Mauritania; Mozambique; Nepal; Niger; Nigeria; Pakistan; Rwanda; Senegal; Sierra Leone; Sudan; Tanzania (U. Rep. of); Togo; Uganda; Yemen; Zambia.

### **Annex 3: Sub-Saharan countries**

Source: World Bank  
<http://www.worldbank.org/afr/countries/htm> (April 2003)

Angola; Benin; Botswana; Burkina Faso; Burundi; Cameroon; Cape Verde; Central African Republic; Chad; Comoros; Congo (Dem. Rep.); Congo (Rep.); Côte d'Ivoire; Equatorial Guinea; Eritrea; Ethiopia; Gabon; Gambia; Ghana; Guinea; Guinea-Bissau; Kenya; Lesotho; Liberia; Madagascar; Malawi; Mali; Mauritania; Mauritius; Mozambique; Namibia; Niger; Nigeria; Rwanda; São Tomé and Príncipe; Senegal; Seychelles; Sierra Leone; Somalia; South Africa; Sudan; Swaziland; Tanzania; Togo; Uganda; Zambia; Zimbabwe.

### **Annex 4: World Bank low-income countries**

Source: World Bank  
<http://www.worldbank.org/data/countryclass/classgroups/htm> (April 2003)

#### **Low-income countries**

Afghanistan; Angola; Armenia; Azerbaijan; Bangladesh; Benin; Bhutan; Burkina Faso; Burundi; Cambodia; Cameroon; Central African Republic; Chad; Comoros; Congo (Dem. Rep.); Congo (Rep.); Côte d'Ivoire; Equatorial Guinea; Eritrea; Ethiopia; Gambia; Georgia; Ghana; Guinea; Guinea-Bissau; Haiti; India; Indonesia; Kenya; Korea, Dem. Rep.; Kyrgyz Republic; Lao PDR; Lesotho; Liberia; Madagascar; Malawi; Mali; Mauritania; Moldova; Mongolia; Mozambique; Myanmar; Nepal; Nicaragua; Niger; Nigeria; Pakistan; Papua New Guinea; Rwanda; São Tomé and Príncipe; Senegal; Sierra Leone; Solomon Islands; Somalia; Sudan; Tajikistan; Tanzania; Timor-Leste; Togo; Uganda; Ukraine; Uzbekistan; Vietnam; Yemen (Rep.); Zambia; Zimbabwe.

#### **Lower-middle-income economies**

Albania; Algeria; Belarus; Belize; Bolivia; Bosnia and Herzegovina; Bulgaria; Cape Verde; China; Colombia; Cuba; Djibouti; Dominican Republic; Ecuador; Egypt, Arab Rep.; El Salvador; Fiji; Guatemala; Guyana; Honduras; Iran, Islamic Rep.; Iraq; Jamaica; Jordan; Kazakhstan; Kiribati; Macedonia, FYR; Maldives; Marshall Islands; Micronesia, Fed. Sts.; Morocco; Namibia; Paraguay; Peru; Philippines; Romania; Russian Federation; Samoa; South Africa; Sri Lanka; St. Vincent and the Grenadines; Suriname; Swaziland; Syrian Arab Republic; Thailand; Tonga; Tunisia; Turkey; Turkmenistan; Vanuatu; West Bank and Gaza; Yugoslavia, Fed. Rep.

#### **Upper-middle-income economies**

American Samoa; Antigua and Barbuda; Argentina; Barbados; Botswana; Brazil; Chile; Costa Rica; Croatia; Czech Republic; Dominica; Estonia; Gabon; Grenada; Hungary; Isle of Man; Latvia; Lebanon; Libya; Lithuania; Malaysia; Malta; Mauritius; Mayotte; Mexico; Oman; Palau; Panama; Poland; Puerto Rico; Saudi Arabia; Seychelles; Slovak Republic; St. Kitts and Nevis; St. Lucia; Trinidad and Tobago; Uruguay; Venezuela, RB;

### **Annex 5: Company contacts**

#### **Abbott:**

Rob Dintruff  
Email: [rob.dintruff@abbott.com](mailto:rob.dintruff@abbott.com)

AXIOS International manages the application process and serves as the central contact:  
The Programme Manager  
Access to HIV Care Programme  
AXIOS International  
P.O. Box 6924  
Kampala, Uganda.  
Tel: +256 75 693 756  
Fax: +256 41 543 021  
Email: [AccessToHIVCare@axiosint.com](mailto:AccessToHIVCare@axiosint.com)  
Website : [www.accesstohivcare.org](http://www.accesstohivcare.org)

#### **Aurobindo Pharma Ltd:**

Venkateshan  
Regional Manager (Latin America & Europe)  
Tel: +91 40 373 7332 (Direct)  
Or +91 98480 257 64 (Mobile)  
Fax: +91 40 374 10 80  
Email: [venky@aurobindo.com](mailto:venky@aurobindo.com)

#### **Bristol-Myers Squibb Co:**

Robert D. Lefebvre  
Senior Director, Project Access  
Bristol-Myers Squibb  
P.O. Box 4000  
Princeton, NJ 08543-4000, USA  
Tel: +1.609.252.4592  
Fax: +1.609.252.4819  
E-mail: [robert.lefebvre@bms.com](mailto:robert.lefebvre@bms.com)

*West Africa:* information can be obtained from Ms Marie-Astrid Mercier, BMS Access Coordinator in BMS Paris office (marie-astrid.mercier@bms.com)

*East Africa:* information can be obtained from BMS main distributor in East Africa – M. Mukesh Mehta at Phillips Pharmaceuticals in Nairobi ([ppl@phillipspharma.com](mailto:ppl@phillipspharma.com)).

*Southern Africa:* information can be obtained from Ms Tamany Geldenhuys in BMS offices in Johannesburg ([tamany.geldenhuys@bms.com](mailto:tamany.geldenhuys@bms.com)).

**Boehringer Ingelheim:**

Laurence Phillips (for preferential prices)

CD Marketing Prescription Medicines  
HIV-Specialists/Virologists

Phone: + 49 6132 77-2081

Fax: +49 6132 77-3829

Email: [phillips@ing.boehringer-ingelheim.com](mailto:phillips@ing.boehringer-ingelheim.com)

Hélène Clary (for donations)  
Marketing Prescription Medicines  
CG HIV-Specialists/Virologists

Tel: + 49 6132 77-34 36

Fax: + 49 6132 77-38 29

Email: [claryh@ing.boehringer-ingelheim.com](mailto:claryh@ing.boehringer-ingelheim.com)

**Cipla Ltd:**

Sanjeev Gupte, General Manager-Exports

Cipla Limited

and Shailesh Pednekar

Executive-Exports, Cipla Limited

Tel: +91 22 3021397 (Direct) 3095521  
3092891

Fax: +91 22

3070013/3070393/3070385

Email: [exports@cipla.com](mailto:exports@cipla.com) and  
[ciplaexp@cipla.com](mailto:ciplaexp@cipla.com)

**Combinopharm:**

Silvia Gil

Managing Director

Combinopharm

Tel: + 34 93 48 08 833

Fax: + 34 93 48 08 832

Email: [export@combino-pharm.es](mailto:export@combino-pharm.es)

**Gilead**

Programme Access (primary contact)

Gilead Access Program

Axios International

Plot 1 Pilkington Road

6th Floor Workers House Building

P.O. Box 6924

Kampala

Uganda

Tel: +256-41-340806/7

Fax: +256-41-340642

Email: [GileadAccess@axiosint.com](mailto:GileadAccess@axiosint.com)

Company contact

Joe Steele

Senior Director, Commercial

Development

Gilead Sciences

333 Lakeside Drive

Foster City, California 94404

1-650-522-5740

**GlaxoSmithKline:**

Jon Pender

Director External Relations

Global Access Issues

Tel: + 44 (0) 20 8047 5489

Fax: + 44 (0) 208 047 6957

Email: [jon.d.pender@gsk.com](mailto:jon.d.pender@gsk.com)

**GPO:**

Sukhum Virattipong

Export Manager

Tel: + 662 248 1482, + 662 203 8808

Fax: + 662 248 1488

Email: [sukhum@health.moph.go.th](mailto:sukhum@health.moph.go.th)

**Hetero:**

Dharmesh Shah

Director International Business

Development, Hetero International

408 Sharda Chambers, 15 New

Marine Lines, Mumbai 400 020, India

Tel: +91 22 563 318 68

Tel (direct): +91 22 563 318 61

Fax: +91 22 220 660 99

Email: [hint@bom5.vsnl.net.in](mailto:hint@bom5.vsnl.net.in)

**Merck & Co. Inc:**

Dr Jeffrey L. Sturchio

Vice President, External Affairs

Human Health Europe, Middle East & Africa

Merck & Co., Inc/WSZA-55

One Merck Drive

Whitehouse Station

NJ 08889-0100 USA

Tel: +1 908 423 39 81

Fax: +1 908 735 1704

Email: [jeffrey\\_sturchio@merck.com](mailto:jeffrey_sturchio@merck.com)

**Ranbaxy:**

Sandeep Juneja

Ranbaxy Laboratories Limited

Tel: + 91 11 600 2120 (Direct)

or + 91 11 645 2666-72

Fax: + 91 11 600 2121

Email: [sandeep.juneja@ranbaxy.com](mailto:sandeep.juneja@ranbaxy.com)

**Roche:**

For information regarding quotations and deliveries to customers contact:

Hanspeter Walchli

Logistics Sales International  
Customers

Dept. PTBS-IM

4070 Basel / Switzerland

Tel: +41 61 688 1060

Fax: +41 61 687 1815

Email: [hanspeter.walchli@roche.com](mailto:hanspeter.walchli@roche.com)



**3TC** lamivudine (Epivir®); nucleoside analogue reverse transcriptase inhibitor

**AAI** United Nations Accelerating Access Initiative; Accelerated Access emerged out of the partnership initiated in May 2000 between the UN (UNFPA, UNICEF, WHO, the World Bank and UNAIDS Secretariat) and five pharmaceutical companies (Boehringer-Ingelheim GmbH, Bristol-Myers Squibb, GlaxoSmithKline, Merck & Co., Inc., and F. Hoffmann-La Roche Ltd (Roche)); Abbott Laboratories Ltd. joined the initiative later) to increase access to HIV/AIDS care, treatment and support. AAI plays a role in facilitating price negotiations between developing country governments and ‘originator’ drug companies that are participating in the AAI.

**ABC** abacavir (Ziagen®); nucleoside analogue reverse transcriptase inhibitor

**AIDS** Acquired Immune Deficiency Syndrome

**ARVs** Antiretroviral drugs

**BMS** Bristol-Myers Squibb

**CDC** Centres for Disease Control and Prevention

**CIF**<sup>51</sup> ‘Cost Insurance and Freight’ means that the seller delivers when the goods pass the ship’s rail in the port of shipment. The seller must pay the costs and freight necessary to bring the goods to the named port of destination BUT the risk of loss or damage to the goods, as well as any additional costs due to events occurring after the time of delivery, are transferred from the seller to the buyer.

**CIP**<sup>51</sup> ‘Carriage and Insurance paid to...’ means that the seller delivers the goods to the carrier nominated by him but the seller must in addition pay the cost of carriage necessary to bring the goods to the named destination. This means that the buyer bears all the risks and any additional costs occurring after the goods have been so delivered. However, in CIP the seller also has to procure insurance against the buyer’s risk of loss of or damage to the goods during the carriage. Consequently, the seller contracts for insurance and pays the insurance premium.

**d4T** stavudine (Zerit®); nucleoside analogue reverse transcriptase inhibitor

**ddI** didanosine (Videx®); nucleoside analogue reverse transcriptase inhibitor

**DDU**<sup>51</sup> ‘Delivered duty unpaid’ means that the seller delivers the goods to the buyer, not cleared for import, and not unloaded from any arriving means of transport at the named place of destination. The seller has to bear the costs and risks involved in bringing the goods thereto, other than, where applicable, any ‘duty’ (which term includes the responsibility for the risks of the carrying out of the customs formalities, and the payment of formalities, customs duties, taxes and other charges) for import in the country of destination. Such ‘duty’ has to be borne by the buyer as well as any costs and risks caused by his failure to clear the goods for the import time.

**EML** Essential Medicines List. First published by WHO in 1977, it is meant to identify a list of medicines, which provide safe and effective treatment for the infectious and chronic diseases, which affect the vast majority of the world’s population. The 12th Updated List was published in April 2002 and includes 12 antiretrovirals.

**EFV** efavirenz (Stocrin®); non-nucleoside analogue reverse transcriptase inhibitor

**EXW**<sup>61</sup> 'Ex-works' means that the seller delivers when he places the goods at the disposal of the buyer at the seller's premises or another named place (i.e. works, factory, warehouse etc.) not cleared for export and not loaded on any collecting vehicle.

**FOB**<sup>61</sup> 'Free on board' means that the seller delivers when the goods pass the ship's rail at the named port of shipment. This means that the buyer has to bear all costs and risks of loss or damage to the goods from that point. The FOB term requires the seller to clear the goods for export.

**Generic drug** According to WHO, a pharmaceutical product usually intended to be interchangeable with the innovator product, which is usually manufactured without a license from the innovator company. Generic products may be marketed either under a non-proprietary or approved name rather than a proprietary name.

**GPO** Governmental Pharmaceutical Organization (Thailand)

**GSK** GlaxoSmithKline

**HIV** Human Immunodeficiency Virus

**IDV** indinavir (Crixivan®); protease inhibitor

**LDCs** Least Developed Countries, according to United Nations classification

**MSD** Merck Sharp & Dome (Merck & Co., Inc.)

**MSF** Médecins Sans Frontières

**NGO** Non Governmental Organization

**NFV** nelfinavir (Viracept®); protease inhibitor

**NNRTI** Non-Nucleoside Reverse Transcriptase Inhibitor

**NRTI** Nucleoside Analogue Reverse Transcriptase Inhibitor

**NtRTI** Nucleotide Reverse Transcriptase Inhibitor

**NVP** nevirapine (Viramune®); non-nucleoside analogue reverse transcriptase inhibitor

**PMTCT** Prevention of Mother-To-Child Transmission

**r** ritonavir (Norvir®), low dose ritonavir used as a booster; protease inhibitor

**SQV hgc** saquinavir hard gel capsules (Invirase®); protease inhibitor

**SQV sgc** saquinavir soft gel capsules (Fortovase®); protease inhibitor

**TDF** tenofovir (Viread®); nucleotide reverse transcriptase inhibitor

**UNAIDS** United Nations Joint Co-sponsored Programme on HIV/AIDS, created in 1996, to lead, strengthen and support an expanded response to the HIV/AIDS epidemic. The six original Cosponsors are UNICEF, UNDR, UNFPA, UNESCO, WHO and the World Bank. UNDCP joined in April 1999

**UNDP** United Nations Development Programme

**UNFPA** United Nations Population Fund

**UNICEF** United Nations Children's Fund

**WHO** World Health Organization

**ZDV** zidovudine (Retrovir®); nucleoside analogue reverse transcriptase inhibitor



## References

- [1] Pilot Procurement, Quality and Sourcing Project: Access to HIV/AIDS drugs and diagnostics of acceptable quality  
<http://www.who.int/medicines/organization/gsm/activities/pilotproc/pilotproc.shtml>
- [2] Sources and prices of selected drugs and diagnostics for people living with HIV/AIDS. A joint UNICEF, UNAIDS Secretariat, WHO, MSF project. May 2003  
(WHO/EDM/PAR/2003.2).  
<http://www.who.int/medicines/library/pa/hivrelateddocs/sourcesandpricesmay.doc>
- [3] Accessing ARVs: Untangling the Web of Price Reductions for Developing Countries, first edition, October 2001 and second edition, June 2002 and third edition, December 2002
- [4] Other generic manufacturers known to be producing one or more ARVs but not included in this document are: Richmond Laboratories, Panalab, Filaxis (Argentina); Pharmaquick (Benin); Far Manguinhos, FURP, Lapefe, Laob, Iquero, IVB (Brazil); Apotex, Novopharm (Canada); Shanghai Desano Biopharmaceutical company, Northeast General Pharmaceutical Factory (China); Biogen (Colombia); Stein (Costa Rica); Zydus Cadila Healthcare, SunPharma, EAS-SURG, Strides, Mac Leods, IPCA (India); LG Chemicals, Samchully, Korea United Pharm Inc. (Korea); Protein, Pisa (Mexico); Andromaco (Spain); T.O. Chemeal (Thailand); Laboratorío Dosa S.A. (US).  
This list is not exhaustive.
- [5] Incoterms 2000  
[http://www.iccwbo.org/index\\_incoterms.asp](http://www.iccwbo.org/index_incoterms.asp)
- [6] “Scaling-up Antiretroviral therapy in Resource Limited Settings: Guidelines for a Public Health approach”, June 2002  
[http://www.who.int/HIV\\_AIDS/CARE/ScalingUp\\_Guidelines\\_Final021002.pdf](http://www.who.int/HIV_AIDS/CARE/ScalingUp_Guidelines_Final021002.pdf)
- [7] “Guidelines for the Use of Antiretroviral Agents in HIV-infected Adults and Adolescents, by the Panel on Clinical Practices for the Treatment of HIV”, 2002  
<http://www.hivatis.org>
- [8] Patent Situation of HIV/AIDS related drugs in 80 countries, WHO/UNAIDS, 2000  
<http://who.int/medicines/library/par/hivrelateddocs/patentshivdrugs.pdf>
- [9] [http://www.accessmed-msf.org/documents/patents\\_2003.pdf](http://www.accessmed-msf.org/documents/patents_2003.pdf)
- [10] To find the HIV prevalence status of countries see  
[http://www.unaids.org/epidemic\\_update/](http://www.unaids.org/epidemic_update/)
- [11] More information about the World Trade Organisation (WTO) Agreement on Trade-related aspects of Intellectual property rights (TRIPS) can be found at  
[http://www.wto.org/english/tratop\\_e/trips\\_e/trips\\_e.htm](http://www.wto.org/english/tratop_e/trips_e/trips_e.htm). The full declaration is also available on the WTO site.
- [12] Abbreviations for the ARVs are taken from the WHO draft guidelines “Scaling-up Antiretroviral therapy in Resource Limited Settings: Guidelines for a Public Health approach”, June 2002  
[http://www.who.int/HIV\\_AIDS/CARE/ScalingUp\\_Guidelines\\_Final021002.pdf](http://www.who.int/HIV_AIDS/CARE/ScalingUp_Guidelines_Final021002.pdf)

